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1.1. Hematopoiesis
As mature blood cells only have a limited life span this pool of  cells needs constant 
replenishment. In this process of  blood cell formation or hematopoiesis, all mature 
blood cells arise via a process of  proliferation and differentiation from a common pool 
of  ancestral cells, the hematopoietic stem cells (HSC). 
The first HSC responsible for all adult hematopoiesis are generated in the aorta-go-
nad-mesonephros (AGM) region of  the embryo1,2. From this region the HSC migrate 
to the fetal liver in which definitive hematopoiesis is initiated. After birth the bone 
marrow (BM) is the preferred hematopoietic site.  
The HSC are characterised by their ability to: a) show extensive self  renewal; b) dif-
ferentiate to both myeloid and lymphoid lineages i.e. they are pluripotent, and c) give 
long term reconstitution of  the hematopoietic system of  a myeloablated recipient3-5. 
Physical separation methods have shown that also within the HSC compartment a 
hierarchy with respect to self-renewal, turnover rate and pluripotency exists6-9. In a 
transplant setting  this hierarchy might be reflected in the different periods of  time in 
which different stem cell clones contribute to the production of  mature blood cells. 
Murine transplantation models indicated that HSC can be divided into two main sub-
populations. One consisting of  cells with long-term repopulating ability, responsible 
for maintaining sustained multilineage repopulation and one consisting of  cells with 
only transient, short-term, repopulating ability10,11. A common tool to characterise and 
purify HSC has been the use of  immunophenotyping and fluorescence activated cell 
sorting (FACS). One of  the major advances using this technique has been the discov-
ery of  the expression of  the transmembrane glycoprotein CD34 on a population of  
hematopoietic cells able to reconstitute both the lymphoid- and myeloid lineages of  
myeloablated recipients12,13. CD34 is expressed on one to four percent of  normal bone 
marrow cells. From this fraction of  CD34+ BM cells HSC can be further purified by 
depletion of  CD38 or lineage marker expressing cells. Nevertheless, recent studies 
have shown the reversible expression of  CD34 and CD38 on both murine and human 
HSC14-17, suggesting that CD34 might be a marker for activated stem cells. Further in-
vestigation is necessary to determine if  CD34+ and CD34- HSC represent the same 
pool of  stem cells and whether CD34 is just an activation marker. 
The homeostasis of  hematopoiesis is closely regulated by the bone marrow microen-
vironment and/or cyto- and chemokines, acting in both synergistic and antagonistic 
fashions. 
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Figure 1. Schematic representation of the hematopoietic system and the growth fac-
tors involved. 
All mature blood cells of  the different lineages arise via a process of  proliferation and differentiation 
directed by growth factors from a common ancestor, the pluripotent hematopoietic stem cell. Though 
the scheme in this figure is far from complete and only the major growth factors involved are depicted, 
it gives a good indication about the complexity of  the hematopoietic system. In italics are depicted a 
number of  the recognisable stages of  differentiation, whilst the boxes indicate the growth factors in-
volved. (HSC: hematopoietic stem cell; CLP: common lymphocyte precursor; CFU-GEMM: colony 
forming unit-granulocyte-erythroid-monocyte-megakaryocyte; CFU-GM: colony forming unit-granu-
locyte-macrophage; CFU-meg: colony forming unit-megakaryocyte; BFU-E: burst forming unit-eryth-
rocyte; CFU-E: colony forming unit-erythrocyte; CFU-M: colony forming unit-monocyte; CFU-G: 
colony forming unit-granulocyte; CFU-Eo: colony forming unit-eosinophilic granulocyte; CFU-Baso: 
colony forming unit-basophilic granulocyte; IL: interleukin; TPO: thrombopoietin; FL: Flt3-ligand; 
EPO: erythropoietin; SCF: stem cell factor; GM-CSF: granulocyte-macrophage-colony stimulating fac-
tor; M-CSF: macrophage-colony stimulating factor; G-CSF: granulocyte-colony stimulating factor).
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The cytokines or hematopoietic growth factors (HGF) acting on the hematopoietic 
system (Figure 1) are produced by a variety of  cells such as stromal cells (fibroblasts 
macrophages, and endothelial cells), mature blood cells (monocytes, T- and B-lym-
phocytes) and hemopoietic cells proper, and are involved in the regulation of  pro-
liferation, differentiation, maturation and cell survival. HGF have in common that 
most display a wide range of  activities (i.e. they are pleiotropic) and similar activities 
might be shared among different HGFs (redundancy). HGF can roughly be divided 
into a group of  early acting cytokines such as Flt3 and SCF, mainly acting on the more 
primitive progenitor cells, and a group of  late acting cytokines such as the colony stim-
ulating factors (CSFs) and erythropoietin (Epo) which mainly induce proliferation and 
terminal differentiation of  the more mature, lineage-committed, progenitor cells18-20. 
However, some HGF such as thrombopoietin (TPO), interleukin-3 and GM-CSF can 
act on both primitive and more committed hematopoietic cells21-23. Binding of  the 
HGFs to their specific receptor will lead to activation of  intracellular signalling path-
ways finally resulting in the activation of  specific genes. The major signalling pathways 
involved in HGF signalling are the Ras/MAPK and the Jak/STAT pathways, though 
also activation of  other pathways has been described24-27. The signalling cascade is fi-
nally tightly controlled by lineage-restricted as well as generally expressed transcription 
factors, co-activators and co-repressors resulting in a fine-tuned response after growth 
factor binding.
As outlined above, during fetal development HSC migrate from the fetal liver to the 
bone marrow. After birth HSC, progenitor cells as well as more mature cells can under-
take targeted migration from one site in the hematopoietic system to another site. This 
process is considered to be a multistep process in which adhesion molecules expressed 
on both the hematopoietic cells and cells of  the microenvironment, such as endothe-
lial cells, are involved28,29. Chemokines (chemotactic cytokines, for a comprehensive 
review see Rollins, 1997 30) or growth factors bound to proteoglycans expressed on 
the extracellular matrix can activate β1- and β2-integrins on HSC and progenitor cells, 
resulting in adhesion and transendothelial migration31-33. 
Whilst its production is not restricted to the hematopoietic microenvironment alone, 
stromal cell derived factor-1 alpha (SDF-1) appears to be the major chemokine released 
by BM-microenvironment34,35, acting on lymphocytes and hematopoietic progenitors. 
In SDF-1 or CXCR-4 (i.e. the SDF-1 receptor) knockout models hematopoietic pre-
cursor cells do not shift to the bone marrow during foetal development, whilst in vitro 
SDF-1 has been shown to activate integrins on these precursor cells and induce their 
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migration36,37. The chemokines Macrophage Inflammatory Protein-3β (MIP-3β) and 
Secondary lymphoid-tissue chemokine (SLC) both binding to CCR-7 originally were 
also described to be chemokines for HSC. However, in contrast to SDF-1 that attracts 
multiple types of  HSC and hematopoietic progenitor cells, both SLC and MIP-3β 
were mainly found to be attractors for macrophage progenitors38,39.   
1.2. Leukemia
1.2.1. Leukemogenesis
The balance between hematopoietic cell proliferation, differentiation, maturation and 
cell survival is crucial to maintain homeostasis. In this process of  hematopoietic de-
velopment errors may occur, resulting in aberrant expression of  genes critical in cell 
development leading to e.g. uncontrolled proliferation, prolonged cell survival or 
blockage of  differentiation pathways. This may finally result in leukemia, a neoplastic 
disorder in which (immature) hematopoietic progenitors accumulate in the BM where 
they fail to fully mature and dislocate the normal progenitor cells hence bringing the 
normal homeostatic processes out of  balance. Finally the neoplastic cells may leave the 
BM and lodge in other organ systems.
It has been generally accepted that leukemogenesis is a multistep process requiring 
multiple genetic lesions. These lesions may be acquired or congenital and involve ab-
errant activation of  (proto-)oncogenes or inactivation of  tumor-suppressor genes40-42. 
These genes encompass for example genes encoding growth factors, growth factor 
receptors, signalling molecules, molecules involved in DNA and RNA synthesis and 
transcription factors. Aberrant expression of  both proto-oncogenes and tumor-sup-
pressor genes can be caused by e.g. genetic instability, exposure to alkylating agents or 
radiation. This then can result in chromosomal translocations, chromosomal deletions, 
chromosomal inversions, aneuploidy, and critical mutations inside a gene43-45. Aberrant 
expression could also be caused by integration of  a virus in a gene or in a locus control-
ling the expression of  a particular gene46-49. Chromosomal translocations or inversions 
might result in the aberrant expression of  the full-length protein or in the expression 
of  fusion proteins which might have aberrant functional characteristics when com-
pared to the normal protein. Aberrant expression of  the oncoprotein can confer a 
growth advantage of  the mutant progenitor cells finally resulting in them outgrowing 
their normal counterparts. In leukemia the genes located at the chromosomal break-
points most often encode for transcription factors50, such as AML-1, CBF-β, MLL and 
RARα51-53. Mutations in tumor-suppressor genes involved in leukemia generally result 
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in a loss-of-function mutation of  these genes, which encode for negative regulators of  
cellular proliferation (e.g. NF1, members of  the INK4 family) and regulators of  apop-
tosis (e.g. p53)54-56.
1.2.2. Acute myeloid leukemia
Leukemias can occur in both the lymphoid and myeloid lineages of  differentiation. 
These leukemias are further subdivided in the more aggressive acute leukemias, char-
acterized by uncontrolled proliferation and abnormal differentiation of  immature 
cells, and the less aggressive chronic leukemias, commonly resulting in the expansion 
and accumulation of  more mature elements. Since the research described in this thesis 
was focussed on acute myeloid leukemia (AML) this paragraph will only focus on this 
type of  malignancy. 
AML can be distinguished from other types of  leukemias based on immunopheno-
typing, cytochemistry and cytogenetics. In the Netherlands the incidence of  AML is 
about 2.8 per 105 inhabitants57. The incidence of  AML increases with age from less 
than 1 per 105 under the age of  20 to over 10 per 105 in persons over 70 years of  age. 
AML is a heterogeneous disorder which, at a morphological level, is classically sub-
divided in 8 subtypes based on the various degrees of  lineage commitment and dif-
ferentiation (FAB-classification, M0-M7)58. Cytogenetic analysis of  leukemic samples 
has identified various non-random chromosomal aberrations in AML. Some of  these 
chromosomal abnormalities correlate with specific FAB subtypes, for instance the 
translocation t(8;21) is present in around 40% of  the FAB-M2 leukemias52 , transloca-
tions involving the retinoic acid receptor alpha (RARα) on chromosome 17 in acute 
promyelocytic leukemia / FAB-M3 ( t(15;17) is present in 98% of  cases59) and inv(16) 
or t(16;16) involved in 80% of  the FAB-M4eo cases60,61 (Table 1). Cytogenetic aberra-
tions can also be used to recognize subgroups of  patients with distinct clinical charac-
teristics and responses to therapy. Based on the molecular and cytogenetic aspects pa-
tients can be classified into distinct prognostic subgroups: e.g. favourable or good risk, 
intermediate or standard risk and unfavourable or poor risk. The favourable risk group 
includes around 15% of  patients with an age below 60 years and is defined by the pres-
ence of  t(15;17), t(8;21) and inv(16) or t(16;16). Patients presenting these mutations 
have an increased rate of  complete remission and a relatively low risk of  relapse. The 
poor prognosis group of  AML is defined by deletions of  chromosomes 5 or 7 (or the 
short-arms of  these chromosomes), abnormalities in the long-arm of  chromosomes 3 
and AML with a complex karyotype (three or more cytogenetic aberrations). In some 
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studies also 11q23 mutations are considerd a marker for poor prognosis. Overall, pa-
tients with adverse risk type mutations generally have a probability of  5-year survival 
of  no more than 20%. Patients presenting with AML with other cytogenetic abnor-
malities or without any apparent cytogenetic abnormalities are considered to have an 
intermediate risk62-64. In a small group of  patients the disease evolves from a prior he-
matological disorder (e.g. Severe Congenital Neutropenia, CML or MDS)65,66, a con-
genital or inherited disorder (e.g. Diamond Blackfan anemia, Fanconi’s anemia)67,68 or 
may be the result of  to exposure to alkylating agents or topoisomerase II inhibitors 
Table 1. French-American-British (FAB) classification of AML and associated cy-
togenetic abnormalities.
FAB
Subtype
Description
Relative
Occurrence*
Associated cytogenetics
aberration
% of  
cases*
M0
Acute myeloblastic leukemia with mini-
mal differentiation
3% inv(3q26),t(3;3) 1%
M1
Acute myeloblastic leukemia without 
maturation
15-20% - -
M2
Acute myeloblastic leukemia with 
maturation
25-30%
t(8;21)
t(6;9) 
40%
1%
M3 Acute promyelocytic leukemia 5-10%
t(15;17) 
t(11;17) 
t(5;17)  
98%
1%
1%
M4 Acute myelomonocytic leukemia 20%
11q23
inv(3q26),t(3;3) 
t(6;9)
~20%
3%
1%
   M4eo
Acute myelomonocytic leukemia with 
abnormal eosinophils
5-10% inv(16), t(16;16) ~80%
M5 Acute monocytic leukemia 2-9%
11q23
t(8,16)
20%
2%
M6 Erythroleukemia 3-5% - -
M7 Acute megakaryocytic leukemia 3-12% t(1;22) 5%
* ref. Löwenberg et al., N Engl J Med 1999 341:1051-62.
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(used in treatment of  other non-related neoplasias, also known as treatment-related 
AML)69,70. These leukemias are generally designated as secondary leukemias. From a 
scientific point of  view secondary AMLs are of  interest as these AMLs clearly suggest 
that multiple genetic aberrations are required for the full manifesation of  the disease 
phenotype71,72. 
1.3. Flt3 and other Class III receptor tyrosine kinases in normal and 
malignant hematopoiesis.
The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) 
or fetal liver tyrosine kinase-2 (FLK-2)73,74 belongs to the class III receptor tyrosine ki-
nases (RTKs) which also include c-Kit, c-Fms, and the PDGF α en β receptors75. Of  
the total number of  90 tyrosine kinases known to date 58 are of  receptor, which are 
distributed over about 20 subfamilies or classes. All RTKs share a similar structure: 
an extra cellular ligand binding domain, a single transmembrane (TM) domain and an 
intracellular tyrosine kinase (TK) domain76,77. The extracellular domains of  the differ-
ent RTKs show a variety of  conserved elements such as Ig-like domains, cysteine-rich 
regions and fibronectin repeats78,79(See Figure 2). Binding of  the ligand to the extra-
cellular domain results in conformational changes that induce and stabilise receptor 
dimerisation. The TM domain mainly consists of  a α-helical structure and anchors the 
receptor to the membrane in the correct orientation. TM domain linked mutations, 
leading to ligand independent dimerisation and constitutive activation, have been de-
scribed in at least two RTK families80. The Class III RTKs are characterised by the 
presence of  five Ig-like domains in their extracellular region and a split catalytic intra-
cellular tyrosine kinase domain (fig. 2). The genomic loci encoding for the intracellular 
catalytic domains overall show a conservation in exon/intron boundaries, exon size 
and sequence, which suggests they have arisen from a common ancestor81-83. Recently, 
the Flt3 gene has been shown to be comprised of  24 rather than 21 exons, typical for 
the other class III members. Seven instead of  four exons encode for the first three Ig-
like domains of  Flt384. With the exception of  PDGFRα almost all class III RTKs play 
an important role in hematopoiesis: Flt3 and c-Kit are both required for the survival, 
proliferation and differentiation of  HSC85,86; c-Fms, the receptor for M-CSF, is crucial 
for the proliferation and differentiation in the monocyte-macrophage lineage87. 
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I. EGFR EGFR, ERBB2-4
s
s
s
s
II. INSR IR,IGF1R
IV. FGFR FGFR1-4
III. PDGFR C-FMS, FLT3, C-KIT,PDGFRa-b
V. VEGFR VEGFR1-3
s
sVI. MET MET, RON
LLLVII. TRK NTRK1-3
VIII. EPH EPHA1-8, EPHB1-6
IX. AXL AXL, MER, TYRO3
s
s
s
s
X. LTK ALK, LTK
XI. TIE TEK, TIE
XII. ROR ROR1-2
XIII. DDR DDR1-2
XIV. RET RET
XV. PTK7 PTK7
LLXVI. RYK RYK
XVII. MUSK MUSK
XVIII. AATYK AATYK1-3
XIX. ROS ROS1
Extracellular TM Kinase Family Members
Ig-like domain
Cystein rich motif
Cadherin domain
Kringle domain
Discoidin domain
Fibronectin type III domain
L Leucin rich motif
EGF-like repeat
Class
Figure 2. Schematic diagram of the receptor tyrosine kinase families. 
For 19 (I-XIX) of  the around 20 receptor tyrosine kinase classes the schematic structure of  the protein 
is depicted. No known structural data of  the other families were available. On the right side of  each dia-
gram the family members are depicted. The nomenclature of  the families is as follows: EGFR, epider-
mal growth factor receptor; INSR, insulin receptor; PDGFR, platelet derived growth factor receptor; 
FGFR, fibroblast growth factor receptor; VEGFR, vascular endothelial growth factor receptor; MET, 
Common name, no abbreviation, also known as hepatocyte growth factor receptor; TRK, Tropomyosin 
receptor kinase; EPH, ephrin receptor; AXL, anexelekto; LTK, leukocyte tyrosine kinase; TIE, tyrosine 
kinase with Ig and EGF homology domains; ROR, Retinoid-related orphan receptor; DDR, discoidin 
domain receptor; RET, rearranged during transformation; PTK7, protein tyrosine kinase-like receptor 
7; RYK, related to tyrosine kinase; MUSK, muscle-specific tyrosine kinase; AATYK, apoptosis-associ-
ated tyrosine kinase; ROS, Common name, no abbreviation. 
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Though the role of  the PDGFRβ in hematopoiesis is less well defined, it most proba-
bly plays an important role in megakaryopoiesis88. The following sections will go more 
into detail about the role of  the individual class III members in both normal and ma-
lignant hematopoiesis.
1.3.1. Flt3
Flt3 (CD135) is expressed on multipotential HSC and progenitor cells, suggesting 
a critical role in stem cell development and differentiation89. This is supported by a 
number of  animal studies in which targeted disruption of  Flt3 results in deficien-
cies in both myeloid and lymphoid progenitors90. Analysis of  Flt3 knockout mice has 
shown that mainly primitive B cell progenitors are reduced. Yet, normal numbers of  
functional B-cells are present in the periphery. Also the composition and numbers of  
cells in the peripheral blood and hematopoietic organs are comparable between Flt3 
knockout and wildtype mice. Only in competitive repopulation assays the Flt3-defi-
cient HSC show a less efficient repopulation in comparison with wildtype HSC, espe-
cially in the lymphoid lineage. Flt3-ligand (FL) knockout mice on the other hand show 
an overt reduction of  leukocyte counts in bone marrow, spleen and thymus as well as 
in the peripheral blood. In addition these animals also show reduced numbers of  both 
myeloid en lymphoid dendritic cells and are deficient in NK-cells. Similar to the recep-
tor knockout mice these animals only show slightly reduced numbers of  myeloid pro-
genitors91. These murine studies appear to indicate that Flt3 is of  a lesser importance 
to primitive HSC when compared to the importance to the more committed lymphoid 
precursors. However, recent studies have shown a difference in the function of  Flt3 
and c-Kit in mouse and humans92-94. Mouse long-term reconstituting HSC (LTR-HSC) 
do not express Flt3 during steady-state hematopoiesis and upregulation of  the Flt3 
expression coincides with a loss of  self-renewal capacity. This lack of  Flt3 expression 
on murine LTR-HSC and the high level of  expression of  c-Kit on these cells corre-
lates with the observation that SCF but not FL efficiently supports survival of  murine 
LTR-HSC. In contrast in the human system SCF only has a limited capacity to support 
CD34+CD38- HSC, which expresses low levels of  c-Kit95-97. Recently, Sitnicka et al.98 
have shown that whilst only a fraction of  the CD34+ long-term culture initiating cells 
express Flt3, most of  the CD34+ cells capable of  inducing multilineage repopulation 
in the NOD/SCID human-chimera model are Flt3+. 
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Upon ligand binding the Flt3-receptor dimerises causing auto-phosphorylation of  cer-
tain tyrosine residues in the cytoplasmatic domain of  the receptor. Although no spe-
cific tyrosine residues have been mapped which mediate interaction with specific signal 
transducing molecules, activation of  Flt3 results in direct association with Grb2 and 
Socs1, phosphorylation of  Cbl, Shc, SHIP, Shp2, Gab1, Gab2 and activation of  the 
MAPK pathway99-101. Whether the STAT pathway is activated remains unclear. In 2000 
Hayakawa et al.102 published that STAT-5 is not phosphorylated following activation 
of  wildtype Flt3, and STAT-5 activation was only observed after constitutive activa-
tion of  a mutant Flt3. In contrast, Zhang et al.103 showed that upon receptor activation 
STAT-5a, but not STAT5b or STATs 1-4, was phosphorylated. They also demonstrat-
ed that the activation of  STAT5a required the kinase activity of  Flt3. Moreover, they 
showed a selective role for STAT5a in the proliferative response of  primary hemat-
opoietic progenitor cells following FL stimulation. Addition of  FL to a CFU-C assay, 
an assay for hematopoietic progenitor cells, only resulted in an increased number of  
colonies when marrow from STAT-5a wildtype, STAT5b wildtype or STAT5b knock-
out animals was used. When STAT-5a knock-out bone marrow was used this increase 
was not observed. 
Data from a number of  groups have suggested a pathogenic role for Flt3 in leukemia. 
Flt3 expression has been documented in most cases of  AML104,105 and exogenous FL 
has been shown to induce proliferation of  AML cells in vitro106. Likewise some AML-
cells have been reported to express both Flt3 and FL, indicating a possible autocrine 
or paracrine stimulation107. Finally long-term over-exposure to FL has been shown to 
induce leukemia in mice, albeit after a long latency period108. 
In 1996 Nakao et al.109 were the first to report a novel mutation in the Flt3 gene in a 
small number of  AML patients. These mutations were shown to be internal tandem 
duplications (ITDs), mainly involving a tyrosine rich stretch at the end of  exon 14 
(587-NEYFYVDFREYEYD-560, see Abu-Duhier et al.84 for revised exon numbering 
of  the Flt3), coding for the juxtamembrane (JM) domain of  the receptor (see Figure 
3, overview of  the Flt3 gene). Also, some ITDs involving exon 15 have been pub-
lished. All ITDs were in frame and resulted in an elongated JM domain. This mutated 
receptor has been reported to result in ligand-independent dimerisation and phospho-
rylation, leading to a constitutive activation in 32D, BA/F or COS-7 cells transfected 
with Flt3/ITD110,111. Yet, Fenski et al.112 observed no correlation between  ligand-in-
dependent phosphorylation and the presence of  ITDs in AML-patients. It is possi-
ble that, analogous to the c-Kit JM mutation reported in the FMA mastocytoma cell 
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line113, the ITD disrupts a negative regulatory domain. Kelly et al.114 showed that in-
troduction of  Flt3/ITDs into a murine bone marrow transplant model resulted in a 
myeloproliferative phenotype characterised by leukocytosis and splenomegaly with ex-
tramedullary hematopoiesis in spleen and liver. As these ITDs were insufficient to in-
duce leukemia in this model, these data suggest that other co-operating mutations are 
necessary for the development of  a leukemic phenotype. 
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Figure 3. Overview of the Flt3 monomer spanning the plasma membrane.
This figure depicts the 5 extracellular Ig-like domains (Ig1-5) in the ligand binding domain of  the extra-
cellular part of  the receptor (ECD), the transmembrane domain (TM), the juxtamembrane domain (JM) 
and the two intracellular tyrosine kinase domains (TK1 and TK2) separated by the kinase insert (KI). 
The positions of  the two known types of  mutations involved in AML, i.e. internal tandem duplications 
(ITDs) in the JM domain and point mutations in the KI, are indicated. Of  each type of  mutation some 
examples are presented. 
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We and others have shown Flt3/ITD mutations to be present in a high number (17 to 
27%) of  AML cases and to correlate with high peripheral white blood cell counts. The 
presence of  these mutations correlates also with an unfavourable patient prognosis in 
both adult and pediatric AML116-120 (See also, Chapter 3 of  this thesis). Absence of  the 
wildtype allele in Flt3/ITD AML predicts a more inferior disease free and overall sur-
vival121. Whereas the number of  Flt3/ITDs appears to be higher in acute promyelo-
cytic leukemia122 the mutation is not correlated with a specific FAB-class or any known 
cytogenetic aberration. The presence of  Flt3/ITDs has also been shown in 3-5% of  
MDS cases123 and rare cases of  biphenotypic leukemias124. No Flt3/ITDs have been 
reported in normal individuals and in juvenile or adult CML patients.
Notwithstanding that ITDs are the most common Flt3 mutations, other mutations 
in the flt3-gene have been reported as well. The observation of  Glover et al.125 that 
mutation of  the Asp802 in the activating loop of  c-Fms and similar mutations in the 
activating loop of  c-kit113 result in factor-independent growth of  the mouse progeni-
tor cell line FDC-P1, led two independent groups to investigate mutations in Asp835 
of  Flt3126,127. Both groups reported the presence of  point mutations in this codon in 
about 7% of  AML patients. Of  these single base mutations the replacement of  aspar-
tic acid to valine is the most common, though other mutations involving the hydro-
phobic amino-acids tyrosine and alanine have been reported122,128. Although all Asp835 
mutations were shown to result in constitutive activation with the ability to transform 
32D cells127 the effects of  these mutations on the signal transduction pathways remain 
to be elucidated. In contrast to the ITDs in Flt3, the Asp835 mutations have not been 
linked to increased white blood cell counts and their influence on patient prognosis 
currently remains unclear129.
1.3.2. c-Kit
Human c-Kit (CD117) encodes the receptor for stem cell factor (SCF, also known as: 
Kit ligand, Steel Factor or Mast Cell Growth Factor). The gene encoding c-Kit was 
identified as the human counterpart of  v-kit, a viral gene from the HZ4 feline sarcoma 
virus130. Within the human hematopoietic system c-Kit is expressed on approximately 
70% of  the CD34+ cells in the bone marrow, including the more committed lineage-
restricted progenitor cells and the more primitive long-term culture initiating cells131,132. 
Cloning of  the loci for Dominant white spotting (W) and Steel (Sl) present in natural 
mouse mutants led to the identification of  mouse c-kit and it’s ligand133,134. Loss-of-
function mutations at either the W or Sl locus results in reduced thymic cellularity, de-
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pletion of  mast cells and erythroid progenitors resulting in macrocytic anemia in these 
animals. In addition there is hypopigmentation and male infertility. The ligand of  c-Kit 
is most commonly expressed as a bivalent dimer of  which both membrane bound and 
soluble isoforms exist135. The ligand for c-Kit is known as stem cell factor as it sup-
ports the survival and self-renewal of  HSC. In synergy with Epo it stimulates the pro-
liferation of  erythroid progenitors, and in synergy with TPO and other cytokines it 
promotes megakaryocytic growth and differentiation136. 
There is ample evidence that mutations in c-Kit are involved in a number of  human 
hematopoietic malignancies. The most common mutation found in the c-Kit gene is 
an amino-acid substitution at codon 816 in the juxtamembrane domain, substituting 
an aspartic acid for valine137. This mutation, resulting in constitutive activation of  the 
receptor has been reported in patients with mastocytosis138 and in patients with germ 
cell tumors139 or myelodysplasia140. More intriguingly, these and other mutations of  the 
same codon have also been linked to AML with an inv(16) or t(8;21) karyotype141. In 
1999 Gari et al.142 reported a series of  exon 8 deletion-plus-insertion mutations with 
a loss of  Asp419 (located in the fifth Ig-like domain), present in one third of  patients 
with AML-M4eo and inv(16). In AML with t(8;21) Care et al.143 reported the presence 
of  Asp419 and Asp816 mutations in 2.1% and 10.6% of  cases respectively. The ap-
parent link between mutations in c-Kit and AML1-CBFβ has led to speculation about 
the role of  these proteins in the pathology of  AML. Recent studies144 have shown that 
mutation of  transcription factors in it self  is not sufficient to induce a leukemic phe-
notype, it could well be that the additional mutations in c-kit function as a second-hit 
with anti-apoptotic or proliferative effects.
1.3.3. c-Fms
The human c-Fms (CD115) is the cellular homologue of  the viral v-fms. In addition 
to the cells of  the monocyte/macrophage lineage in the hematopoietic system it is 
expressed on pre-B cells, placental throphoblasts, neurons in the CNS and microglial 
cells145-147. The importance of  c-Fms in the monocyte/macrophage lineage has been 
demonstrated in the CSF-1 mutant op/op-mouse148. This osteopetrotic mouse has an 
impaired bone remodelling due to the absence of  osteoclasts. In these mice also other 
types of  phagocytes, including macrophages, are depleted from liver, kidney, spleen 
and gut. However, macrophages for the lymph nodes remain relatively normal. A simi-
lar, yet more pronounced phenotype is observed in c-Fms deficient mice. Enforced 
expression of  Bcl-2 in monocytes from the op/op mice can rescue macrophages and 
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partially reverses the osteopetrosis, suggesting that CSF-1/c-Fms signalling provides a 
survival signal to cells149.  
In 1990 a number of  groups reported the presence of  point mutations in c-fms in 
around 18% of  AML cases and 15% of  MDS cases150,151. Recent studies using more 
sensitive techniques failed to corroborate these results152. On the other hand, allelic 
loss of  c-Fms has been reported in refractory anemia and in 5q- associated MDS153. 
Yet, these studies can not exclude the role of  other genes located on this arm of  the 
chromosome. Altogether, the role of  c-Fms in leukemogenesis for the time being re-
mains controversial.
1.3.4. PDGFR
The PDGF receptors α and β are two highly related RTKs. Whilst the Tk-domains 
have around 80% sequence homology the c-terminal domains only share around 27% 
homology154. The ligands for PDGFR-β, PDGF AB or BB are potent stimulators 
of  mesenchymal cell proliferation and differentiation and play a fundamental role in 
wound healing155. PDGFR-β has also been detected on a number of  hematopoiet-
ic cells, including multipotent stem cells, mast cells, B and T-lymphocytes and NK-
cells156,157. Yet, PDGF is only able to stimulate the growth of  primitive progenitors 
and erythroid precursors in unsorted bone marrow cultures, most likely by stimulat-
ing the release of  other factors from stromal cells158. In 1994 Golub et al.159 reported a 
t(5;12)(q31;p13) occurring in a substantial fraction of   chronic myelomonocytic leuke-
mia (CMML). This translocation resulted in the TEL/PDGFRβ fusion protein. The 
pathogenicity of  this fusion gene is dependent on PDGFR activity as PDGFR-specific 
kinase inhibitors block the action of  the fusion protein in vitro160. Apart from this mu-
tation also other oncogenic fusion proteins involving PDGFRβ (e.g. t(5;10)(q33;q21) 
and t(5;17)(q33;p13)) have been reported in hematological malignancies161-163.
Recently, it has been suggested that the hypereosinophilic syndrome may result from 
a novel, imatinib sensitive, fusion tyrosine kinase - FIP1L1-PDGFRα - that is a con-
sequence of  an interstitial chromosomal deletion164. In contrast to the other Class III 
RTKs, no point mutations have been reported which result in oncogenic variants of  
the PDGFRs. 
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1.4. Outline of this thesis
Late in 1996, the paper of  Nakao et al.109 in which ITDs in Flt3 were first presented 
aroused our interest. As little was known about the biological characteristics and clini-
cal relevance of  Flt3/ITD we performed some pilot cultures which showed that AML 
samples with Flt3/ITD had a reduced in vitro proliferation when compared to Flt3-
Wildtype (Flt3/WT) AML. This led us to further characterise these mutations, the 
main aim of  the experiments described in this thesis. After an optimisation of  the cul-
ture conditions we investigated the effects of  the presence of  Flt3/ITDs on the nu-
cleated cell production in long-term, stroma supported, cultures of  AML cells, either 
without the addition of  exogenous cytokines or in the presence of  a combination of  
IL-3 and G-CSF or a combination of  IL-6, SCF, TPO and FL (Chapter 2 of  this the-
sis). We also investigated the impact of  Flt3/ITDs on the proliferation of  AML cells 
in short-term in vitro cultures in response to a panel of  cytokines. 
Focussing on the leukemic progenitor cell population we investigated the outgrowth 
of  Flt3/ITD AML in the immunodefiecient NOD/SCID mouse, a model which al-
lows for the in vivo outgrowth of  human AML progenitors165,166, whilst in vitro the 
leukemic progenitor cell subsets were assayed using the leukemic cobblestone area 
forming cell assay (L-CAFC)167 (Chapter 3 of  this thesis). As Flt3/ITDs were present 
in around 25% of  our AML samples, and thus potentially clinically very interesting, 
we also investigated the clinical characteristics of  Flt3/ITD AML with regard to initial 
therapy response, leukemia free survival and overall survival (also Chapter 3 of  this 
thesis). In view of  the reduced proliferation we observed in both short- and long-term 
culture, we speculated that Flt3/ITD might exert its effects on patient prognosis by 
inducing an anomalous organ distribution rather than inducing an increased prolif-
erative potential. Recently it has been shown that in both normal hematopoietic cells 
and AML the CXCR-4 expression correlates with the SDF-1 induced chemotaxis168,169, 
suggesting that SDF-1/CXCR-4 might be involved in the trafficking of  leukemic cells. 
Hence, we analysed the SDF-1 induced chemotaxis and the expression of  CXCR-4 on 
Flt3/ITD and Flt3/WT AML (Chapter 4). 
In chapter 5 we investigated whether exclusion of  Flt3/ITD AML would lead to a bet-
ter correlation between the cytokine-induced proliferation and patient prognosis. In 
this study we specifically focussed on further distinguishing the prognosis of  patients 
who, based on cytogenetics, were currently assigned to the intermediate risk group, the 
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group of  patients who might benefit most of  further risk assessment. 
One of  the assays used throughout this study has been the the transplantation of  hu-
man AML cells in the NOD/SCID mouse model. The nonobese diabetic (NOD) / 
LtSz scid/scid strain appears to be most useful in allowing the engraftment of  human 
AML cells. However, the large variability in ability to engraft and the levels of  engraft-
ment reached have not been explained. To address these issues we have investigated 
the NOD/SCID repopulating ability of  27 newly diagnosed AML samples (Chapter 
6 of  this thesis).  
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2.1. Abstract
Recently in-frame internal tandem duplications have been reported within the regions 
coding for the juxtamembrane through the first tyrosine kinase domain of  the Flt3 
gene. These duplications have been reported to lead to autophosphorylation of  the 
receptor. In this study we investigated the effect of  such mutations in the Flt3 gene on 
the in vitro proliferation of  human acute myeloid leukemia cells. 
The mutations were detected in 10 out of  59 AML bone marrow samples analysed and 
were not restricted to a specific FAB-class or cytogenetic aberration. PCR analysis of  
those samples showed all mutations to be present in exon 11 of  the gene. 
Whilst samples without a mutation of  the Flt3 gene showed an increased cell produc-
tion in response to either Il-3 and G-CSF or Il-6, SCF, TPO and Flt3l in long-term 
stroma supported cultures, mutant samples failed to do so. 
As we could not find a relation between the absence of  a response and either FAB-
class or cytogenetic aberrations we interpret these results as an indication that the in-
ternal tandem duplications in the Flt3 gene are the prime cause of  this unresponsive-
ness. Though our study does not explain the mechanism by which these mutations 
cause this unresponsiveness it does suggest that AML cells need a wildtype Flt3 for 
optimal in vitro proliferation.
2.2. Introduction
In normal hematopoiesis proliferation and differentiation is regulated by highly spe-
cific growth factor / growth factor receptor interactions1,2. 
The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) 
or fetal liver tyrosine kinase-2 (FLK-2)3-5 belongs to the group of   receptor tyrosine 
kinases (RTKs), which also include the receptors c-kit (the receptor for Kit-ligand or 
stem cell factor) and c-fms (the receptor for CSF-1). The RTKs have similar structural 
characteristics such as the presence of  five Ig-like domains in their extracellular region. 
Signals generated by ligand-induced dimerisation of  these receptors involve tyrosine 
phosphorylation of  certain regions of  the receptor and activation of  cellular tyrosine 
kinases. 
Whilst a large proportion of  acute myeloid leukemias (AML) has been found to ex-
press c-kit and c-fms6-8 and these are absent on blast cells of  acute lymphoid leukemia, 
the potential role of  this class III receptor superfamily is still unclear.
Flt3 ligand (Flt3l) and Flt3 are both expressed on B-ALL and AML cells9-12 as wells as 
on normal progenitor cells13-15. 
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Recently internal tandem duplications (ITDs) were reported in the part of  the flt3 
gene coding for the juxtamembrane (JM) through first tyrosine kinase (TK-1) domains 
of  the protein. Flt3/ITD’s appeared to be present in 17-20% of  AML patients16,17 as 
well as in leukemic transformation of  myelodysplasia18, including 20% of  patients with 
acute promyelocytic leukemia (APL)19. However these types of  mutations have not 
been found in chronic myeloid leukemia (CML) or in CML blast crisis20, nor have they 
been reported in cells of  normal individuals. 
Kiyoi et al.21 have shown that elongation of  the JM domain causes ligand-independent 
dimerisation of  the mutant receptor, thus resulting in a constitutive activation. This ef-
fect was seen in both mutant/mutant and in mutant/wildtype dimers of  the receptor. 
Immunoprecipitation studies of  those mutant receptors showed evidence for a con-
formational change in the C-terminal region of  the mutant receptor. 
In the present study we investigated whether Flt3/ITD’s would affect the proliferative 
capacity of  leukemic cells on stroma-supported cultures.  In addition we also inves-
tigated whether a possible effect could be abrogated or enhanced by the addition of  
cytokines including Il-3 and G-CSF or Il-6, SCF, TPO and Flt3l.
We found that the presence of  the mutation in 10 of  30 AML-samples investigated 
correlated with a significant reduction in the ability to generate non-adherent cells dur-
ing the entire culture period. This effect was most profound during weeks two and 
three of  the culture period when most active proliferation was observed, while it was 
not affected by the cytokine combinations tested. We also found that both the muta-
tion and its effect in the cultures were not correlated to either a specific FAB classifica-
tion or cytogenetic background of  the sample.
2.3. Materials and methods
Patient samples
Bone marrow cells were obtained after informed consent of  patients with AML. Cases 
were classified according to the French-American-British committee (FAB)22. Mono-
nuclear cells were isolated by ficoll separation followed by T-cell depletion, typically 
resulting in a population containing over 95 percent blasts.  After isolation cells were 
subjected to controlled freezing and stored in liquid nitrogen. Before use cells were 
thawed by stepwise dilution in Iscoves modified Dulbecco’s medium (IMDM, Gibco, 
Breda, The Netherlands) containing 1% BSA. After thawing viability varied between 
70 and 90 percent as assessed by dye exclusion.
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Determination of Flt3 mutants
All AML samples were analysed for mutations in exons 11 and/or 12 of  the Flt3 gene 
by using a modified PCR procedure as described elsewhere16 using the following prim-
er sets: 11F (5’-CAATTTAGGTATGAAAGCC-3’ ) , 11R (5’-CAAACTCTAAATTT-
TCTCT-3’) covering the complete exon 11 and 12F (5’-TGTCTTTGCAGGGAAG-
GTTAC-3’) and  12R(5’-GTACCTTTCAGCATTTTGAC-3’) covering exon 12 of  the 
gene. These exons 11 and 12 allowed us to cover the whole JM and the first part of  the 
TK-1 domain where most of  the reported mutations are located.
Genomic DNA was prepared using a standard procedure23. Briefly DNA from around 
104 cells was amplified in a total of  50 µl reaction mixture, containing 1x PCR buffer, 
10 pM of  each primer, 10 mM dNTP’s and 0.5 U Taq polymerase (Supertaq, SpheroQ, 
Leiden, The Netherlands). Preheating of  the samples at 95oC was followed by amplifi-
cation for 35 cycles consisting of: 1 min. at 43 oC, 1 min. at 72 oC, 1 min. at 95 oC. Fol-
lowing these cycles a final extension at 72 oC was performed for 10 min.
PCR products were stained with SYBR green I (Molecular Probes, Leiden, The Neth-
erlands) and resolved on 3% agarose gel.
As a confirmation samples positive for a flt3-mutation were reanalysed in a second 
PCR using the primers 11F and 12R. 
Sequencing of patient samples with a mutated Flt3 gene
If  both PCR reactions using the 11F/11R and 11F/12R combinations resulted in an 
abnormal PCR product, this was purified from the gel using a JETsorb kit (Genomed, 
Bad Oeyenhausen, Germany). This purified PCR product was subjected to a second 
PCR using fluorescent ddNTP’s after which sequencing was carried out using an auto-
mated DNA sequencing system (ABI PRISM 310 genetic analyzer, Perkin Elmer Ap-
plied Biosystems, Foster City, CA, USA). 
Long-term culture of AML cells
To asses the optimal conditions for long term in-vitro growth of  the AML, we cul-
tured the samples under the following conditions: A) serum free Stem Cell Growth 
Medium (SCGM, Biowithaker, Alkmaar, The Netherlands) without stromal support; 
B) SCGM with support of  a stromal layer formed by the murine FBMD-1 cell line24 
and C) LTC-medium consisting of  IMDM, supplemented with 10% heat inactivated 
fetal calf  serum (Summit Biotechnology, Fort Collins, Co.), 5% horse serum (Gibco), 
β-mercaptoethanol (5x10-5 mol/l) and hydrocortisone-21-hemisuccinate ( 10-6 mol/l, 
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Sigma) in the presence of  a stromal layer. All of  the above media were supplemented 
with penicillin (100U/ml) and streptomycin (100 µg/ml). 
rhIl-3 (8 ng/ml), rhG-CSF (20 ng/ml) and rhIl-6 (100 ng/ml) were a generous gift of  
the Genetics Institute, Cambridge, MA, USA, rhSCF (50 ng/ml) and rhFlt3l (50 ng/
ml) were a gift of  Amgen, Thousand Oaks, CA and rhTPO (10 ng/ml) was a gift of  
Genentech. All cultures were performed in 6-well cluster plates (Costar, Cambridge, 
MA) at 37oC and 10% CO
2
 in a humidified atmosphere. Volumes were standardized at 
2 ml/well. Weekly half  of  the medium was replaced and non-adherent nucleated cells 
were counted.
Detection of AML cells in culture
If  numbers of  cultured cells produced allowed us, we determined their leukemic or 
normal hematopoietic background. This was done by May-Grunwald-Giemsa staining 
of  cytospin preparations taken from the cultures. The lack of  terminal differentiation 
and their strong resemblance to the original cell inoculum strongly suggested a leuke-
mic origin. 
Statistical analysis
Statistical analysis of  the data was performed using the SPSS software package (SPSS 
Inc., Chicago Il.). Significance of  differences was determined by the non-parametri-
cal Mann-Whitney U test. Values were considered significant if  p-values were below 
0.05.
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Patient
No.
Sex Age FAB 
Cytogenetic
aberrations
Flt3/ ITD
1 male 70 M5 +
2 male 69 M0 -y +
3 male 65 M2 +
4 male 73 M2 +
5 female 50 M2 t(8:21) +
6 male 62 M5 +
7 female 67 M2 2q- +
8 male 50 M5 +
9 female 34 M5 +8 +
10 male 29 M3 t(15:17),+8 +
11 female 68 M2 +8 -
12 female 69 M4 7q-,+8 -
13 female 77 M0 7q-,+8 -
14 male 50 M2 +8 -
15 male 74 M0 -5 -
16 female 35 M2 t(8:21) -
17 male 40 M1 -
18 male 62 M0 -
19 male 19 M1 -
20 female 21 M3 t(15:17) -
21 female 69 M1 -
22 female 28 M2 -
23 female 61 M2 +4,+13,+14 -
24 male 39 M2 t(8:21) -
25 male 16 M4 -
26 female 78 M4 -
27 female 46 M5 -
28 female 54 M5 7q- -
29 male 51 M5 -
30 male 49 M5 +8 -
Table 1: Patient distribution
A total of  30 AML patient samples were included in this study. Patients 
were selected to give a good representation through out the FAB classes. 
Cytogenetics were determined for all samples, cytogenetic abnormalities 
are included if  observed.
Ten patients were selected on basis of  the presence of  an internal tandem 
duplication in exon 11 of  the Flt3 gene as determined by exon 11 specific 
PCR.
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2.4. Results
Screening for the Flt3 mutation
A total of  59 bone marrow samples from patients with AML were screened for the 
presence of  a Flt3 mutation. A total of  10 patients (17%) were found to be positive. 
All mutations found were in the exon 11 region of  the gene whilst none were found 
in exon 12 (data not shown). All patients, except for patient 2 who had a homozygous 
mutation, showed a heterozygous mutation with both normal and mutated alleles de-
tectable by PCR. The mutation was randomly distributed over the FAB classes and did 
not show a correlation with any known cytogenetic aberration. 
As we were not aware of  any reports on the presence of  these types of  mutations 
in the normal population we also checked 46 healthy volunteers. No mutations were 
found in these samples, thus reducing the possibility that these mutations reflect gene 
polymorphisms.
In this study the 10 AML-patients with the mutation and 20 AML-patients without 
such a mutation were more extensively studied. Patient details are shown in Table 1.
The sequence analysis of  the Flt3 mutant samples (Table 2) shows tandem duplica-
tions varying in length from 10 to 26 amino acids (30-78 bp). All mutations were re-
stricted to the JM domain of  the receptor. Four out of  nine mutant samples show 
the same location for the start of  the mutation whilst all others differ in their starting 
position. Patient number 7 starts with a valine to leucine mutation caused by a G to C 
point mutation in the DNA. 
All ITD’s have the duplication of  the putative SH2 binding motif  YFYV as a common 
factor. Patients 2,3,6 and 10 also have a duplication of  a second putative SH2 binding 
motif  YEYD. The involvement of  these motifs in the binding of  SH2-containing sig-
nalling molecules by Flt3 however remains to be elucidated.
Selection of the optimal culture conditions
To determine the optimal conditions for long-term culture the cells were grown in 
serum-free medium, with or without support of  an adherent FBMD-1 stromal layer 
or in LTC-medium (including 10% FCS and 5% HS) on a stromal layer. As shown 
in Fig. 1, after three weeks of  culture, the stroma-supported cultures produced more 
cells than did the stroma-free cultures. This suggests a supporting role for stroma in 
maintaining long-term cultures of  AML cells.  In contrast to the cultures with stromal 
support, in stroma-free cultures cell production ceased between week 4 and 5 of  cul-
ture. Stroma-supported cultures maintained production until the end of  the 8-week 
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observation period (data not shown). As the most optimal growth was observed in se-
rum-containing stroma-supported cultures we performed all subsequent studies under 
these conditions. 
Patient   duplicated amino acid sequence   Length
  No.
1                EYFYVDFREY    10 AA
2           QLQMVQVTGSSDNEYFYVDFREYEYD          26 AA
3  QLQMVQVTGSSDNEYFYVDFREYEYD          26 AA
4  QLQMVQVTGSSDNEYFYVDF     20 AA
5  QLQMVQVTGSSDNEYFYVDFRE    22 AA
6      SSDNEYFYVDFREYEYD   17 AA
7                              LTGSSDNEYFYVDFREY    17 AA
8         not done
9     YESQLQMVQVTGSSDNEYFYVDFREY                         26 AA
10    GSSDNEYFYVDFREYEYDLKWEF    23 AA
Exon 11 wild type
QFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEF
Of  the 10 patients positive for Flt3/ITD’s by PCR the exact nature of  the mutations was deter-
mined by sequence analysis of  exon 11 of  the Flt3 gene. We were able to analyse 9 out 10 patients. 
This table shows the duplicated amino acid sequence found in these patients. L in patient 7 depicts 
a valine to leucine mutation in the duplicated sequence. Boxed A.A. sequences in the wild type 
sequence represent possible SH2 binding domains which might be involved in binding of  SH2-
containing cytoplasmic signalling proteins.
Table 2: Sequence analysis of the Flt3/ITD’s
Effect of the Flt3 mutation on the production of non-adherent cells
At week one of  culture only few samples showed a non-adherent (NA) nucleated cell 
production above the input value of  1x105 cells/well (Table 3). With increasing culture 
time the various samples showed an increased variability in cumulative NA cell produc-
tion. This is most clear in Il-3 and G-CSF containing cultures at week eight where the 
lowest cumulative NA cell production, (patient 3) was equal to the input value whilst 
the highest (patient 11) was 3.9x1011 cells/well. In the absence of  exogenous cytokines 
we observed a distinct group of  samples with a significant (0.030 > p > 0.001) higher 
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Patient 
No.
No GF Il-3, G-CSF Il-6, SCF, TPO, Flt3l
*1 3 8 1 3 8 1 3 8
1 @0.1 0.2 2.2 0.3 0.3 - 0.7 1.1 47
2 0.1 0.1 2.8 0.1 0.1 - 0.1 0.1 7
3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
4 0.1 0.3 8 0.1 0.2 - 0.1 0.8 2400
5 0.1 0.9 20 0.1 1 740 0.1 1.6 16
6 0.1 1.4 24 0.1 2 210 0.1 1 43
7 0.1 1.5 8.5 0.1 2 25 0.1 0.3 28
8 0.1 0.1 7.7 0.1 0.73 140 0.2 0.3 10
9 0.1 0.1 14 0.1 0.1 14 0.1 0.9 110
10 0.1 2.4 - 0.1 3.4 460 0.1 3.7 480
11 0.3 4 13000 0.2 37 390000 0.1 36 -
12 0.1 8.7 21000 0.1 12 66000 0.1 29 6600
13 0.1 2.7 35000 0.1 11 - 0.1 38 14000
14 0.1 10 33000 0.1 4.8 34000 0.1 6.2 -
15 0.1 1.6 17 0.1 5.4 7800 0.2 2.4 4400
16 0.1 0.5 49 0.1 0.9 50 0.1 0.8 54
17 0.1 0.3 12 0.2 3.3 10 0.1 1.3 4.1
18 0.1 0.3 9.1 0.1 0.3 14 0.2 0.5 13
19 0.1 0.7 9.6 0.2 1.1 12 0.6 1 8.7
20 0.1 0.3 13 0.1 1.1 14 0.1 1.5 25
21 0.1 11 - 0.2 72 - 0.1 56 -
22 0.1 0.8 - 0.1 0.4 - 0.1 0.7 -
23 0.1 0.3 37 0.1 1.9 15 0.1 0.4 22
24 0.1 0.2 24 0.1 5.2 54 0.13 1.1 22
25 0.1 0.2 19 0.1 2.7 35 0.15 0.8 31
26 0.1 2.1 53 0.1 23 579 0.60 65 493
27 0.1 3.5 210 0.1 6.3 320 0.1 4 33
28 0.1 6.5 56 0.7 16 50 3.6 5.6 40
29 0.1 0.8 - 0.1 0.9 43 0.1 35 54
30 0.1 0.8 - 0.1 0.2 146 0.1 3.1 107
Table 3: Cumulative non-adherent nucleated cell production 
Cultures were initiated with 105 nucleated cells/ well. Weekly half  of  the medium was re-
placed and non-adherent nucleated cells were counted. *culture time (weeks);  @ cumula-
tive non adherent cell production per well (x10-6); - time point not reached due to loss of  
culture (infection or detachment of  the stromal layer)
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cumulative NA cell production. This group was comprised of  patients 9 to 14 which 
all had a trisomy of  chromosome 8 as a common aberration. At weeks three and eight 
the cumulative NA cell production by the Flt3 mutant samples was significantly re-
duced in the groups without addition of  growth factors and in those containing Il-3 
and G-CSF (0.05 > p > 0.001). This reduction was also observed in the groups cul-
tured with Il-6, SCF, TPO and, although only significantly at week three.
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Figure 1: Effect of culture condition on the cumulative non-adherent nucleated cell 
production during three weeks of culture. 
All cultures were initiated with 105 nucleated cells/ well. Cells were either cultured in: SCGM without 
support of  a stromal layer and without serum (open bars); SCGM with support of  a stromal layer but 
without serum (grey bars) or in IMDM with support of  a stromal layer and serum (black bars). Values 
represent mean +/- SEM, N depicts the number of  AML samples tested.
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The weekly NA cell expansion, which is defined as the fold-increase between two 
weekly counts (Fig. 2), enables a better understanding of  the kinetics of  the cell pro-
duction. Expansion is maximal on weeks 2 and 3, irrespective of  the growth factors 
used. At this time point the expansion in the non-mutant population is significantly 
higher than in the mutant population (0.05 > p > 0.02) when cultured either with 
the addition of  Il-3 and G-CSF or without cytokine addition. No significant differ-
ences were found in the Il-6, SCF, TPO and Flt3l stimulated groups at week 3 but at 
week 2 the mutant population showed less expansion than the non-mutant popula-
tion (p=0.03). The analysis was repeated excluding the trisomy 8 samples as these are 
observed to grow more vigorously than the other samples (see table 3). Though this 
exclusion reduced the significance (0.05>p>0.04, data not shown) the differences be-
tween non-mutant and mutant groups remained. 
A selection of  the samples according to their FAB classification (Fig. 3) allowed a fur-
ther analysis of  the responses to cytokine addition between the mutant and non-mu-
tant groups. Although the effect of  cytokine addition was visible throughout all FAB 
classes we also noted different cytokine responses between samples of  specific FAB 
classes. In cultures that included Il-3 and G-CSF we observed a large expansion of  the 
E
xp
an
si
on
fa
ct
or
No growth factors
40
30
20
10
0
1 2 3 4 5 6 7 8
Il-3, G-CSF
40
30
20
10
0
1 2 3 4 5 6 7 8
Il-6, SCF, TPO, Flt3L
40
30
20
10
0
1 2 3 4 5 6 7 8
Weeks in culture
Figure 2: Effect of Flt3 exon 11 mutation 
on the weekly expansion of the total AML 
population.
The expansion factor is defined as the fold increase 
between two consecutive weekly counts. The hori-
zontal black lines in these figures represent the me-
dian weekly expansion factors, Shaded bars represent 
the interquartile range, whilst the error bars indicate 
extreme cases, eventual outlayers are marked by an 
asterix. Light shaded bars represent non-mutant sam-
ples, Dark shaded bars the mutant samples.
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non-mutant samples in the M1, M2 and M5 groups. Remarkably the Flt3 mutants with-
in these groups did not respond. In the two-week cultures that contained Il-6, SCF, 
TPO and Flt3l a clear response of  the non-mutant samples was seen in FAB classes 
M0, M1, M2 and M4. The mutant samples showed no significant response to the ad-
dition of  cytokines in any of  the FAB classes.
As the subdivision of  AML into FAB classes is mainly based on morphological and 
cytological criteria, we also classified the samples according to their cytogenetic aber-
rations. As is apparent from Table 1, most cytogenetic aberrations are present in a low 
frequency. To allow for analysis we tentatively defined groups that contain multiple 
aberrations, i.e.: (A) samples without any known aberrations; (B) samples exclusively 
containing one or more deletions; (C) samples exclusively containing additions; (D) 
translocations; (E) samples containing combinations of  additions and deletions and 
(F) samples containing additions and translocations. Most samples were present in the 
groups with either no or a single type of  aberration. 
At week two of  culture, proliferative responses to cytokine addition were almost ex-
clusively observed in the non-mutant samples within the cytogenetics groups B, C, D 
and E (Fig. 4). Group B responded dramatically to Il-3 and G-CSF (median increase 18 
fold) whilst group E showed a large response in the presence of  Il-6, SCF, TPO and 
Flt3l. Groups C and D responded more or less equally to both cytokine combinations. 
Again, in none of  the groups the mutant samples responded to cytokine addition. Af-
ter three weeks of  culture only limited response to cytokine addition was observed in 
the different cytogenetic groups. However in group A, lacking cytogenetic aberrations, 
the response to cytokines increased when compared to week two. Again no significant 
responses of  the mutant groups were seen with the exception of  cytogenetics group 
C when cultured in the presence of  Il-6, SCF, TPO and Flt3l and in group D where 
the mutant samples showed a higher median expansion compared to the non-mutant 
samples at this time point. 
2.5. Discussion.
To our knowledge this is the first report suggesting a proliferative defect of  AML cells 
carrying internal tandem duplications in exon 11 of  the Flt3 gene. While non-mutant 
samples showed increased NA cell production in response to cytokine addition espe-
cially in week two and three of  stroma-supported cultures, Flt3 mutant cells failed to 
do so. Other receptor mutations have been reported to have severe effects on prolif-
eration or differentiation as well. As an example, specific truncations of  the cytoplas-
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mic domain of  the human G-CSF-receptor gene cause almost complete abrogation of  
granulocytic differentiation and are associated with a propensity of  affected individu-
als towards myelodysplasia and leukemia25,26.
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Figure 3: Effect of the Flt3 exon 11 mutation during weeks 2 and 3 of culture in rela-
tion to FAB-classification. 
The horizontal black lines in these figures represent the median weekly expansion factors, Shaded bars 
represent the interquartile range, whilst the error bars indicate extreme cases, eventual outlayers are 
marked by an asterix with the sample number.
Numbers below the x-axis depict the number of  cases within each group.
Light shaded bars represent non-mutant samples, Dark shaded bars the mutant samples. 
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Figure 4: Effect of the Flt3 exon 11 mutation during weeks 2 and 3 of culture in rela-
tion to their cytogenetic background. 
Cytogenetic groups: (A) normal; (B) deletions; (C) additions; (D) translocations; (E) deletions and addi-
tions; (F) additions and translocations. The horizontal black lines in these figures represent the median 
weekly expansion factors, Shaded bars represent the interquartile range, whilst the error bars indicate 
extreme cases, eventual outlayers are marked by an asterix with the sample number.
Numbers below the x-axis depict the number of  cases within each group.
Light shaded bars represent non-mutant samples, Dark shaded bars the mutant samples. 
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In our study we have attempted to see whether the observed low proliferative ability 
and unresponsiveness of  Flt3 mutant samples to exogenous cytokines is related to ei-
ther FAB class or cytogenetic aberrations. As we did not observe such a relation, we 
interpret this as an indication that the Flt3 gene ITD’s are the prime cause of  the de-
fective proliferative response rather than another defect in a specific AML subclass. We 
realise that all M3 and most M2 samples are included in the cytogenetic translocation 
group and that alternative classifications may, or may not, reveal a possible linkage of  
Flt3 gene ITD’s with an AML subtype.
It is surprising that the cells carrying the Flt3/ITD’s, in addition to Flt3L, showed 
unresponsiveness to a series of  cytokines, including Il-3, Il-6, G-CSF, SCF and TPO. 
Our initial experiments indicated that AML cells could only be propagated ex vivo for 
a short time in serum-containing medium complemented with these cytokines, while 
stromal support was required for long-term cell production. Although stromal cells 
elaborate low concentrations of  some of  the cytokines employed in our study (i.e. Il-6, 
SCF and Flt3L), the stromal support is presumably contributing to a different presen-
tation of  these growth factors (e.g. glycosaminoglycans), or the elaboration of  alterna-
tive cytokines, inhibitors and/or expression cell-adhesion molecules.
Our study does not explain the mechanism by which ITD’s in the Flt3 receptor gene 
cause a defect in the proliferative response of  mutant AML cells. It seems, however, 
plausible to conclude that these mutations do not only affect the response to the Flt3L, 
but in addition that to other cytokines. This effect of  the Flt3/ITD’s is unlikely caused 
by a defect in a common intracellular signalling cascade may rather be the result of  
either a disturbed synergy between Flt3 and other cytokines, or a disturbance in the 
sequence of  cytokine signals which should lead to proliferation. As far as the limited 
number of  analyses permit us to speculate, Flt3 mutant samples grow less well on a 
stromal layer in the absence of  exogenous cytokines than do non-mutant samples (Fig. 
3a and 4a), an observation suggesting that AML cells need a wild-type Flt3 receptor 
for optimal proliferation. Alternatively, if  the Flt3 mutant samples would contain rela-
tively less AML progenitor cells than do normal samples, this may lead to reduced cell 
production and therefore an apparently diminished cytokine response. This alternative 
could be substantiated by assessing the actual number of  AML stem and progenitor 
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cells present in the starting population by leukemic CAFC and LTC assays27,28  which 
will be included in a subsequent study. 
Another interesting observation was that AML samples with trisomy of  chromosome 
8 showed a much higher proliferative activity than did other AML samples, irrespec-
tively of  the presence of  a Flt3 gene ITD. A possible explanation for this observation 
is the over-expression of  c-myc  located on chromosome 8q24. Over-expression of  
c-myc has been described for immortalised tumor cell lines, while c-myc down-regula-
tion in these cells often leads to differentiation29-32. This observation suggests that se-
lection of  a small AML subset may strongly bias the results obtained.
The presently described functional defects in AML cells caused by Flt3 gene ITD’s 
may contribute to our understanding of  how a single cytokine receptor gene defect 
may influence the response to other cytokines and the potential role this might have in 
the development and progression of  leukemia.   
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3.1. Abstract
Internal tandem duplications of  the Flt3 gene (Flt3/ITDs) are present in about 18 
percent of  all AML cases and are therefore one of  the most frequent somatic gene 
mutations in AML. Little is known about the role of  Flt3/ITDs in leukemogenesis 
or their clinical relevance. In this study we compared 18 samples with Flt3/ITDs and 
63 AML samples without these mutations with respect to clinical prognosis, cytokine 
responsiveness, progenitor cell content and repopulation in the NOD/SCID mouse. 
We found that in patients with a mutation CR rates are reduced (p=0.03) and relapse 
rates are increased (p=0.01), indicating the prognostic importance of  Flt3/ITDs. This 
is also emphasized by the finding that in patients under the age of  60 as well as in 
older patients the event-free survival was more unfavourable for the mutant patients 
(p=0.003 and p=0.03 respectively).
At diagnosis Flt3/ITD and non-mutant AML bone marrow samples did not differ in 
their progenitor/stem cell frequencies. Cobblestone area forming cell (CAFC) subsets 
showed a similar frequency distribution in mutant and non-mutant samples. 
In 7-day liquid cultures, Flt3/ITD samples showed a reduced growth in response to a 
variety of  myeloid growth factors. In contrast, Flt3/ITD samples displayed a higher 
ability to engraft the NOD/SCID bone marrow with leukemic cells.
Together these data show that the Flt3/ITD represents an important diagnos-
tic marker for patient prognosis, and that the presence of  these mutations is as-
sociated with altered proliferative ability of  progenitors in vivo and in vitro. 
3.2. Introduction
The fms-like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) 
or fetal liver tyrosine kinase-2 (FLK-2)
1-4
, belongs to the group of  class III receptor 
tyrosine kinases (RTKs), which also include the receptors c-kit and c-fms. Signals gen-
erated by ligand-induced dimerisation of  these receptors involve tyrosine phosphor-
ylation of  certain regions of  the receptor and activation of  cellular tyrosine kinases. 
Whilst a large proportion of  acute myeloid leukemias (AML) have been found to ex-
press class III RTKs
5-8 their potential role in leukemia is still unclear. Flt3 ligand (Flt3l) 
and Flt3 are both expressed on precursor-B ALL and AML cells
9-12
 as well as on nor-
mal progenitor cells
13-16
. 
In 17-20% of  AML patients in the Japanese
17
 and west-European
18
 population, as well 
as in patients with leukemic transformation of  myelodysplasia
19
, internal tandem du-
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plications (ITDs) have been reported in the part of  the Flt3 gene coding for the jux-
tamembrane (JM) through first tyrosine kinase (TK-1) domains of  the protein. These 
types of  mutations have not been found in acute lymphoid leukemia(ALL), chronic 
myeloid leukemia (CML), blast crisis CML, nor have they been reported in cells of  
normal individuals. In ALL Flt3/ITDs have only been reported in two patients which 
at closer examination were considered to be biphenotypic leukemia
20
. 
Though Flt3/ITDs are also observed in childhood AML their frequency is significant-
ly lower when compared to adult AML. Frequencies reported for the Japanese child-
hood AML population vary between 11% (Kondo et al.,  7 out of  64 cases studied)
21
 
and 5.3% (Iwai et al., 5 out of  94 cases studied)
22
. A possible explanation for the ob-
served lower incidence in childhood AML could be that Flt3/ITDs results from ge-
nomic instability as was postulated by the latter authors.
Kiyoi et al.
23
 have shown that in COS-cells, transduced with cDNA encoding for Flt3/
ITDs, elongation of  the JM domain and ligand-independent dimerisation of  the mu-
tant receptor occurs, thus resulting in a constitutive activation. This effect was seen 
in both mutant/mutant and in mutant/wildtype dimers of  the receptor. Immunopre-
cipitation studies of  those mutant receptors showed evidence for a conformational 
change in the C-terminal region of  the mutant receptor. 
Recently we have shown
18
 that in comparison to non-mutant AML cells, cells with 
Flt3/ITDs have a reduced proliferative ability in stroma-supported cultures. This ef-
fect could not be abrogated by the addition of  cytokines to these cultures. We have 
now investigated whether the presence of  Flt3/ITDs in AML cases within the adult 
population correlated with (A) their short-term proliferative response to single cy-
tokine stimulation; (B) the ability of  these cells to engraft in the bone marrow of  im-
munodeficient mice (NOD/SCID)
24-26
 and (C) the frequency of  leukemic progeni-
tor and stem cells, as measured by a leukemic cobblestone area forming cell assay 
(L-CAFC)
27,28
. Furthermore, we have analysed whether the presence of  Flt3/ITDs 
in AML in the Dutch population of  patients predicts prognosis, as was recently pub-
lished for the Japanese population
29
.
3.3. Materials and methods
Patient samples
Diagnosis bone marrow samples of  patients with AML were obtained after informed 
consent. Cases were classified according to the French-American-British (FAB) com-
mittee recommendations
30
. Mononuclear cells were isolated by ficoll separation fol-
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lowed by T-cell depletion, typically resulting in a population containing over 95 percent 
blasts.  After isolation cells were subjected to controlled freezing and stored in liquid 
nitrogen. Before use cells were thawed by stepwise dilution in Iscoves Modified Dul-
becco’s medium (IMDM, Gibco, Breda, The Netherlands) containing 1% BSA. After 
thawing viability varied between 70 and 90 percent as assessed by dye exclusion. 
After diagnosis patients were treated according to studies of  the adult Dutch-Belgian 
Heamato-Oncology Group HOVON. Patients were treated according to protocols 
HOVON-29 (less then 60 yrs of  age, 27 patients)
31
, HOVON-4 (less then 60 yrs.,12 
patients)
32
, HOVON-31 (60 yrs+, 13 patients), AML-11 (60 yrs+, 12 patients)
33
 proto-
cols. Six patients received palliative treatment only and were therefore excluded form 
the survival analysis. In these protocols induction therapy included an anthracyclin and 
cytarabine and in patients less then 60 yrs allogeneic and autologous stem cell trans-
plantation or intensive chemotherapy for consolidation were applied as post-remission 
therapy. In the Hovon-29 study induction therapy consisted of  Ara-C (200 mg/m2) 
for 7 days combined for the last three days with Idarubicin (12 mg/m2) (Cycle I) fol-
lowed by a second cycle consisting of  Ara-C (6 days, 1000 mg/ m2) combined with 
Amsacrine (days 3-5, 120 mg/ m2). Half  of  the patients according to randomizing re-
ceived G-CSF (120 µg/m2, s.c.) during both cycles. Within the Hovon-4 protocol the 
induction therapy was equal to the Hovon-29 protocol except for the fact that in cycle 
I Daunomycin (45 mg/m2) was used instead of  Idarubicin. For the Hovon-31 pro-
tocol induction therapy consisted of  Ara-C 200 mg/m2 for 7 days combined for the 
first three days with Daunomycin (45 mg/m2) in arm 1 of  the study, or Daunomycin 
(35mg/m2) + PSC833 (10 mg/kg) in arm 2. Finally, in the AML-11 study induction 
therapy consisted of  Ara-C 200 mg/m2 for 7 days combined with Daunomycin 30 
mg/kg on days 1-3. 
Stratification according to karyotype-risk groups
As cytogenetic aberrations are thought to be one of  the most important prognostic 
factors for AML
34,35
 patients were stratified in three groups i.e. a good-risk group con-
sisting of  patients defined by a karyotype of  t(8;21), t(15;17) or inv(16); a poor-risk 
group defined by del(5), del(7), or deletions of  the q-arms of  these chromosomes, 
t(6,9), alterations in the 11q23 region or the presence of  multiple aberrations (more 
than 3) in the karyotype. All other karyotypic aberrations and the normal karyotype 
were included in an intermediate-risk group.
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Determination of Flt3 mutants
All AML samples were analysed for mutations in exons 11 and/or 12 of  the Flt3 gene 
by using a modified PCR procedure as described elsewhere17 
The use of  exon 11 and 12 specific primers allowed us to cover the whole JM and the 
first part of  the TK-1 domain where most of  the reported mutations are located.
Genomic DNA was prepared using a standard procedure36. Briefly, DNA from about 
104 cells was amplified in a total of  50 μl reaction mixture, containing single strength 
PCR buffer, 10 pM of  each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Su-
pertaq, SpheroQ, Leiden, The Netherlands). Preheating of  the samples at 95oC was 
followed by amplification for 35 cycles consisting of: 1 min. at 43 oC, 1 min. at 72 oC, 
1 min. at 95 oC. Following these cycles a final extension at 72 oC was performed for 
10 min. PCR products were stained with SYBR green I (Molecular Probes, Leiden, 
The Netherlands) and resolved on 3% agarose gel. As a confirmation samples positive 
for a Flt3-mutation were reanalyzed in a second PCR using the primers 11F and 12R. 
Sequencing of patient samples with a mutated Flt3 gene
If  both PCR reactions using the 11F/11R and 11F/12R combinations resulted in an 
abnormal PCR product, this was purified from the gel using a JETsorb kit (Genomed, 
Bad Oeyenhausen, Germany). This purified PCR product was subjected to a second 
PCR using fluorescent ddNTP’s after which sequencing was carried out using an auto-
mated DNA sequencing system (ABI PRISM 310 genetic analyzer, Perkin Elmer Ap-
plied Biosystems, Foster City, CA, USA). 
Short-term proliferative response to single cytokine stimulation
To determine the proliferative response of  AML samples to single cytokine stimula-
tion we used a thymidine incorporation assay. As monocytes are known to produce 
many cytokines and thus potentially may perturb the results we removed these cells 
prior to their use in culture by adhesion to plastic (1hr incubation at 37oC in alpha-
MEM (Gibco) + 1% BSA (Sigma, St. Louis, MO, USA). The non-adherent cells were 
plated in 96-well plates at a density of  2x104 cells/well in serum free medium
37
 and 
cultured for six days. The cytokines used were either hIL-3 (25ng/ml, Genetics Insti-
tute, Cambridge, MA, USA.), hGM-CSF (10ng/ml, Immunex, Seattle, WA, USA), hG-
CSF(100ng/ml, Amgen, Thousand Oaks, CA, USA), hM-CSF(100 U/ml, Genetics 
Institute) or hSCF(100 ng/ml, Amgen). After six days the cells were incubated over-
night with 0.1 µCi tritiated-thymidine (Amersham, Buckinhamshire, UK) per well and 
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harvested onto nitrocellulose filters. Thymidine incorporation was determined using a 
liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden) as counts per minute 
(CPM). All cultures were done in triplicate. 
The stimulation index was calculated by dividing the mean CPM of  the triplicate cul-
tures and the mean CPM of  a 30Gy irradiated control of  the sample.
Leukemic Cobblestone area forming cell assay
The cobblestone area forming cell assay was performed as described
38
. Briefly, conflu-
ent FBMD-1 stromal layers in 96-well plates (Costar, Cambridge, MA) were overlaid 
with AML cells in a limiting dilution setup. The cells were cultured in medium con-
sisting of  IMDM (Gibco) supplemented with 10% heat-inactivated fetal calf  serum 
(Summit Biotechnology, Fort Collins, Co.), 5% horse serum (Gibco), β-mercaptoetha-
nol (5x10-5 mol/l) and hydrocortisone-21-hemisuccinate ( 10-6 mol/l, Sigma). rhIl-3 (8 
ng/ml) and rhG-CSF (20 ng/ml) (both a generous gift of  the Genetics Institute) were 
added to the medium and all cultures were performed  at 37oC and 10% CO
2
 in a hu-
midified atmosphere. Input values were equivalent to 1x105 nucleated cells/well and 
12 dilutions three fold apart were used for each sample with 15 replicates per dilution. 
The percentage of   cells wells with at least one phase-dark clone (Cobblestone area, 
consisting of  at least 5 cells) beneath the stromal layer was determined weekly and 
leukemic CAFC (L-CAFC) frequencies were calculated using Poisson statistics
39
.
Based on evidence from murine correlation studies it is assumed that both normal and 
leukemic cobblestone areas that are observed late in culture are indicators of  primi-
tive long-term repopulating cell in vivo, whilst early appearing clones are indicators of  
transiently repopulating and less primitive cells.
The NOD/SCID mouse model
Among a variety of  immunodeficient mouse strains we and others have evaluated the 
nonobese diabetic (NOD) /LtSz scid/scid strain appears to be most useful in allow-
ing the engraftment of  human AML progenitors
40,41
. In contrast to the CB17/SCID 
strain, which is only defective in B- and T-cell function, this strain is characterized by 
an additional functional deficit in NK-cell function as well as defective antigen-pre-
senting cells and an absence of  circulating complement.
NOD/SCID mice were bred in the Erasmus animal facility and housed under speci-
fied pathogen free conditions, using laminar air flow units. Mice were supplied with 
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sterilized food and acidified tap water to which 100mg/l ciprofloxacine (Bayer AG, 
Leverkusen, Germany) was added. Both food and drink were available ad lib.
Before transplantation of  the AML cells the mice received a total body irradiation of  
3.5 Gy gamma radiation ( 137Cs source, Gammacell, Atomic Energy of  Canada, Ot-
tawa, Canada). Transplantation of  the AML cells was done by injecting 3x107 AML 
cells in the lateral tail vein.  After 30 days the mice were sacrificed by CO
2
 inhalation in 
accordance with the institutional animal research regulations.
Cell suspensions were made from both femora and used for flowcytometry.
Flowcytometry 
To determine the percentage of  AML cells in  bone marrow cell suspensions from 
mice that had been transplanted, cells were stained with  antibodies against the human 
common leukocyte antigen (CD45), CD34, CD33 and CD38 (CD45-FITC, CD38-
FITC, CD33-PE and CD34-APC, all obtained from Coulter Immunotech, Marseille, 
France) and measured using a FACScalibur (Becton Dickinson Immunocytometry sys-
tems, San Jose, CA, USA).  Analysis was done using the Cell Quest software package 
(Beckton Dickinson).  Erythrocytes were excluded from analysis by gating on  for-
ward and perpendicular light scatter whilst dead cells were excluded by staining with 
7-amino-actinomycin D  (7-AAD, Molecular Probes, Eugene, OR, USA). Human cells 
were considered to have engrafted when the percentage of  CD45-positive cells in 
the mouse bone marrow was at least 0.5%.  Because, in contrast to human umbilical 
cord blood cells, almost all samples expressed over 90% CD33 either in combination 
or absence of  CD38 we considered them to be of  leukemic origin. The only samples 
not abundantly expressing CD33 were the AML-M0 samples which, after passage in 
NOD/SCID, could be characterized by a high expression of  CD34 (50-100 %). 
Statistical analysis
Statistical analysis of  the data was performed using the SPSS software package (SPSS 
Inc., Chicago Il.). Significance of  differences for the proliferation, L-CAFC and SCID 
assays was determined by the non-parametrical Mann-Whitney U test. The Fisher’s ex-
act test for 2x2 tables was used to evaluate complete remission (CR) and relapse rates. 
For the survival analysis the Kaplan-Meier method of  the same software package was 
used. The Breslow test was used to check for equality of  the survival distributions. 
Overall survival was calculated from date of  diagnosis to date of  (leukemia-related) 
death. The leukemia-free survival (LFS) was calculated from date of  diagnosis to date 
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of  relapse or death. Patients not achieving CR we scored as having an LFS of  0.01. Pa-
tients dying from non-leukemia related causes during first CR were included until date 
of  death. In all evaluations values were considered significant if  p-values were below 
0.05.
3.4. Results
Characterization of patients
A total of  81 diagnosis samples (bone marrow) from patients with AML were screened 
for the presence of  a Flt3 mutation. Of  the samples 18 patients (22%) were found to 
have such a mutation. 
All Flt3/ITD mutations found were in the exon 11 region of  the gene whilst none 
were found in exon 12. However, sequence analysis showed an involvement of  one 
or more amino acids of  exon 12 in two of  the exon 11 mutant samples (see below). 
As previously shown
18,42
 the mutation was randomly distributed over the FAB classes 
while no correlation with any known cytogenetic aberration was observed. In most of  
the Flt3/ITD positive patients the mutation was present as a heterozygous mutation 
but in 4 cases the ITD appeared as a single aberrant band on gel, indicating the pres-
ence of  either as a homozygous mutation or, more likely, a hemizygous deletion of  the 
wildtype gene.
The characteristics of  18 AML-patients with the mutation and 63 AML-patients with-
out such a mutation included in this study are shown in Table 1.
Sequence analysis of  the Flt3 mutant samples (Table 2) showed tandem duplications 
varying in length from 10 to 35 amino acids (30-105 bp). All mutations were restricted 
to the JM domain of  the receptor. All ITDs included the duplication of  at least one 
putative SH2 binding motif  (YFYV and / or YEYDLK). Four patients additionally 
showed mutations in the amino acid (AA) sequence.  These mutations were either in 
the starting or terminal AA of  the duplicated sequence. The mutation in patient 1 was 
ending with a mutation of  the last two AA’s i.e. tyrosine and aspartate to serine and 
proline, respectively.  The mutation in patient number 7 was valine to leucine, in patient 
15 lysine to threonine, and in patient number 16 phenylalanine to leucine. Two patients 
showed an involvement of  the first (patient 14) or first and second (patient 12) AA of  
exon number 12.
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Table 1: Patient characteristics
Flt3/ITD
AML
 Flt3/wildtype
AML
Total number 18 63
Age
Mean (yr.)
Range (yr.)
<= 60 yr.
52.1
25-73
10
50.3
4-88
36
Gender
Male 
Female 
7
11
34
29
WBC
at diagnosis (x10-9)
Mean
Range
125
2-319
62
1-343
FAB Classification
Unclassified
M0
M1
M2
M3
M4
M5
0
1
2
4
2
3
6
2
4
11
15
4
14
13
Cytogenetic
risk group*
Good prognosis
Intermediate prognosis
Poor prognosis
2
16
0
6
50
6
Background of  
AML**
De novo AML
Secondary
Relapse
Unknown
14
2
2
0
45
9
3
6
Induction Therapy
Response***
CR
Failure
8
9
43
10
*Cytogenetic stratification was performed according to the criteria described in the 
materials and methods section. **Patients were devided into four classes on basis 
of  their AML background i.e. de Novo AML, if  the AML was not preceded by an-
other hematopoeitic disorder; Secondary, if  the AML originated from a previous 
hematological disorder such as MDS, or if  the patient had a previous history of  
exposure to chemo- or radiotherapy; Relapse, if  the sample was from a patient with 
a leukaemia relapse; unknown, if  non of  the other cases applied. *** For a total of  
70 patients we were able to define their response to therapy.  Patients were divided 
in two groups: patients who obtained complete remission (CR) and patients who 
either had a partial or no response to therapy (Failure).
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Clinical response and prognosis of AML patients with and without Flt3/ITD
All 70 patients of  whom we were able to obtain therapy response data were evaluated 
for their initial therapy response. From Table 1 it can be deduced that the CR rate of  
8/17 (47.1%) patients in the population with Flt3/ITD was significantly reduced when 
compared to that of  39/49 (79.6%) patients in the population without Flt3/ITDs 
(p=0.03). At a median follow up period of  23 months in the group without ITDs 
Table 2: Sequence analysis of the Flt3/ITDs
Patient
 No.   duplicated amino acid sequence   Length
1                YFYVDFREYESP   12AA
2           QLQMVQVTGSSDNEYFYVDFREYEYD          26 AA
3  QLQMVQVTGSSDNEYFYVDFREYEYD          26 AA
4                                     DFREYEYDLKWEFPRENLEF 20 AA
5  QLQMVQVTGSSDNEYFYVDFRE    22 AA
6              SSDNEYFYVDFREYEYD   17 AA
7                               LTGSSDNEYFYVDFREY    17 AA
8   Not done
9      YESQLQMVQVTGSSDNEYFYVDFREY                         26 AA
10           GSSDNEYFYVDFREYEYDLKWEF    23 AA
11                REYEYDLKWEFPRENLEF 18 AA
12   QVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGK 35 AA
13     YESQLQMVQVTGSSDNEYFYVDFRE    25 AA
14       VTGSSDNEYFYVDFREYEYDLKWEFPRENLEFG  33 AA
15            GSSDNEYFYVDFREYEYDLT   20 AA
16    QVTGSSDNEYFYVDFREYEYDLKWEFPRENLEL 33 AA
17            VTGSSDNEYFYVDFRE    16 AA
18            GSSDNEYFYVDF     22 AA
Exon 11 wild type
QFRYESQLQMVQVTGSSDNEYFYVDFREYEYDLKWEFPRENLEF
Of  17 out of  18 patients positive for Flt3/ITDs by PCR the exact nature of  the mutations was 
determined by sequence analysis of  exon 11 of  the Flt3 gene. This table shows the duplicated 
amino acid sequence found in these patients. Amino acids printed in italics reflect mutations 
(patients 1, 7, 15 and 16) or involvement of  exon 12 (patients 12 and 14). Boxed AA sequences 
in the wild type sequence represent  tentative binding domains for SH2-containing intracellular 
signalling proteins.
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10 of  the 39 (25.6%) patients who had achieved CR had relapsed, whilst 6 out of  8 
(75.0%) patients with ITDs had relapsed (p=0.01).
The overall survival (OS) curves (Fig. 1A) and leukemia-free survival (LFS) curves 
(Fig. 1B) clearly suggest a significant reduction in CR rate and prognosis by the pres-
ence of  Flt3/ITD in AML (p=0.002 for OS and 0.001 for LFS). Details for the LFS 
of  the mutant population are shown in table 3. As we are aware that a bias can be in-
troduced by comparing the total heterogeneous AML population, we also looked at 
the LFS for the two largest sub-populations that could be distinguished within our da-
taset, i.e. patients with de novo AML (Fig. 1C) and patients with an intermediate-risk 
karyotype (Fig. 1D). In both cases the differences still remained significant (p= 0.004 
and p=0.008 respectively). 
Patient 
No.
Time
to event
(Months)
Cause of  death
Cumulative 
EFS**
Standard Error
of  EFS**
1 0.01 Induction failure
2 0.01 Induction failure
3 0.01 Induction failure
4 0.01 Induction failure
5 0.01 Induction failure
6 0.01 Induction failure
7 0.01 Induction failure
9 0.01 Induction failure
10 0.01 Induction failure 0.4706 0.1211
11 1 Relapse 0.4118 0.1194
12 2 Relapse 0.3529 0.1159
13 7 Relapse 0.2941 0.1105
14 11 Alive
15 12 Relapse 0.2206 0.1045
16 15 Relapse 0.1471 0.0920
17 16 Dead CR1
18 20 Relapse 0.0000 0.0000
Table 3: Kaplan Meier Survival Table of the leukemia-free survival of the AML 
patients with Flt3/ITDs
* The survival indicator is the status of  the patient at that time point i.e.: CR = 
patient still in complete remission; Dead CR1 = patient died of  non-leukemic 
disease during the first complete remission. ** EFS = Event Free Survival
No survival data could be obtained for patient nr. 8.
Chapter 3
68
Internal tandem duplications in the Flt3-gene
69
As also age is known to be an important prognostic factor we divided the samples in 
two groups according to age (Fig. 2). In both the age group of  under 60 yr. (Fig. 2A) 
and over 60 yr. (Fig. 2B) the differences between the Flt3/ITD and non-mutant group 
with respect to LFS remained significant (p=0.003 and 0.03 respectively).
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Figure 1. Kaplan-Meier survival curves of the effect of Flt3/ITDs in AML.
Solid lines, Flt3/ITD negative samples, dashed lines Flt3/ITD positive population. Censored cases are 
marked by an asterisk.
Panel (A) cumulative overall survival of  all cases investigated; (B) cumulative leukemia-free survival of  
all cases; (C) leukemia free-survival based on a selection of  only de novo AML; (D) leukemia-free sur-
vival of  the population with intermediate-risk cytogenetics.
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Short term proliferative response of AML.
We have recently shown
18
 that the presence of  Flt3/ITDs in AML reduces the prolif-
erative ability of  AML in stroma-supported cultures. As this was a rather unexpected 
finding in the light of  the poor prognosis of  this type of  AML, we investigated wheth-
er this reduced proliferative response could also be seen in short-term cultures (7 days) 
without stromal support (Figure 3). We used single cytokines with a well-defined pro-
liferative effect on the myeloid compartment of  the bone marrow. As depicted by the 
large numbers of  outlayers in both the Flt3 mutant and non-mutant samples of  the 
de novo AML group, the cytokine response in this population is very heterogeneous. 
However, in almost all cases the Flt3/ITD positive samples showed a decreased re-
sponse to cytokines.  Statistical analysis revealed that for the combined AML popula-
tion (Fig. 3A) differences were significant in response to either G-CSF, GM-CSF, Il-3 
or SCF (respective p-values: 0.01 , 0.01, 0.02 and 0.03). Analyzing only the de novo 
AML samples (Fig. 3B) differences were significant for G-CSF, GM-CSF and SCF (re-
spective p-values: 0.004, 0.04 and 0.05).  A similar reduced response of  the Flt3-mu-
tant samples was observed when sub-dividing the samples according to FAB class or 
cytogenetic aberrations (data not shown). 
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Figure 2. Leukemia-free survival in patients with and without Flt3/ITDs in patients 
with an age below 60 years and those older then 60 years.
Panel A, patients below 60 years of  age; panel B, patients over 60 years of  age. Solid lines indicate the 
Flt3/ITD negative samples, dashed lines represent the Flt3/ITD positive population. Censored cases 
are marked by a asterisk.
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Figure 3. Effect of single cytokine stimulation on the short-term proliferation of AML 
cells.
Patients samples were divided into three groups on the basis of  their disease history, i.e. de novo AML, 
Secondary or relapsed AML.
The stimulation index is defined as the fold-increase in thymidine incorporation of  the tested sample 
over that of  a 30 Gy-irradiated control of  the sample.
The horizontal black lines in these figures represent the median stimulation index. Shaded bars repre-
sent the interquartile range. Error bars indicate extreme cases, whilst circles indicate outlayers.
Light shaded bars represent Flt3/wildtype samples; Dark shaded bars the Flt3/ITD samples. The 
number of  cases within each group is depicted below the respective bars.
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Frequency analysis of AML-progenitors using the L-CAFC assay
In an attempt to investigate whether the L-CAFC content of  AML with Flt3/ITDs 
differed from samples without such a mutation, we analyzed a panel of  27 AML-sam-
ples (10 with Flt3/ITDs and 17 without Flt3/ITD).  Irrespective of  the presence or 
absence of  FLT3/ITDs we did not observe significant differences in CAFC frequen-
cies in the AML bone marrow when the samples were subdivided on the basis of  FAB 
classification, cytogenetics or hematological background (data not shown). As shown 
in Figure 4 there is no difference in the frequency of  the CAFC-subsets (week-types) 
between mutant and non-mutant samples. Both Flt3 mutant and non-mutant samples 
showed a decreased frequency of  the later (i.e. more primitive) CAFC subsets as com-
pared to the week 1-2 frequencies. This is in contrast to the frequency of  the various 
CAFC subsets in normal human bone marrow and mobilized peripheral blood, which 
are about similar
38
. 
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Figure 4. Effect of the presence of Flt3/ITDs on the Cobblestone Area Forming Cell 
frequency in AML samples. 
The figure depicts the mean leukemic CAFC frequency of  both the Flt3/wildtype (solid line) and the 
Flt3/ITD population (dashed line). Error bars indicate 1x SEM. 
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Not clear from Figure 4 is that there is a large heterogeneity in the CAFC frequencies 
of  the various AML-samples. This is especially prominent at the early weeks after over-
lay (e.g. at week two the highest observed frequency was 4791 CAFC/105 cells whilst 
the lowest was 0.32 CAFC/105 cells.). This heterogeneity could not be correlated with 
any specific subgroup of  AML (i.e. FAB class, cytogenetics or hematological back-
ground). 
Outgrowth of AML cells in the NOD/SCID mouse.
The NOD/SCID mouse model was used to investigate the in vivo leukemia-initiating 
capacity of  both Flt3/ITD positive and negative AML.  Due to the large number of  
cells needed for a reproducible engraftment (3x107 cells/mouse) and the limited avail-
ability of  animals we were only able to analyze a limited number of  samples. Groups 
of  3 mice/sample were injected with AML cells and analyzed at day 30 after transplan-
tation. We were unable to analyze samples of  FAB class M3 as all samples of  this type 
injected into NOD/SCID resulted in death of  the mice within 24 hours after injec-
tion, with the highest mortality within 1 hour. This was most probably due to in vivo 
lysis of  the cells.
Analysis of  the percentage of  engraftment in the total AML population (Fig 5A) 
pointed to an increased ability of  the Flt3/ITD-samples to repopulate the NOD/
SCID mouse bone marrow (p=0.01). This difference could also be observed when 
selecting the samples on basis of  FAB classification (Fig. 5B). Whilst the non-mutant 
samples of  the M2 and M5 type showed the lowest median repopulation of  all sam-
ples investigated, the Flt3/ITD mutant samples of  these FAB types showed a marked 
increase in human chimerism. Furthermore this figure also indicates great variability 
between the FAB classes where in the non-mutant population the M0 samples gave 
rise to the highest median level of  chimerism. The most variable responses with both 
low and high repopulating samples were observed in the M4 FAB class. Though only 
a limited number (n=4) of  Flt3-mutant samples could be analyzed, we conclude that 
the increased outgrowth in the NOD/SCID mice is indeed related to the presence of  
Flt3/ITDs as this effect can also be observed when arranging the samples according 
to cytogenetics (Fig. 5C) or previous hematological history (Fig. D).
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Figure 5: Outgrowth of AML in the NOD/SCID model. 
NOD/SCID mice were i.v. injected with 3x107 AML cells and the percentage of  human AML cells in 
the NOD/SCID bone marrow was determined at day 30 after transplantation. Horizontal bold lines in 
these figures represent the median chimerism; shaded bars, interquartile range; error bars indicate ex-
treme cases; Circles denote outlayers.
light shaded bars represent Flt3/wildtype samples; Dark shaded bars the Flt3/ITD samples. The 
number of  cases within each group is indicated below the x-axis.
The extent of  human chimerism is depicted for the total population (panel A) in relation to the FAB 
type (panel B), cytogenetics (panel C) or background of  the AML (panel D).
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3.5 Discussion
Our current study clearly demonstrates that AML patients who present with an Flt3/
ITD mutation at diagnosis have a significantly poorer prognosis when compared to 
patients without such a mutation. This effect on the survival of  AML patients is also 
evident in the elderly patients (>60 yr.) or in patients without any known cytogenetic 
aberrations. Our study on the Dutch population therefore confirms and extends the 
recent report on the clinical impact of  Flt3/ITDs in the Japanese population
29
. How-
ever, in contrast to this study we found a significant reduction in the remission rate in 
the Flt3/ITD mutant population. 
In our previous report
18
 we have shown that Flt3/ITD mutant AML has a reduced 
proliferative ability in long-term stroma-supported cultures when compared to non-
mutant samples. This aberrant characteristic behaviour is also observed in short-term 
cultures as described here. The short-term proliferation of  Flt3/ITD samples is lower 
(though not always significant) when compared to non-mutant samples and independ-
ent of  cytokines used. In contrast, Löwenberg et al.
43
 have shown that a higher au-
tonomous in vitro proliferation of  AML correlates with a poorer prognosis. A similar, 
though less significant, correlation was also observed in cytokine-stimulated cultures
44
. 
It therefore seems opportune to re-evaluate a large group of  AML samples, that ex-
clude patients carrying an Flt3/ITD mutation, with respect to growth factor response 
and patient prognosis.
The decreased proliferation of  the mutant samples is not reflected in the L-CAFC as-
say as all CAFC subset frequencies in the L-CAFC analysis are similar in both mutant 
and non-mutant populations. We also observed no differences in size of  the cobble-
stone areas derived from either Flt3/ITD mutant or non-mutant CAFC.
Though the number of  AML progenitors thus does not seem to differ between mu-
tant and non-mutant populations we observed that the Flt3/ITD population had a 
better ability to engraft the bone marrow of  NOD/SCID mice. One explanation for 
this might be that these mice provided a microenvironment, which more closely mim-
icked the human (in vivo) situation than did the ex vivo cultures, and favoured out-
growth of  the mutant samples. Another possible explanation might be that the mu-
tation in the Flt3 gene causes an aberrant activation of  the receptor resulting in an 
inhibited apoptosis
9
 leading to a higher surviving fraction, which is able to repopulate 
the mouse.  Actual proof  of  which mechanisms are involved in the aberrant behaviour 
of  AML with Flt3/ITD will require an in-depth molecular characterisation of  both 
the wildtype and mutant Flt3.
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In the light of  the observed aberrant proliferative ability of  Flt3/ITD AML it would 
be extremely interesting to re-evaluate current prognostic parameters based on exclu-
sion of  the Flt3/ITD samples. 
In conclusion, our clinical data suggest that prognosis is strongly related to the pres-
ence of  Flt3/ITDs. We therefore regard patients with Flt3/ITDs to belong to a dis-
tinct AML sub-population that seems to poorly respond to current treatment proto-
cols and thus should have risk stratification with treatment tailored to their prognostic 
factors.
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4.1 Abstract.
Recently it was shown that, analogous to normal hematopoietic cells, the level of  
CXCR-4 expression on AML cells correlates with SDF-1 induced chemotaxis. As we 
speculated that an anomalous organ distribution of  AML cells could affect cell sur-
vival and thus result in an altered fraction surviving chemotherapy, we examined a 
possible correlation between patient prognosis and CXCR-4 expression in AML pa-
tients. We also studied chemotaxis and NOD/SCID repopulating ability of  AML cells 
differing in CXCR-4 expression, and investigated the role of  the CXCR-4/SDF-1 axis 
in G-CSF-induced myeloid differentiation.
We found that patients with a high CXCR-4 expression in the CD34+ subset had a 
significantly reduced survival and a higher probability of  recurrence of  leukemia, 
resulting in a median relapse free survival (RFS) of  only 8.3 months. Bone marrow 
cells from these patients showed an increased ability to repopulate NOD/SCID mice. 
Expression of  CXCR-4 was significantly higher in Flt3/ITD AML than in Flt3/wt 
AML. Covariate analysis indicated that the negative prognostic significance of  Flt3/
ITDs with respect to RFS was no more apparent when analysed in conjunction with 
the expression of  CXCR-4 in the CD34+ subset, suggesting that the poor prognosis of  
Flt3/ITD AML patients might be subordinate to the increased CXCR-4 expression. 
Using a G-CSF-R expressing 32D cell line we observed that SDF-1/CXCR-4 interac-
tion is required for the survival of  myeloid differentiating cells and it also induces a 
block in G-CSF-induced myeloid differentiation.
These data suggest that the SDF-1/CXCR-4 axis may influence therapy responsive-
ness and defines unfavourable prognosis in AML.
4.2 Introduction 
Stromal cell derived factor-1 alpha (SDF-1) is the major chemokine released by the 
bone marrow microenvironment1,2, acting on lymphocytes and hematopoietic progen-
itors. SDF-1 has been shown to activate integrins on these precursor cells and induce 
their migration in vitro3-5. In SDF-1 or CXCR-4 (i.e. the SDF-1 receptor) knock-out 
models, hematopoietic precursor cells fail to migrate to the bone marrow during fetal 
development6,7. CXCR-4, also called LESTR or FUSIN8,9, belongs to the G-protein 
coupled receptors (GPCRs). Previous studies have suggested that this receptor might 
play a role in malignant hematopoiesis. CXCR-4 is over-expressed and functionally 
active in B-CLL and might contribute to the bone marrow tropism of  B-CLL cells10. 
SDF-1 has also been implicated in influencing the localisation of  precursor B-ALL cells 
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in niches in the bone marrow microenvironment that favour their survival and prolif-
eration11. In childhood ALL a high expression of  CXCR-4 has been shown to predict 
for extramedullary infiltration12 and might be associated with a poor outcome13. 
In acute myeloid leukemia (AML) the immature malignant cells frequently leave the 
bone marrow, populate the blood and lodge in extramedullary sites such as spleen and 
liver14. Recently it has been shown that analogous to normal hematopoietic cells also 
in AML the level of  CXCR-4 expression correlates with the SDF-1 induced chemo-
taxis of  these cells15,16. This indicates that SDF-1/CXCR-4 might be involved in the 
trafficking of  the leukemic cells. We investigated whether the expression of  CXCR-4 
and / or the chemotactic response to SDF-1 correlates with the clinical outcome in 
patients with acute myeloid leukemia. We show that patients with a high expression of  
CXCR-4 in the CD34+ subset of  cells have a significantly reduced overall survival and 
are at greater risk of  recurrence of  leukemia. We also observed that Flt3/ITD AML 
has a significantly greater level of  CXCR-4 expression as compared to Flt3/wt AML, 
suggesting the possibility that the poor prognosis of  Flt3/ITD AML might depend on 
the increased CXCR-4 expression. 
4.3 Materials and methods.
Patient samples.
Bone marrow samples of  patients with AML were obtained after informed consent at 
the time of  diagnosis. Cases were classified according to the French-American-Brit-
ish (FAB) committee recommendations17. Mononuclear cells were isolated by Ficoll 
separation followed by T-cell depletion, typically resulting in a population containing 
over 95 percent blasts. After isolation cells were subjected to controlled freezing and 
stored in liquid nitrogen. Before use cells were thawed by stepwise dilution in Iscoves 
Modified Dulbecco’s medium (IMDM [Invitrogen, Merelbeke, Belgium]) containing 
1% BSA. Post-thawing viability varied between 70 and 90 percent as assessed by dye 
exclusion. Patients were treated according to studies of  the adult Dutch-Belgian He-
mato-Oncology Cooperative Group HOVON, HOVON study AML-29 (less then 60 
yrs of  age, 44 patients)18, AML-4 (less then 60 yrs., 27 patients)19, AML-31 (60 yrs+, 
11 patients) or AML-11 (60 yrs+, 6 patients)20. In these protocols, induction therapy 
included an anthracyclin and cytarabine and in patients less then 60 yrs allogeneic and 
autologous stem cell transplantation or intensive chemotherapy were applied as post-
remission therapy. In the AML-29 study, induction therapy consisted of  Ara-C (200 
mg/m2) for 7 days combined for the last three days with Idarubicin (12 mg/m2) (Cy-
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cle I) followed by a second cycle consisting of  Ara-C (6 days, 1000 mg/ m2) combined 
with Amsacrine (days 3-5, 120 mg/ m2). Patients were randomised during the first in-
duction cycle to priming with G-CSF (150 µg/m2, s.c.) during both cycles. Within the 
AML-4 protocol the induction therapy was similar to that of  the AML-29 protocol, 
except that in cycle I Daunomycin (45 mg/m2) was used instead of  Idarubicin. Induc-
tion therapy according to the Hovon-31 protocol consisted of  Ara-C 200 mg/m2 for 7 
days combined for the first three days with Daunomycin (45 mg/m2) in arm 1 of  the 
study, or Daunomycin (35mg/m2) + the multidrug-resistance modulator PSC833 (10 
mg/kg) in arm 2. Finally, in the AML-11 study induction therapy consisted of  Ara-C 
200 mg/m2 for 7 days combined with Daunomycin 30 mg/kg on days 1-3. 
Stratification according to karyotype-risk groups
As cytogenetic aberrations are considered to be important prognostic factors for 
AML21 patients were classified in three groups, i.e. a favourable-risk group consisting 
of  patients defined by a karyotype of   t(8;21), t(15;17) or inv(16) and a unfavourable-
risk group defined by del(5), del(7), or deletions of  the q-arms of  these chromosomes, 
t(6,9), alterations in the 11q23 region or the presence of  multiple aberrations (more 
than 3) in the karyotype. All other karyotypic aberrations and normal karyotypes were 
considered intermediate-risk.
Detection of Flt3 mutants.
All AML samples were analysed for internal tandem duplications (ITDs) in exons 14 
and 15 (the exons formerly designated as exons 11 and 12, see Abu-Duhier et al.22 for 
revised exon numbering) of  the Flt3-gene. The samples were also screened for the 
presence of  the D835 mutation in the activation loop23. ITDs were detected by us-
ing a modified PCR procedure as described elsewhere24. The use of  exon 14 and 15 
specific primers allowed us to cover the whole juxtamembrane (JM) and the first part 
of  the first kinase domain (TK-1) where most of  the reported ITDs are located. Ge-
nomic DNA was prepared using a standard procedure25. Briefly, DNA from about 104 
cells was amplified in a total of  50-µl reaction mixture, containing single strength PCR 
buffer, 10 pMol of  each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Supertaq, 
SpheroQ, Leiden, The Netherlands). Preheating of  the samples at 95oC was followed 
by amplification for 35 cycles consisting of: 1 min. at 43 oC, 1 min. at 72 oC and 1 min. 
at 95 oC. Following these cycles a final extension at 72 oC was performed for 10 min. 
PCR products were stained with SYBR green I (Molecular Probes, Leiden, The Neth-
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erlands) and resolved on 3% agarose gel. As a confirmation samples positive for an 
Flt3-mutation were reanalysed in a second PCR using the primers 14F and 15R. 
The D835 mutation in the 2nd tyrosine kinase domain (exon 20, previously exon 17) 
was detected as described by Yamamoto et al.23 Approximately 100ng of  DNA was 
added to a reaction mix containing single strength PCR buffer, 10pMol of  each primer 
(D835-forward: 5’-CGCCAGGAACGTGCTTG- 3’, D835-reverse: 5’-GCAGCCT-
CACATTGCCCC-3’), 200 µM dNTPs and 0.5 U Taq polymerase (Supertaq, Sphe-
roQ). Preheating of  the samples at 95oC was followed by amplification for 35 cycles 
consisting of: 1 min. at 63 oC, 1 min. at 72 oC and 1 min. at 95 oC. Following these cycles 
a final extension at 72 oC was performed for 10-min. Amplified PCR products were 
digested with EcoRV and subsequently electrophorised through four-percent agarose. 
Alleles containing the D835-mutation were identified by an uncut 114-bp PCR frag-
ment whilst wildtype alleles were identified by a digested PCR product with fragments 
of  68 and 46 base pairs.
Migration assay.
Migration assays were performed as previously described26. Briefly, transwell plates 
(Costar Corning, Cambridge, MA, USA) of  6.5mm diameter and a pore size of  5µm 
were coated overnight at 4oC with 100µl of  20µg/ml fibronectin16 (FN, Fibronectin 
from Bovine plasma, Sigma, St. Louis, MO, USA). Before addition of  the cells, the 
transwells were washed three times with assay medium (IMDM + 0.5% Bovine Serum 
Albumin [BSA fraction V, Sigma]). After this 2x105 AML cells in 100µl of  assay me-
dium were added to the upper compartment of  the transwell. To the lower well 600µl 
of  assay medium was added in the presence or absence of  SDF-1 (100 ng/ml, R&D-
systems, obtained through ITK-Diagnostics, Uithoorn, The Netherlands). The tran-
swell plates were then incubated for 4 hrs. at 37oC and 10% CO
2
. After incubation the 
number of  cells that had migrated to the lower well was determined using a Sysmex 
cell counter (Toa Medical Electronics, Hamburg, Germany). The percentage of  specif-
ic i.e. chemokine-induced, chemotaxis was calculated by dividing the number of  input 
cells by the number of  migrated cells from which the number of  cells that migrated in 
medium alone was subtracted. 
As the process of  cryopreservation and the subsequent thawing is very likely a stressful 
event for cells, this may alter their responses when assayed immediately after thawing. 
We therefore compared the migratory abilities of  a random selection of  7 AML sam-
ples after overnight incubation of  the cells in assay-medium (37oC and 10% CO
2
) with 
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those of  the same samples assayed directly after thawing.  In all conditions assayed, 
the chemotaxis after overnight incubation was significantly increased (P <=0.05, data 
not shown). Therefore,  all subsequent experiments were performed after overnight 
incubation. 
In vitro proliferation and differentiation of 32D/G-CSF-R cells.
The 32D/G-CSF-R cell line27 was cultured in RPMI 1640 medium (Gibco) supple-
mented with 100 IU/ml penicillin, 100 ng/ml streptomycin and 10% Fetal bovine se-
rum and 10ng/ml of  murine IL-3 (CHO-supernatant). Differentiation was started by 
replacing the IL-3 for 100 ng/ml G-CSF (Amgen, Thousand Oaks, CA). Cells were 
counted and the cell density was readjusted to 2x105 cells daily. Morphologic analysis 
of  differentiation was performed by microscopy of  May-Grünwald-Giemsa stained 
cytospins. Specificity of  SDF-1 binding was tested by blocking SDF-1/CXCR-4 in-
teractions using CXCR-4 blocking or SDF-1 neutralizing antibodies (5μg/ml, R&D 
systems).
Flow cytometry.
To determine the antigen expression profile of  both freshly thawed and overnight-
incubated AML samples (See Migration Assay), the cells were harvested and pelleted 
at 1600g for 5’. Cells were washed and resuspended in PBS+1% FCS+0.1% sodium 
azide. Fifty microliter aliquots of  this suspension, containing 1 - 2x105 cells, were la-
belled for 30’ on ice with the appropriate dilutions of  αCD34-APC and αCXCR-4-PE 
(both from Coulter Immunotech, Marseille, France). After staining the samples were 
diluted to 300µl with PBS+1% FCS+0.1% sodium azide to which 2µl of  7-amino-
actinomycin D (7-AAD, Molecular Probes, Leiden, The Netherlands) was added to al-
low for the exclusion of  dead cells. Cells were measured on a FACScalibur cytometer 
(Beckton Dickinson Immunocytometry systems, San Jose, CA, USA) and analysed us-
ing the CellQuest software package (Beckton Dickinson).
In the 32D cell system the number of  apoptotic cells was quantified by determining 
the number of  annexin V positive cells using the Apoptest kit (NeXins research, Kat-
tendijke, The Netherlands).
Transplantation of human AML cells in the NOD/SCID mouse.
NOD/LtSz-Prkdcscid (NOD/SCID) mice were bred in the Erasmus animal facility and 
housed under specified pathogen free conditions, using individually ventilated cages. 
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Mice were supplied with sterilised food and acidified tap water to which 100mg/l cipro-
floxacine (Bayer AG, Leverkusen, Germany) was added. Both food and drink were 
available ad lib. Housing, care and all animal experiments were done in accordance 
with Dutch legal regulations, which includes approval by a local ethical committee.
Before transplantation of  the AML cells the mice received a total body irradiation of  
3.5 Gy gamma radiation ( 137Cs source, Gammacell, Atomic Energy of  Canada, Ot-
tawa, Canada). Transplantation of  the AML cells was done by injecting groups of  3-5 
mice with 3x107 AML cells in the lateral tail vein. After six weeks, the mice were sacri-
ficed by CO
2
 inhalation after which both femora were isolated and bone marrow sus-
pensions prepared. To determine the percentage of  AML cells in the bone marrow 
suspensions, cells were stained with antibodies against the human common leukocyte 
antigen (CD45), CD34, CD33 and CD38 (CD45-FITC, CD38-FITC, CD33-PE and 
CD34-APC, all obtained from Coulter Immunotech) and measured using a FACScali-
bur (Beckton Dickinson Immunocytometry systems). Analysis was done using the Cell 
Quest software package (Beckton Dickinson). Erythrocytes were excluded from analy-
sis by gating on forward and perpendicular light scatter whilst dead cells were excluded 
by staining with 7-AAD.
Statistical analysis.
Statistical analysis of  the data was performed using the SPSS software package (SPSS 
Inc., Chicago Il., USA). Differences between unrelated samples were analysed using 
the Mann-Whitney U-test. The Wilcoxon rank sum test was used for the analysis of  
paired samples. Initial screening of  the correlations between the CXCR-4 expression 
and patient prognosis was performed by multivariate Cox regression analysis using 
the rank numbers of  the CXCR-4 expression as a variable to test for trend. Variables 
which showed a significant correlation in this initial screening were studied in further 
detail by stratification of  the patients in high and low CXCR-4 expressing categories 
based on the optimal cut-point for the CXCR-4 expression. In this analysis the opti-
mal cut-point is defined as the percentage of  cells expressing CXCR-4, at which the 
difference in patient prognosis between low and high expressing categories is largest. 
Patients with a CXCR-4 expression up to the cut-point were considered to be low ex-
pressing whilst all others were considered to be high expressing. To generate these cat-
egories, half  of  the samples were used as a training set to determine the optimal cut-
point of  the CXCR-4 expression. The optimal cut-points determined in the training 
set were then used to categorise all samples in low and high expressing categories. In 
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the analysis for the co-expression of  CD34 and CXCR-4 we observed that the differ-
ences between the two categories were significant if  the cut-point was chosen in the 
range between 0.4 and 1.2 percent of  cells co-expressing CD34 and CXCR-4 (optimal 
cut-point at 1.0%). For the analysis of  the fraction of  CD34+ cells expressing CXCR-4 
we observed significant differences for cut-points in the range between 12 and 25 per-
cent of  CD34+ cells expressing CXCR-4 (optimal cut-point at 20%).
For the survival analysis the Kaplan-Meier method of  the SPSS software package was 
used. The Logrank test was used to check for equality of  the survival distributions. 
The relapse-free survival (RFS) was calculated from date of  CR to date of  relapse. In 
this analysis, patients dying from non-leukemia related causes during first CR were in-
cluded until date of  death. The overall survival (OS) was calculated from date of  diag-
nosis to date of  death. Multivariate Cox regression analysis was used to identify other 
predictor variables present in the study population. In all evaluations values were con-
sidered significant if  p-values were below 0.05.
Total number 90
Age
Median (yrs.) 44
Range (yrs.) 16-88
<= 60 yrs. (n) 72
Gender
Male 44
Female 46
WBC
Median (10-9/l) 58
Range (10-9/l) 1-319
FAB class
M0 3
M1 18
M2 19
M3 5
M4 23
M5 22
Cytogenetic Risk*
favourable 14
intermediate 69
unfavourable 7
Table 1: Clinical and hematological characteristics
 of patients
* Favourable cytogenetic abnormalities included t(8;21), t(15;17) or inv(16); unfavourable cytoge-
netic abnormalities included  del(5), Del(7), deletions of  the long arms of  chromosomes 5 or 7 
(5q- , 7q-), t(6;9), 11q23 abnormalities and complex karyotypes. (>3 abnormalities).Other karyo-
typic aberrations and normal karyotypes were included in the intermediate prognostic category.
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4.4 Results
High percentages of CXCR-4 within the CD34+ fraction of cells predict for an 
increased relapse rate in primary AML.  
We analysed the expression of  CXCR-4 together with the expression of  CD34 in a se-
ries of  90 samples of  adult patients with AML. Patient details are given in table 1. The 
results of  the flow cytometric analysis are summarised in Table 2. On average, around 
one third  (median 36.4%) of  the ficoll fraction of  marrow cells from AML patients 
expressed CXCR-4. As indicated by the broad range of  the mean fluorescent index 
(MFI) we observed a large variation in the level at which CXCR-4 was expressed. In 
most cases, the cells expressed relatively low levels of  CXCR-4, but in certain cases the 
cells showed an excessively high expression. While a median of  22.6 percent of  cells 
expressed CD34, only 3.9 percent (median) of  cells co-expressed CD34 and CXCR-4, 
indicating that the percentages of  cells expressing CXCR-4 within the CD34+ subset 
of  cells was considerably less than that of  the total cell population.
Marker
median range
n=90
CXCR-4
% 36.4 1.6 - 96.4
MFI 39.3 6.9 - 523.3
% CD34+ 22.6 0.2 - 96.3
%CXCR-4+CD34- 23.6 0.1 - 97.3
%CXCR-4+CD34+   3.9 0.2 - 93.5
% CXCR-4-CD34- 18.8 0.3 - 97.0
%CXCR-4-CD34+   8.6 0.0 - 92.0
Table 2: Phenotypic analysis of the 
expression of CXCR-4 and CD34
Marrow  samples were labeled with fluorescently labeled monocolonal 
antibodies and analysed by flow cytometry. Values indicate the median 
percentages of  cells expressing the indicated markers, MFI refers to the 
mean fluorescent index of  the CXCR-4 expression. 
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Figure 1: Overall survival and relapse-free survival of  patients with primary  AML in 
relation to the co-expression of CXCR-4 and CD34.
OS (panel A) and RFS (panel B) for AML is expressed in relation to the percentages of  cells co-
expressing CXCR-4 and CD34. Solid lines, patients in which < 1% of  cells co-expressed CXCR-4 and 
CD34; dotted lines, patients in which ≥ 1% of  cells co-expressed CXCR-4 and CD34. In Panels C and 
D, OS and RFS are given in relation to the fraction of  CD34+ cells expressing CXCR-4. Solid lines, pa-
tients in which < 20% of  the CD34+ cells expressed CXCR-4, Dotted lines patients in which ≥ 20% of  
the CD34+ cells expressed CXCR-4. 
asterisk refers to censored cases.
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Initial screening using Cox regression analysis showed that the CXCR-4 expression 
proper only marginally correlated with patient prognosis (data not shown). Yet, the 
number of  cells co-expressing CXCR-4 and CD34 showed a good correlation with 
patient prognosis and was studied in further detail (Fig. 1A+1B). At the optimal cut-
point of  1% of  cells co-expressing CD34 and CXCR-4, patients with comparatively 
high percentages of  double positive cells had a reduced overall survival (OS) and a 
reduced relapse free survival (RFS). The impact of  the CXCR-4 expression on prog-
nosis was even more prominent when the percentage of  CXCR-4+CD34+ cells was 
expressed as a fraction of  the total number of  CD34+ cells (Fig. 1C+1D, optimal cut-
point 20% of  CD34+ cells expressing CXCR-4), resulting in a median OS and RFS 
of  11 and 8.3 months respectively for patients with a high proportion of  CD34+ cells 
expressing CXCR-4. The latter values compared to a median OS and RFS of  over 96 
months (p<0.01) for patients with a small fraction of  CD34+ cells expressing CXCR-4. 
At a median follow-up of  18 months, 22 of  33 patients with a high CXCR-4 expres-
sion had relapsed following complete remission (relative risk of  relapse: 6.1, 95% con-
fidence interval 2.1-18.1). 
Flt3/ITD AML shows an increased CXCR-4 expression.
To be able to more accurately define the significance of  the observed correlation be-
tween disease outcome and CXCR-4 expression we performed a multivariate Cox re-
gression analysis with the fraction of  CD34+ cells expressing CXCR-4, the presence of  
Flt3-mutations, cytogenetic abnormalities and age as variables in the regression analy-
sis. For the analysis of  Flt3-mutations all samples were analysed by PCR for the pres-
ence of  Flt3/ITDs and Flt3/D835 mutations. Of  the 90 samples, 22 were shown to be 
positive for the presence of  Flt3/ITDs and three contained the Flt3/D835 mutation. 
As the number of  Flt3/D835 mutations was too low to allow for a separate statistical 
evaluation and the impact on patient prognosis is not as clear as for the Flt3/ITDs, 
these samples were not analysed separately. In multivariate Cox regression analysis the 
percentage of  CD34+CXCR-4+ cells and also age, unfavourable cytogenetics and the 
presence of  Flt3/ITDs were significant predictive factors as regards OS and RFS (Ta-
ble 3). In addition, when the fraction of  CD34+ cells expressing CXCR-4 was consid-
ered, the presence of  Flt3/ITDs lost its impact on patient prognosis (Table 4).
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Variable
Overall survival Relapse free survival
Relative risk
(95% CI)
p
Relative risk
(95% CI)
p
n= 90 n=62
Co-expression of  CD34 and 
CXCR-4
3.19
(1.62-6.27)
0.001
3.92
(1.57-9.8)
<0.001
Presence Flt3/ITDs
3.01
(1.59-5.66)
0.001
2.86
(1.2-6.7)
0.015
Unfavourable cytogenetics*
2.26
(0.93-5.47
0.014
3.00
(1.01-9.34)
0.047
Age
1.02
(1.00-1.03)
0.024
0.99
(0.98-1.02)
0.490
Table 3: Prognostic impact of the co-expression of CD34 and CXCR-4 and 
other prognostic variables as regards overall survival and relapse free 
survival.
To more accurately define the significance of  the observed correlation between prognosis 
and the number of  cells co-expressing CXCR-4 and CD34, we performed a multivariate Cox 
regression analysis with age, the presence Flt3-mutations and cytogenetics as variables in the 
regression analysis. Results are presented as relative risks with the 95% confidence intervals 
and respective p-values.
n=the number of  samples included in the analysis. 
* See legend table 1
As this indicated that the presence of  Flt3/ITDs was not an independent predictive 
factor in this analysis, we further analysed this subtype of  AML. Analysis of  the flow 
cytometric data showed that the CXCR-4 expression (median expression 72.1 percent 
vs. 28.1 percent, p<0.01) was increased in Flt3/ITD AML when compared to Flt3/wt 
AML. On the other hand, the number of  CD34+ cells was reduced (median expression 
9.5% in Flt3/ITD AML compared to 42.1% in Flt3/wt AML, p= 0.03), resulting in a 
significantly greater fraction of  CD34+ cells expressing CXCR-4 in Flt3/ITD AML.
Chapter 4
94
Internal tandem duplications in the Flt3-gene
95
The percentages of CXCR-4+ cells within the CD34+ cluster correlates with 
the outgrowth of AML cells in the NOD/SCID mouse model.
It has been shown that SDF-1/CXCR-4 interactions may play an essential role in the 
homing and high level multilineage engraftment of  hematopoietic stem cells from 
healthy donors in the NOD/SCID human-mouse chimera model28,29. We and others 
have also shown that Flt3/ITD AML has a significantly increased SCID repopulat-
ing ability when compared to Flt3/wt AML30,31. As levels of  CXCR-4 expression ap-
pear to be increased in Flt3/ITD AML, we set out to analyse whether the levels of  
CXCR-4 expression could be correlated with the NOD/SCID repopulating abilities 
of  both Flt3/ITD and Flt3/wt AML.  Due to the relatively high cell numbers needed 
to achieve reproducible and stable levels of  chimerism in this model32, we were only 
able to analyse 21 AML samples (15 Flt3/wt and 6 Flt3/ITD). 
As shown in Table 5, at six weeks post transplantation there is a large variation in the 
percentages of  AML cells repopulating the bone marrow of  the NOD/SCID mice 
Variable
Overall survival Relapse free survival
Relative risk
(95% CI)
p
Relative risk
(95% CI)
p
n= 90 n=62
CXCR-4 within the CD34+ 
subset
5.12
(2.38-11.01)
<0.001
13.4
(3.87-25.0)
<0.001
Presence Flt3/ITDs*
1.69
(0.91-3.15)
0.054
1.54
(0.67-3.54)
0.327
Unfavourable cytogenetics*
1.74
(0.73-2.47)
0.314
1.50
(0.81-2.63)
0.048
Age
1.02
(1.00-1.04)
0.035
0.57
(0.27-2.61)
0.370
Table 4: The prognostic impact of Flt3/ITDs in relation to the fraction of 
CD34+ cells expressing CXCR-4
We performed a multivariate Cox regression analysis with age, the presence Flt3-mutations and 
cytogenetics and the fraction of  CD34+ cells expressing CXCR-4, as variables in the regression 
analysis. Whereas age and unfavourable cytogenetics maintain ther independent prognostic val-
ue, Flt3/ITDs do not have a significant impact on patient prognosis when analysed in conjunc-
tion with the fraction of  CD34+ cells expressing CXCR-4.
n=the number of  samples included in the analysis. 
*See legend table 1
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(median 12.6% human cells, range 0.5% - 97.8%). Correlation analysis showed that the 
level of  human chimerism in the NOD/SCID mice correlated with both the overall 
expression of  CXCR-4 (correlation coefficient 0.588, p= 0.01) and the expression of  
CXCR-4 within the CD34+ cluster of  cells ((correlation coefficient 0.708, p= 0.001, 
Figure 2).
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Figure 2: Correlation between the percentage of CD34+ cells expressing CXCR-4 and 
the outgrowth in NOD/SCID. 
Samples from 21 AML patients were injected in NOD/SCID mice (3x107 cells per mouse, 3-5 mice per 
group). After 6 weeks the mice were sacrificed and the number of  human AML cells in the bone mar-
row was determined by flowcytometry. The outgrowth of  AML cells in NOD/SCID was then corre-
lated with the percentages of  CD34+ cells expressing CXCR-4.
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Chemotaxis in response to SDF-1 does not correlate with patient prognosis 
or with the percentage of CXCR-4 expression in the CD34+ cluster of cells.
Recently Voermans et al.16 reported that, similar to normal hematopoiesis, also in AML 
there is a linear correlation between chemotactic response and the expression levels of  
CXCR-4. To investigate if  the migratory abilities correlated with patient prognosis we 
analysed the migratory abilities in response to SDF-1 in a subset of  60 AML samples. 
After four hours of  incubation the median percentage of  cells that had migrated in the 
presence of  SDF-1 was 13.3 percent, which exceeded the comparative 2.5% value in 
medium alone (p<0.01). Correlation analysis revealed a low but significant correlation 
between chemotaxis and the overall CXCR-4 expression as well as the percentage of  
CXCR-4+CD34+ cells (correlation coefficient 0.326, p= 0.01 and 0.368 p= 0.004 re-
spectively, data not shown). However, the SDF-1 induced chemotaxis did not correlate 
with patient prognosis. 
SDF-1/CXCR-4 interactions are required for the survival of differentiating 
32D cells, and induce a block in myeloid differentiation.
It has been shown that low levels of  SDF-1 may enhance myeloid progenitor cell sur-
vival in vitro33,34. Further, the expression of  CXCR-4 undergoes complex lineage-de-
pendent regulation during myeloid differentiation35. We therefore investigated the ef-
fect of  SDF-1 on the survival and G-CSF induced differentiation of  the myeloid cell 
line 32D/G-CSF-R, a subclone of  the 32D cell line known to express CXCR-436. To 
study whether SDF-1/CXCR-4 interactions influenced cell survival and neutrophil 
differentiation, 32D/G-CSF-R cells were cultured with G-CSF (100 ng/ml) and G-
CSF+ SDF-1 (100ng/ml). G-CSF induced a rapid increase in the number of  terminal-
ly matured neutrophils between day 6 and 12, which was suppressed in the presence of  
SDF-1 (Figure 3). In order to check for the specificity of  the SDF-1 inhibition through 
binding to CXCR-4 we performed the same experiment in the presence of  a CXCR-4 
blocking-antibody. Instead of  rescuing the impairment of  differentiation the CXCR-4 
blocking antibody induced apoptosis in the 32D system. As induction of  apoptosis by 
the blocking antibody was also seen in the absence of  exogenously added SDF-1 (data 
not shown) these data strongly suggest the presence of  SDF-1 in the culture medium 
where it is may provide a survival signal to the differentiating 32D cells. In order to 
exclude the possibility that the observed apoptosis was due to non-specific toxicity we 
also verified the effect of  inhibiting SDF-1/CXCR-4 interactions by the addition of  a 
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SDF-1 neutralising antibody. Both the SDF-1 neutralising antibody and the CXCR-4 
blocking antibody induced a strong increase in apoptotic cells during the six days of  
culture (Fig 4.). Incubation of  a CXCR-4 negative cell line (i.e. KG-1) with the CXCR-
4 and SDF-1 specific antibodies did not result in induction of  apoptosis, excluding the 
possibility that the antibody preparations contained aspecific cytotoxic activity
Figure 3: Effect of the addition of SDF-1 on the G-CSF-induced differentiation of 
32D/G-CSF-R cells.
Differential countings after 7, 9 and 12 days of  culture in the presence of  G-CSF (-) or G-CSF + SDF-1 
(+SDF). The white parts of  the histograms indicate the percentage of  terminally matured neutrophils, 
the grey parts indicate the percentage of  intermediately matured granulocytic cells and black parts indi-
cate the percentages of  blast cells in the cultures.
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4.5 Discussion
In the past few years our understanding of  the presence and prognostic value of  spe-
cific genetic defects (such as Flt3/ITD, AML-1-CBFβ, PML-RAR and various others) 
in human AML has increased. Notwithstanding this progress, there is a large subset of  
AML patients with prognostic heterogeneity and no detectable molecular or chromo-
somal aberrations. As it has been suggested that SDF-1/CXCR-4 interactions might 
be involved in the trafficking of  leukemic cells, with possible prognostic implications, 
we investigated the expression of  CXCR-4 and the chemotactic response to SDF-1 in 
relations to the clinical outcome of  patients with newly diagnosed AML.
Figure 4: Blocking of SDF-1/CXCR-4 interactions induces apoptosis in 32D cells.
On day 0 cultures were initiated with 2x105 32D/G-CSF-R cells/ml. Cells were counted and cultures 
were readjusted to 2x105 cells/ml on a daily basis. Cultures were either performed in the presence of  
G-CSF, G-CSF + a CXCR-4-blocking antibody (5 µg/ml) or G-CSF+ a SDF-1 neutralizing antibody. 
The percentage of  cells in apoptosis (y-axis) was determined by a flowcytometric analysis of  the number 
of  annexin-V+7-AAD- cells. The x-axis shows the number of  days after the start of  the culture. 
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While the expression of  CXCR-4 proper had a borderline prognostic value, the per-
centage of  CD34+CXCR-4+ double positive cells and the fraction of  CD34+ cells ex-
pressing CXCR-4 appeared to be significant negative predictors of  both overall sur-
vival and relapse free survival. In multivariate analysis the predictive value proved to be 
independent of  other previously established prognostic markers such as age and cyto-
genetic abnormalities. A particularly interesting observation of  the studies presented 
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here, is that Flt3/ITD AML was characterised by an increased expression of  CXCR-4 
(both in the number of  cells expressing CXCR-4 and the level of  CXCR-4 expression 
per cell). The difference in CXCR-4 expression between Flt3/ITD and Flt3/wt AML 
was also reflected in the fraction of  CD34+ cells expressing CXCR-4, which with a 
median value of  52.7% was significantly more in Flt3/ITD AML when compared 
to the median value of  19.8% in Flt3/wt AML (p < 0.01). We also observed that in 
Flt3/ITD AML the expression of  CXCR-4 correlated with the mutant to wildtype 
ratio present in the respective samples and that activation of  the wildtype-Flt3 result-
ed in an up-regulation of  the CXCR-4 expression (data not shown), suggesting a link 
between the expression of  CXCR-4 and Flt3/ITDs. Furthermore, whilst Flt3/ITDs 
had a significant negative impact on the RFS when analysed as a single variable (data 
not shown), the impact of  Flt3/ITDs was no longer apparent when it was analysed 
in conjunction with the fraction of  CD34+ cells expressing CXCR-4. Taken together 
these data might suggest that the poor prognosis of  Flt3/ITD AML depends on the 
increased CXCR-4 expression in this type of  AML.
In order to investigate whether the correlations between the CXCR-4 expression and 
prognosis could be explained by a different organ distribution of  AML cells, we ana-
lysed the in vitro migratory behaviour of  these cells in response to SDF-1, the ligand 
of  CXCR-4. We observed that AML with high percentages of  CXCR-4 expression 
showed an increased chemotactic response in culture. However, the low correlation 
coefficient between CXCR-4 expression and chemotactic response would suggest 
that factors other than the expression of  CXCR-4, such as the expression of  adhe-
sion molecules and cell cycle induction, might play a role in determining the migra-
tory abilities. Ponomaryov et al.37 observed an increased expression of  SDF-1 in the 
bone marrow following conditioning with DNA-damaging agents (ionising radiation, 
cyclophosphamide and 5-FU), this resulted in an increase in CXCR-4 dependent hom-
ing to the bone marrow, which consequently facilitated engraftment of  hematopoietic 
stem cells. Though not shown to be true for leukemic stem cells, these observations 
on normal bone marrow cells fit well with our observation of  a significant correlation 
between the expression of  CXCR-4 and the outgrowth of  AML cells in the NOD/
SCID mouse model.
Apart from its chemotactic activity, SDF-1 has also been suggested to play a role in 
hematopoietic (stem) cell survival and function by suppression of  apoptosis and pro-
moting the G0/G1 transition37-40. The observation that blocking of  CXCR-4 induces 
apoptosis in the 32D system may suggest that also in myeloid cells SDF-1/CXCR-4 
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interactions provide strong anti-apoptotic signals. However, in the 32D cell system 
high levels of  SDF-1 induced a partial block in differentiation. This raises the possi-
bility that increased expression of  CXCR-4 contributes to leukemogenisis by induc-
ing a block in differentiation. Recently Jorda et al.41 have observed that Cb2, another 
Gαi-GPCR and a frequent proviral target in Cas-Br-M-MuLV-induced myeloid leuke-
mias, produces an arrest in myeloid differentiation in the 32D system, suggesting a 
more general role of  Gαi-GPCRs in leukemogenesis.
In conclusion, our data indicate that a high expression of  CXCR-4 in the CD34 clus-
ter of  cells defines unfavourable prognosis of  AML. Little is known about the role of  
CXCR-4 / SDF-1 in the development, therapy responsiveness and disease progression 
of  AML. Which of  the three possible mechanisms, i.e. an increased homing, a block 
in differentiation and anti-apoptotic signalling, by it self  influences disease prognosis 
remains to be seen. To this end, these data warrant a more extensive study into the role 
of  CXCR-4 in the pathobiology of  acute myeloid leukemia.
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Improved prognostic significance of cytokine-induced 
proliferation in vitro in patients with de novo acute 
myeloid leukemia of intermediate risk: impact of 
internal tandem duplications in the Flt3 gene
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5.1. Abstract  
The heterogeneity of  acute myeloid leukemia is reflected in many clinical, biological 
and genetic features that are used to predict the response to therapy. On the basis of  
chromosome aberrations patients can be stratified in groups reflecting either good or 
poor prognosis. However, the majority of  patients fall in an ‘intermediate risk’ group. 
Internal tandem duplications in the hematopoietic growth factor receptor Flt3 have 
been shown to separate a subset of  high-risk patients from intermediate or low risk 
cases.
In an attempt to further characterize the heterogeneity of  prognosis among the cy-
togenetic intermediate risk group of  AML, we investigated the overall survival, fail-
ure-free survival, initial therapy response and relapse rates of  103 patients with de novo 
AML in relation to autonomous proliferation and the proliferative response to a panel 
of  10 cytokines in a short-term thymidine incorporation assay. 
To exclude perturbation of  the responses by other (known) risk factors our final inter-
mediate risk population was comprized of  patients with intermediate risk cytogenet-
ics, having an age of  60 years of  younger and not showing tandem duplications in the 
Flt3 gene.
Among this intermediate risk group, only the responses to M-CSF and Il-1α were 
found to be predictive for therapy outcome. Results obtained by a 7-day culture with 
these cytokines revealed two subpopulations characterized by a good and a poor prog-
nosis, respectively. The complete remission rates in these subpopulations were similar, 
but the relapse rates, failure-free survival and overall survival differed. If  further study 
extends and supports our data, it should be considered to include these patients in the 
poor risk arms of  treatment protocols and offer them intensified treatment or bone 
marrow transplantation.
5.2. Introduction 
The term acute myeloid leukemia (AML) encompasses a range of  clonal hematopoi-
etic disorders with aberrant proliferation and differentiation. The malignant clone out-
grows the normal hematopoietic cells resulting in an accumulation of  immature cells 
in the hematopoietic tissues. Over the past decade progress in both therapy and di-
agnosis have improved the outlook for certain AML patients. However, despite these 
improvements the overall survival rate is still only 40 percent in patients with an age of  
less than 65 years whilst for patients with an age of  65 years and beyond this survival 
is below 10 percent
1
. A number of  clinical, hematological and (cyto)genetical features 
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reflecting the heterogeneity of  the disease are used to predict the outcome of   therapy. 
Adverse prognostic factors include (a) an age over 60 years, (b) AML resulting from 
a prior hematological disorder such as MDS and (c) a high white blood cell count
2
. 
Adverse cytogenetics, e.g. deletions of  chromosome 5 or 7 or deletions of  the long 
arm of  these chromosomes, expresses a considerable prognostic value. In contrast, 
the cytogenetic translocations t(8:21), t(15:17) or inv(16) define a group of  patients 
with good prognosis. Other patients are classified in an intermediate or standard risk 
group.
The fms like tyrosine kinase 3 (Flt3), also known as stem cell tyrosine kinase-1 (STK1) 
or fetal liver tyrosine kinase-2 (FLK-2)
3-6
, belongs to the group of  class III receptor 
tyrosine kinases (RTKs), which also include the receptors c-kit and c-fms. Signals gen-
erated by ligand-induced dimerisation of  these receptors involve tyrosine phosphor-
ylation of  certain regions of  the receptor and activation of  cellular tyrosine kinases. 
While a large proportion of  AML cases has been found to express class III RTKs
7-10 
, their potential role in leukemia development is still unclear. Recently it has been re-
ported that internal tandem duplications in the Flt3 gene (Flt3/ITDs) occur in 17-20% 
of  AML patients and are significantly associated with a poor patient prognosis
11-13
. 
Except in AML, these duplications have also been found in patients with leukemic 
transformation of  myelodysplasia
14
, but not in patients suffering from acute lymphoid 
leukemia, chronic myeloid leukemia (CML), blast crisis CML, or in normal individu-
als. We have shown that AML cells with Flt3/ITDs have a reduced proliferative ability 
in both long-term stroma-supported cultures
15
 and short-term stroma-free cultures
11
. 
The apparent contrast between this reduced proliferative ability in vitro and the poor 
prognosis of  AML patients with Flt3/ITDs led us to investigate whether exclusion of  
Flt3/ITD samples would lead to a better correlation between either autonomous or 
cytokine-induced proliferation, and patient prognosis. Specifically, we have examined 
the possibility to further distinguish the prognosis of  patients that are currently as-
signed to the ‘intermediate risk’ group on the basis of  cytogenetics. For this purpose 
we have correlated the in vitro autonomous proliferation in combination with the pro-
liferative response to a panel of  ten cytokines to (a) response to remission induction 
treatment, (b) relapse probability, (c) overall survival (OS) and  (d) failure-free survival 
(FFS) of  103 patients with de novo AML.
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5.3. Materials and methods
Patient samples
Diagnosis bone marrow samples of  patients with AML were obtained after informed 
consent. Cases were classified according to the French-American-British (FAB) com-
mittee recommendations 
16
. Mononuclear cells were isolated by ficoll separation fol-
lowed by T-cell depletion, typically resulting in a population containing over 95 percent 
blasts.  After isolation cells were subjected to controlled freezing and stored in liquid 
nitrogen. Before use cells were thawed by stepwise dilution in Iscoves Modified Dul-
becco’s medium (IMDM, Gibco, Breda, The Netherlands) containing 1% BSA. Post-
thawing viability varied between 70 and 90 percent as assessed by dye exclusion. 
After diagnosis patients were treated according to studies of  the adult Dutch-Belgian 
Heamato-Oncology Group HOVON, i.e. the HOVON-29 (less then 60 yr. of  age, 45 
patients)
17
, HOVON-4 (less then 60 yr., 44 patients)
18
, HOVON-31 (60 yrs+, 11 pa-
tients) and the AML-11 (60 yrs+, 3 patients)
19
 protocols. In these protocols induction 
therapy included an anthracyclin and cytarabine, while in patients less then 60 yr. al-
logeneic and autologous stem cell transplantation or intensive chemotherapy for con-
solidation were applied as post-remission therapy. In the HOVON-29 study induction 
therapy consisted of  Ara-C (200 mg/m2) for 7 days combined with Idarubicin (12 mg/
m2) for the last three days (Cycle I) followed by a second cycle consisting of  Ara-C (6 
days, 1000 mg/ m2) combined with Amsacrine (days 3-5, 120 mg/ m2). Half  of  the pa-
tients according to randomising received G-CSF (120 µg/m2, s.c.) during both cycles. 
Within the HOVON-4 protocol the induction therapy was equal to the HOVON-29 
protocol except for the fact that in cycle I Daunomycin (45 mg/m2) was used instead 
of  Idarubicin. For the HOVON-31 protocol induction therapy consisted of  Ara-C 
200 mg/m2 for 7 days combined for the first three days with Daunomycin (45 mg/m2) 
in arm one of  the study, or Daunomycin (35mg/m2) + PSC833 (10 mg/kg) in arm two. 
Finally, in the AML-11 study induction therapy consisted of  Ara-C 200 mg/m2 for 7 
days combined with Daunomycin 30 mg/kg on days 1-3. 
Stratification according to karyotype-risk groups
As cytogenetic aberrations are thought to be important prognostic factors for AML
20,21
 
patients were stratified in three groups i.e. a good-risk group consisting of  patients de-
fined by a karyotype of   t(8;21), t(15;17) or inv(16) and a poor-risk group defined by 
del(5), del(7), or deletions of  the q-arms of  these chromosomes, t(6,9), alterations in 
the 11q23 region or the presence of  multiple aberrations (more than 3) in the karyo-
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type. All other karyotypic aberrations and a normal karyotype were included in an in-
termediate-risk group.
Determination of Flt3 mutants
All AML samples were analysed for mutations in exons 11 and 12 of  the Flt3 gene by 
using a modified PCR procedure as described elsewhere
22
. The use of  exon 11 and 12 
specific primers allowed us to cover the whole JM and the first part of  the TK-1 do-
main where most of  the reported ITDs are located.
Genomic DNA was prepared using a standard procedure
23
. Briefly, DNA from about 
104 cells was amplified in a total of  50 µl reaction mixture, containing single strength 
PCR buffer, 10 pMol of  each primer, 10 mM dNTPs and 0.5 U Taq polymerase (Su-
pertaq, SpheroQ, Leiden, The Netherlands). Preheating of  the samples at 95oC was 
followed by amplification for 35 cycles consisting of: 1 min. at 43 oC, 1 min. at 72 oC 
and 1 min. at 95 oC. Following these cycles a final extension at 72 oC was performed 
for 10 min. PCR products were stained with SYBR green I (Molecular Probes, Leiden, 
The Netherlands) and resolved on 3% agarose gel. As a confirmation samples posi-
tive for an Flt3-mutation were reanalyzed in a second PCR using the primers 11F and 
12R. 
Short-term proliferative response to single cytokine stimulation
To determine the proliferative response of  AML bone marrow samples to single cy-
tokine stimulation we used a thymidine incorporation assay. As monocytes are known 
to produce many cytokines and thus potentially may perturb the results, we removed 
these cells prior to their use in culture by adhesion to plastic (1hr incubation at 37oC 
in alpha-MEM [Gibco, Breda, The Netherlands] + 1% BSA [Sigma, St. Louis, MO, 
USA]). FAB M5 samples were excluded from this treatment as the leukemic cells from 
this monocytic leukemia also adhere to the plastic. The non-adherent cells were plated 
in 96-well plates at a density of  2x104 cells/well in serum free medium24 and cultured 
for six days. The cytokines used were either hIl-1α (100 U/ml),  hIl-7 (100U/ml), 
hGM-CSF (10ng/ml) all a generous gift from Immunex (Seattle, WA, USA); hIl-11 
(10ng/ml), hM-CSF (100 U/ml), hIL-3 (25ng/ml) all a gift from Genetics Institute, 
Cambridge, MA, USA; TNFα (1000U/ml, Boehringer, Ingelheim, Germany), hEPO 
(1U/ml, Janssen Cilag, Berchem, Belgium), hG-CSF (100ng/ml) or hSCF (100 ng/ml) 
both a gift from Amgen (Thousand Oaks, CA, USA). After six days the cells were in-
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cubated overnight with 0.1 µCi tritiated-thymidine (Amersham, Buckinhamshire, UK) 
per well and harvested onto nitrocellulose filters. Thymidine incorporation was de-
termined using a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden) as 
counts per minute (cpm). All cultures were done in triplicate. 
Statistical analysis
Statistical analysis of  the data was performed using the SPSS software package (SPSS 
Inc., Chicago Il., USA). The usual χ2 test was used to evaluate complete remission (CR) 
and relapse rates. For the survival analysis the Kaplan-Meier method of  the same soft-
ware package was used. The logrank test was used to check for equality of  the survival 
distributions. Overall survival was calculated from the date of  diagnosis to the date of  
(leukemia-related) death. The failure-free survival (FFS) was calculated from the date 
of  diagnosis to the date of  relapse. Patients not achieving CR were scored as having an 
FFS of  0.01. Patients dying from non-leukemia related causes during first CR were in-
cluded until date of  death. Patients not showing any event were considered “censored” 
observations at the date of  last follow up. 
Initial screening of  the correlations between growth factor responses and prognosis 
was performed by multivariate Cox-regression analysis using the rank numbers of  the 
growth factor responses as a variable to test for trend.  Growth factors which showed 
a significant correlation in this initial screening were studied in further detail by strati-
fication of  the patients in high and low responders based on the optimal cut-point for 
the cytokine response. In this analysis the optimal cut-point is defined as the amount 
of  thymidine incorporation, measured as counts per minute, at which the difference in 
patient prognosis between low and high responders is largest. Patients with a growth 
factor response up to and including the cut-point were considered to be low respond-
ers whilst all others were considered to be high responders. 
Multivariate Cox-regression analysis was also used to identify other predictor variables 
present in the total study population and for the calculation of  the relative hazards of  
these variables. In all evaluations values were considered significant if  p-values were 
below 0.05.
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5.4. Results
Characterization of patients.
Bone marrow samples from 103 patients with primary AML were screened for the 
presence of  an Flt3/ITD. Of  the 103 samples, 25 patients (25%) were found to have 
such a mutation. All Flt3/ITDs were in the exon 11 region of  the gene, none in exon 
12. As previously shown
15,25
 the mutation was randomly distributed over the FAB 
classes and there was no apparent correlation with any known cytogenetic aberration. 
In most of  the Flt3/ITD positive patients the mutation was present as a heterozygous 
mutation but in 5 cases the ITD appeared as a single aberrant band on gel, indicating 
the presence of  either a homozygous mutation or, more likely, a hemizygous deletion 
of  the wildtype gene.
The characteristics of  these 25 AML patients with an Flt3/ITD and the 78 AML pa-
tients without such mutations included in this study are shown in Table 1.
 Flt3/ITD
AML
Flt3/wildtype
AML
Total number 25 78
Age
Mean (yr.)
Range (yr.)
43
18-73
25
16-76
Gender
Male 
Female 
11
14
42
36
WBC
(x10-9)
Mean
Range
64.5
1-253
25.0
1-158
FAB 
Classification
Unclassified
M0
M1
M2
M3
M4
M5
0
0
3
5
2
8
7
1
2
12
19
4
20
20
Cytogenetic
Risk group*
Good prognosis
Intermediate prognosis
Poor prognosis
4
21
0
15
52
11
Table 1. Patient characteristics
* Cytogenetic stratification was performed according to the criteria described in 
the Materials and Methods section.
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Short-term proliferative response of primary AML.
We have recently shown
11
 that the presence of  Flt3/ITDs in AML correlates with a 
reduced proliferative ability of  AML in short-term cultures (7 days) without stromal 
support. We have now extended the analysis to 10 cytokines (Table 2). In almost all 
cases the Flt3/ITD positive samples showed a tendency for a decreased response to 
cytokines as compared to those from non-mutant cases. However, impaired cytokine 
responsiveness of  Flt3/ITD AML-blasts was only significant for G-CSF and GM-CSF 
(respective p-values: 0.02 and 0.05). Within the Flt3 wildtype population, the strongest 
responses were observed for Il-3, GM-CSF or G-CSF and the lowest median respons-
es were seen when AML cells were stimulated with Il-7, Il-11 or TNFα (all of  them 
even showed a median <0, indicating inhibition). None of  the cytokine responses re-
vealed a correlation with age, white blood cell counts at diagnosis or cytogenetics (data 
not shown). Correlations could neither be detected between proliferative ability and 
FAB classification except for an increased autonomous proliferation in the FAB M5 
samples. This observation can be explained by the fact that in the preparation of  the 
FAB M5 samples the plastic adhesion step was omitted, as explained in the Materials 
and Methods section, thus allowing for the presence of  cytokine-producing mono-
cytes.
Flt3 Wildtype Flt3/ITD
N
Median 
response
Range N
Median 
response
Range
Autonomous 78 649 0 – 15776 25 714 0 – 19532
Il-1α 78 150 -1833 – 35350 25 58 -1172 – 5009
Il-3 77 3208 -1907 – 32908 25 2240 -111 – 52189
Il-5 68 102 -1124 – 14465 18 23 -591 – 16492
Il-7 69 -9 -1991 – 2257 18 -4 -8 – 112
Il-11 62 -5 -3046 – 1510 15 -35 -319 – 145
TNFα 73 -140 -14209 – 12212 23 -289 -5088 – 2456
EPO 77 139 -712 – 30495 25 29 -1413 – 1333
SCF 63 838 -851 – 27859 16 676 -99 – 3546
M-CSF 78 225 -1170 – 20440 25 63 -1124 – 4735
G-CSF 77 1996 -2483 – 48333 25 702 -668 – 9658
GM-CSF 78 2039 -1164 - 20647 25 910 -708 - 15288
Table 2. Response of primary AML to growth factor stimulation.
Responses are given as counts per minute (cpm), defined as the difference in cpm between the test 
sample and an irradiated control sample. All cytokine stimulation data were corrected for the com-
ponent caused by the autonomous proliferation, thus explaining negative values.
Chapter 5
116
Internal tandem duplications in the Flt3-gene
117
Clinical response and prognosis of AML patients.
Within our total study population, multivariate analysis with the rank number of  the 
cytokine responses as variables, only showed the autonomous proliferation to be a sig-
nificant predictor for prognosis (Table 3). None of  the panel of  10 cytokines tested 
proved to be a significant predictor. For further survival analysis patients were classi-
fied into low and high autonomous proliferation groups according to the criteria de-
scribed in the Materials and Methods section (optimal cut point 3000 CPM). The lat-
ter analysis showed an even better distinction in both failure-free and overall survival 
between low and high autonomous responders (Figure 1).
Variable No. of  observations P-value
Autonomous proliferation 103 0.003*
GM-CSF induced 103 0.3
G-CSF induced 102 0.2
M-CSF induced 103 0.08
Il-lα induced 103 0.09
Il-3 induced 102 0.2
Il-5 induced 86 0.5
Il-7 induced 87 0.06
Il-11 induced 77 0.2
TNFα induced 96 0.08
SCF induced 79 0.9
EPO induced 102 0.9
Table 3. Significances for cox regression analysis deter-
mining the relations between the growth factor responses 
and failure free survival. 
For this analysis the rank number of  the growth factor response was 
used as input variable for the regression analysis. 
* values considered to be statistically significant
Variable P-value Relative Risk
Intermediate risk cytogenetics 0.06 3.2
Poor risk cytogenetics 0.001* 7.0
Age above 60 years 0.003* 2.7
Flt3/ITD 0.0002* 2.9
Table 4. Relative hazards within the total study 
population as calculated by cox regression analysis.
* values considered to be statistically significant
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To be able to more accurately define the intermediate risk group within our study 
population we performed a multivariate analysis with age, FAB-classification, gender, 
the presence of  Flt3/ITD and conventional cytogenetics as variables in the regression 
analysis. Of  these variables poor-risk cytogenetics, an age over 60 years and the pres-
ence of  Flt3/ITDs (Figure 2) appeared to represent independent predictors of  poor 
prognosis (Table 4). We therefore defined our intermediate risk population as that 
population of  patients without either poor or good risk cytogenetics, not having an 
Flt3/ITD with an age of  60 years or younger.  Analysis of  the failure-free survival of  
the resulting good, intermediate and poor risk populations is shown in Figure 3.
Though the autonomous proliferation was a significant predictor for survival with in 
the total primary AML population this parameter was not a significant predictor within 
the intermediate risk population. On the other hand two of  the tested cytokines, i.e. 
M-CSF and Il-1α were shown to be significant predictors within this population (Ta-
ble 5).  
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Figure 1. Cumulative failure-free (panel A) and overall (panel B) survival of the total 
primary AML population. 
Stratification was based on the autonomous proliferation in a 7-day thymidine incorporation assay. Solid 
lines, population with a low (<=3000 cpm) autonomous proliferation. Dotted lines, population with a 
high (>3000 cpm) autonomous proliferation. In the inserts values under “N” depict the total number 
of  samples in each population whilst the values under “O” depict the numbers of  observed events in 
each population.
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Figure 2. Cumulative failure-free  survival of primary AML patients with or without 
internal tandem duplications. 
Solid lines, Flt3-wildtype population. Dotted lines, population with Flt3/ITD. In the insert values un-
der “N” depict the total number of  samples in each population whilst the values under “O” depict the 
numbers of  observed events in each population.
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Figure 3. Cumulative failure-free survival of poor, intermediate or good risk AML. 
Solid lines, Population with favorable or good risk AML.  Dashed lines, population with intermediate 
risk AML. Dotted lines, population with poor risk AML. In the insert values under “N” depict the total 
number of  samples in each population whilst the values under “O” depict the numbers of  observed 
events in each population.
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In univariate analysis, stratification of  the patients in low and high responders at an 
optimal cut-point of  300 and 400 CPM for Il-1α and M-CSF respectively, proved both 
growth factors to be good predictors for both failure-free and overall survival (Figures 
4 and 5). These figures also show the initial therapy response of  high and low respond-
ers to both Il-1α and M-CSF not to be different. However, at a median observation 
time of  15 months, significantly different relapse rates could be observed (Table 6). 
Relapse rates varied form 5/21 and 4/17 (24%) for the low responder groups of  M-
CSF and Il-1α respectively to 5/5 (100%) for the M-CSF high responder population 
and 6/9 (67%) for the Il-1α high responder population.
Variable No. of  observations P-value
Autonomous proliferation 41 0.1
GM-CSF induced 41 0.2
G-CSF induced 40 0.08
M-CSF induced 41 0.03*
Il-lα induced 41 0.008*
Il-3 induced 41 0.4
Il-5 induced 35 0.6
Il-7 induced 35 0.5
Il-11 induced 32 0.9
TNFα induced 37 0.9
SCF induced 33 0.4
EPO induced 41 0.3
Table 5. Cox regression for failure free survival within the in-
termediate risk population in relation to growth factor 
responses.
For this analysis the rank number of  the growth factor response was used 
as input variable for the regression analysis. The intermediate risk popula-
tion studied was comprized of  patients with a primary AML, having an age 
of  60 years or younger, having intermediate risk cytogenetics and not show-
ing a Flt3/ITD. * values considered to be statistically significant
Table 6. Therapy response of intermediate risk AML at the median observation 
period of 15 months.
M-CSF induced proliferation Il-1 induced proliferation
<= 400 cpm >400 cpm N total <= 300 cpm > 300 cpm N total
No CR 3 3 16 2 4 6
CR 16 0 10 13 3 16
Relapse 5 5 6 4 6 10
N total 24 8 32 19 13 32
P-value 0.005 0.04
The response to therapy at the median observation time of  15 months was determined for each of  
the indicated response groups. No Cr, patients who failed to respond to therapy or only had a partial 
response. CR, the number of  patients who still showed a complete remission. Relapse the number 
of  patients who had relapsed before the median observation period.
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5.5. Discussion.
In the past few years much progression has been made in the identification of  spe-
cific genetic defects, such as Flt3/ITD, AML-1-CBFβ, PML-RAR and various others, 
their respective role in the pathogenesis of  AML and their clinical prognostic impact. 
Notwithstanding, there is a large population of  patients who can not be stratified in 
specific cytogenetic risk groups. According to the conventional cytogenetic risk strati-
fication there is a large number of  patients with no detectable aberrations or with ab-
errations without prognostic value. Such patients are currently considered to have an 
“intermediate risk”. This group probably is heterogeneous and includes a mixture of  
favourable and unfavourable risk individuals. 
Hematopoietic growth factors may stimulate the in vitro proliferation of  AML
26,27
. 
Correlations between the in vitro cytokine responsiveness and patient prognosis have 
been previously been reported
28-30
. 
Our observation that patients with a Flt3/ITD comprise a “low” cytokine responder 
population coupled to a poor prognosis, combined with the poor prognosis of  pa-
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Figure 4. Cumulative failure-free (panel A) and overall (panel B) survival of the inter-
mediate risk AML population, stratified according to the M-CSF induced prolifera-
tion. 
The intermediate risk population studied was comprized of  patients with a primary AML, having an age 
of  60 years or younger, having intermediate risk cytogenetics and not showing an Flt3/ITD.
Solid lines, population with a low (<=400cpm) M-CSF induced proliferation. Dotted lines, population 
with a high (>400 cpm) M-CSF induced proliferation. In the insert values under “N” depict the total 
number of  samples in each population whilst the values under “O” depict the numbers of  observed 
events in each population.
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tients with an age over 60 years, led us to define our intermediate risk population as 
that population of  primary AML patients with an age below 60 years not having a 
tandem duplication in the Flt3 gene and with intermediate risk cytogenetics. Here we 
show that among this intermediate risk population, poor and good risk patient prog-
nosis can be further stratified based on the short-term (7-day) in vitro response to either 
G-CSF or Il-1α. Our observation that the autonomous proliferation, though predic-
tive in the total study population, was not predictive in the intermediate risk population 
could not be explained by the absence of  a specific high autonomous responder, poor 
prognosis, population in our intermediate risk population (data not shown). 
Though the survival curves of  both M-CSF and Il-1α resemble each other (Figs 4-5), 
analysis of  the individual patients showed different responses to both growth factors 
i.e. patients within the high responder population after Il-1 stimulation could be low 
responders after M-CSF stimulation and vice versa (data not shown). 
Time (Months)
4842363024181260
cu
m
ul
at
iv
e
pe
rc
en
ta
ge
100
80
60
40
20
0
<= 300 cpm
>300 cpm
Logrank p=0.001
<=300 25 7
>300 16 12
N O
A
4842363024181260
100
80
60
40
20
0
<= 300 cpm
>300 cpm
Logrank p<0.001
<=300 15 4
>300 16 15
N O
B
Figure 5. Cumulative failure-free (panel A) and overall (panel B) survival of the inter-
mediate risk AML population, stratified according to the Il-1α induced proliferation. 
The intermediate risk population studied was comprized of  patients with a primary AML, having an age 
of  60 years or younger, having intermediate risk cytogenetics and not showing an Flt3/ITD.
Solid lines, population with a low (<=300cpm) Il-1α induced proliferation. Dotted lines, population 
with a high (>300 cpm) Il-1α induced proliferation. In the insert values under “N” depict the total 
number of  samples in each population whilst the values under “O” depict the numbers of  observed 
events in each population.
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As calculated from the Kaplan-Meier survival analysis within the subpopulation of  
the redefined intermediate risk patients, the low responder groups had a four-year OS 
of  around 60-80 percent whilst the four-year FFS of  these groups varied between 60-
70 percent. This is in sharp contrast with the high responder populations where these 
values were between 0-10% for both OS and FFS. The difference in the FFS of  the 
intermediate risk population was also visible when calculating the median duration 
of  the FFS (Table 7). In both cytokine combinations the median FFS for the low re-
sponder groups was over 60 months whilst this value was around 6-7 months for the 
high responders. In the cytokine responses that were found to be predictive, the better 
prognosis of  the low responder group was not based on an increased initial therapy re-
sponse. Rather, high responders had both a shorter FFS and an increased relapse rate. 
However, the biological significance in AML progression or AML relapse of  both the 
autonomous and M-CSF or Il-1α induced response observed in vitro would require 
further study. 
M-CSF induced proliferation Il-1 induced proliferation
<= 400 cpm >400 cpm <= 300 cpm > 300 cpm
Median duration 
(months)
> 60 6.0 >60 7.0
Standard Error 0.9 1.6
95% conf. interval 4.2 - 7.8 3.9 - 10.1
P-value 0.0003 0.0014
Table 7. Median duration of failure free survival in patients with 
intermediate risk primary AML.
Of  patients with intermediate risk AML, i.e. those patients with an age below 60 years with 
intermediate cytogenetics and a wildtype Flt3 gene, the median duration of  failure free sur-
vival was calculated by Kaplan-Meier analysis. Patients were stratified in to either a low or 
high response group based to the response to cytokines (see Results section).
As cytokine responses might be limited in time we also studied the cytokine responses 
after three days in vitro culture (data not shown). Though we did observe differences in 
the levels of  responses (both increases and decreases were found when compared to 
day 7) neither of  the cytokines tested at this time point was predictive for survival. 
In the present study we have focussed on the total primary AML population and the 
population with an intermediate risk. We argued that the sub classification of  the lat-
ter population into variable prognosis subgroups would be clinically most relevant. We 
also showed, that a poor patient prognosis is not linked to high overall cytokine re-
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sponses of  the patients AML-blasts, as is indicated by the significance of  both M-CSF 
and Il-1 which only caused a modest proliferation in most samples (see Table 2). To 
date, the median follow-up period of  our patient population is 15 months, which limits 
the predictive value of  our experiments. Therefore, we plan to extend the observation 
period in the near future.
In conclusion, our present data indicate that within the intermediate risk group addi-
tional risk stratification is possible. Despite the fact that further follow-up of  especially 
the good risk groups is required to study their disease progression over a prolonged 
period of  time, we consider the detection of  a high responder “poor risk” population 
in the intermediate risk group to be of  importance. Whilst the initial therapy response 
of  the patients within this population equals that of  the other response groups, they 
are characterised by an increased relapse rate as well as a shorter overall and failure-
free survival. If  further study extends and supports our data, it should be considered 
to include these patients in the poor risk arms of  treatment protocols and offer them 
intensified treatment or bone marrow transplantation.
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6.1. Abstract
Among a variety of  immunodeficient mouse strains the nonobese diabetic (NOD) / 
LtSz scid/scid strain appears to be most useful in allowing the engraftment of  human 
AML. However, the large variability in ability to engraft and the levels of  engraftment 
reached have not been explained. To address these issues we have investigated the 
NOD/SCID repopulating ability of  27 newly diagnosed AML samples. Patients were 
selected for the absence of  internal tandem duplications in the Flt3 gene as we previ-
ously reported this mutation to be associated with an enhanced engraftment potential 
in this model.
We observed that secondary AML (n=6) had a significantly increased level of  engraft-
ment when compared to primary AML (n=21, median levels 73.3% for secondary 
AML vs. 8.94% for primary AML, p=0.01). Within the primary AML, a significantly 
higher engraftment was observed of  the FAB class M0 than of  FAB classes M2, M4 
and M5. Within primary AML, samples of  patients who failed to respond to the ini-
tial therapy gave rise to a higher level of  engraftment than samples of  patients who 
did respond to therapy. A similar observation of  an increased engraftment correlating 
with a poorer patient prognosis could be made when applying cytogenetic risk strati-
fication. However, within the primary AML the most important clinical parameter 
correlating with the level of  engraftment appeared to be the patient’s WBC counts at 
diagnosis (p=0.0000). Covariate analysis with the WBC count as a covariate could also 
fully explain the differences observed in the cytogenetic risk groups, or on the basis of  
the initial therapy response. Though large differences could be observed, the ability to 
engraft the NOD/SCID mice was not linked to either the autonomous or cytokine-in-
duced proliferation in vitro. As the leukemic cobblestone area forming cell frequencies 
also revealed no correlation with repopulation in the NOD/SCID model, we consider 
it very likely that the level of  engraftment reflects the in vivo proliferative ability of  the 
AML samples assayed rather than the number of  leukemia-initiating cells infused into 
the NOD/SCID mice. Phenotypic analysis based an the expression of  CD33, CD34 
and CD38 before and after passage in NOD/SCID showed that in 10 out of  16 sam-
ples investigated phenotypes were different. 
In summary, in addition to the Flt3 internal tandem duplications we have identified a 
series of  clinical parameters that determine the NOD/SCID repopulating ability of  
AML samples, whilst our data strongly suggest that AML in NOD/SCID does not re-
flect the leukemic process in the patient.
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6.2. Introduction
The term acute myeloid leukemia (AML) encompasses a range of  clonal hematopoi-
etic disorders with an aberrant proliferation and differentiation. Generally, these leuke-
mic cells are committed to the myelo-monocytic lineage though they might also be 
show erythroid or megakaryocytic lineage characteristics. Analysis of  clonal markers1-3 
has shown that leukemic transformation may occur at the level of  the pluripotent or 
the less primitive, committed, hematopoietic stem progenitor cell. We and others have 
recently shown that these primitive leukemic progenitors can give rise to long-term 
malignant hemopoiesis in vitro when supported by a feeder of  murine stromal cells4-6.
In normal hemopoiesis murine transplantation models have played a crucial role in 
our understanding of  the most primitive stem/progenitor cells able to give multiline-
age engraftment. Until recently, research in normal human hemopoiesis was hampered 
by a lack of  suitable in vivo assays. This has changed with the availability of  chimeric 
models in which human hemopoietic progenitors exhibit multilineage engraftment 
when injected into sublethally irradiated immunodeficient mice7-9.
Immunodeficient mice can also support the growth of  malignant progenitors of  
chronic myeloid leukemia (CML) and AML10-13.  Among a variety of  immunodeficient 
mouse strains, we and others have evaluated, the nonobese diabetic (NOD) /LtSz 
scid/scid strain appears to be most useful in allowing the engraftment of  human AML 
progenitors14,15. In contrast to the CB17/SCID strain, which is only defective in B- and 
T-cell function, this strain is characterized by an additional functional deficit in NK-
cell function as well as defective antigen-presenting cells and an absence of  circulating 
complement. Injection of  AML-cells into these mice reportedly results in engraftment 
and development of  leukemia in the murine hematopoietic tissue in a similar way to 
that seen in patients16. Though in most AML cases the cells able to initiate engraftment 
(SCID Leukemia-initiating cells or SL-IC) were phenotypically characterized as CD34+ 
CD38-6, some cases have been reported in which these SL-IC were CD34-CD38- 4.  The 
ability of  SL-IC to engraft after a prior in vitro incubation with 5-FU suggests that these 
cells, analogous to normal hemopoiesis, belong to a more quiescent population
5
.
The large variability between AML samples in their ability to engraft the bone marrow of  
NOD/SCID mice has thus far not been explained. Also, little is known about the corre-
lation between engraftment in NOD/SCID and clinical or biological characteristics of  
the AML sample. To address several of  these issues we have investigated a series of  newly 
diagnosed AML samples in their ability to engraft in the NOD/SCID mice. These data 
were correlated with clinical parameters such as prognosis, cytogenetics, white blood 
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cell counts and FAB classification.  We also looked for correlations with the Leukemic-
Cobblestone Area Forming Cell (L-CAFC) content of  the samples as well as the short-
term in vitro proliferation in response to a panel of  cytokines. As we have previously 
shown that AML samples from patients with an internal tandem duplication in the Flt3 
gene (Flt3/ITD) represent a distinct subpopulation of  AML with a greatly enhanced 
potential to engraft in the NOD/SCID27 these samples were excluded from this study.
6.3. Materials and methods
Patient samples
Diagnosis bone marrow samples of  patients with newly diagnosed AML were obtained 
after informed consent. Cases were classified according to the French-American-Brit-
ish committee (FAB)17. Mononuclear cells were isolated by ficoll separation followed 
by T-cell depletion, typically resulting in a population containing over 95 percent blasts. 
After isolation, cells were subjected to controlled freezing and stored in liquid nitro-
gen. Before use cells were thawed by stepwise dilution in Iscove’s Modified Dulbecco’s 
medium (IMDM, Gibco, Breda, The Netherlands) containing 1% BSA. After thawing 
viability varied between 70 and 90 percent as assessed by dye exclusion. 
After diagnosis patients were treated according to studies of  the adult Dutch-Belgian 
Heamato-Oncology Group HOVON and the Dutch childhood leukemia group SN-
WLK. Patients were treated according to protocols HOVON-29 (less than 60 yr. of  
age, 11 patients)18, HOVON-4 (less than 60 yr., 3 patients)19, HOVON-31 (60 yrs+, 4 
patients), AML-11 (60 yrs+, 5 patients)20 or SNWLK-ANLL-94 protocols (less than 15 
yr. of  age, 2 patients). Two patients received palliative treatment only. In these proto-
cols induction therapy included an anthracyclin and cytarabine and in patients less then 
60 yrs allogeneic and autologous stem cell transplantation or intensive chemotherapy 
for consolidation were applied as postremission therapy.
Stratification according to karyotype-risk groups
As cytogenetic aberrations are thought to be one of  the most important prognostic 
factors for AML21,22 patients were stratified in three groups i.e. a good-risk group con-
sisting of  patients defined by a karyotype of  t(8;21), t(15;17) or inv(16) and a poor-
risk group defined by del(5), del(7), or deletions of  the q-arms of  these chromosomes, 
t(6,9), alterations in the 11q23 region or the presence of  multiple aberrations (more 
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than 3) in the karyotype. All other karyotypic aberrations and the normal karyotype 
were included in an intermediate-risk group.
Determination of the short-term proliferative response to single cytokine 
stimulation
To determine the proliferative response to single cytokine stimulation we used a thymi-
dine incorporation assay. As monocytes and macrophages are known to produce many 
cytokines and thus potentially may perturb the results we removed these cells prior 
to their use in culture by adherence to plastic (1hr incubation at 37oC in alpha-MEM 
(Gibco) + 1% BSA (Sigma, St. Louis, MO, USA). The non-adherent cells were plated 
in 96-well plates at a density of  2x104 cells/well in serum free medium23 and cultured 
for six days. The cytokines used were hIL-3 (25ng/ml, a gift from Genetics Institute, 
Cambridge, MA, USA.), hGM-CSF (10ng/ml, Immunex, Seattle, WA, USA), hG-CSF 
(100ng/ml, a gift from Amgen, Thousand Oaks, CA, USA), hM-CSF (100 U/ml, gen-
erously supplied by Genetics Institute) or hSCF (100 ng/ml, a gift from Amgen). Af-
ter six days cells were overnight incubated with 0.1µCi tritiated-thymidine (Amersham, 
Buckinhamshire, UK) per well and harvested onto nitro-cellulose filters. Thymidine 
incorporation was determined in a liquid scintillation counter (Pharmacia-LKB, Bro-
mma, Sweden) as counts per minute (CPM). All cultures were done in triplicate. 
The stimulation index was calculated by dividing the mean CPM of  the triplicate cul-
tures by the mean CPM of  a 30Gy-irradiated control of  the sample.
Leukemic Cobblestone area forming cell assay
The cobblestone area forming cell assay was performed as described24. Briefly, conflu-
ent FBMD-1 stromal layers in 96-well plates (Costar, Cambridge, MA) were overlaid 
with AML cells in a limiting dilution set-up. The cells were cultured in medium con-
sisting of  IMDM (Gibco) supplemented with 10% heat-inactivated fetal calf  serum 
(Summit Biotechnology, Fort Collins, Co.), 5% horse serum (Gibco), β-mercaptoetha-
nol (5x10-5 mol/l) and hydrocortisone-21-hemisuccinate (10-6 mol/l, Sigma). rhIl-3 (8 
ng/ml) and rhG-CSF (20 ng/ml) (both a generous gift of  the Genetics Institute) were 
added to the medium and all cultures were performed at 37oC and 10% CO
2
 in a hu-
midified atmosphere.
Input values were equivalent to 1x105 nucleated cells/well and 12 dilutions three-fold 
apart were used for each sample with 15 replicates per dilution. The percentage of  
wells with at least one phase-dark clone (cobblestone area, consisting of  at least 5 cells) 
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beneath the stromal layer was determined weekly and leukemic CAFC (L-CAFC) fre-
quencies were calculated using Poisson statistics25.
Based on evidence from murine correlation studies it is assumed that both normal and 
leukemic cobblestone areas that are observed late in culture are indicators of  primi-
tive long-term repopulating cell in vivo, whilst early appearing clones are indicators of  
transiently repopulating and less primitive cells.
The NOD/SCID mouse model
NOD/SCID mice were bred in the Erasmus animal facility and housed under speci-
fied pathogen free conditions, using laminar airflow units. Mice were supplied with 
sterilised food and acidified tap water to which 100mg/l ciprofloxacine (Bayer AG, 
Leverkusen, Germany) was added. Both food and drink were available ad lib.
Before transplantation of  the AML cells the mice received a total body irradiation of  
3.5Gy gamma radiation ( 137Cs source, Gammacell, Atomic Energy of  Canada, Ottawa, 
Canada). Transplantation of  the AML cells was done by injecting 3x107 AML cells in 
the lateral tail vein.  After 30 days, the mice were sacrificed by CO
2
 inhalation in ac-
cordance with the institutional animal research regulations.
Cell suspensions were made from both femora and used for flowcytometry.
Flow cytometry 
To determine the percentage of  AML cells in bone marrow suspensions from mice 
that had been transplanted, cells were stained with an antibodies against the human 
common leukocyte antigen (CD45), CD34, CD33 and CD38 (CD45-FITC, CD38-
FITC, CD33-PE and CD34-APC, all obtained from Coulter Immunotech, Marseille, 
France) and measured using a FACScalibur (Beckton Dickinson Immunocytometry 
systems, San Jose, CA, USA).  Analysis was done using the Cell Quest software pack-
age (Beckton Dickinson).  Erythrocytes were excluded from analysis by gating on  for-
ward and perpendicular light scatter whilst dead cells were excluded by staining with 
7-amino-actinomycin D  (7-AAD, Molecular Probes, Eugene, OR, USA). 
Statistical analysis
Statistical analysis of  the data was performed using the SPSS software package (SPSS 
Inc., Chicago Il.). Significance of  differences for the proliferation, L-CAFC and SCID 
assays was determined by either the non-parametrical Mann-Whitney U test or the 
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Kruskal Wallis test for multiple independent parameters. Correlation analysis was per-
formed using Spearmans rho test for nonparametrical correlation.
patient
No
Age FAB
classification
Cytogenetics Initial therapy
response
WBC
(x 10-9/l)
1 74 M0 -5,-2,-17,-18 No Cr 129
2 77 M0 7q-,+8 No Cr 214
3 62 M0 N No Cr 39
4 19 M1 N CR 50
5 40 M1 N CR 72
6 79 M1 N CR 260
7 61 M2 +4,+13,+14 No Cr 1
8 35 M2 t(8:21) CR 16
9 28 M2 t(8:21) CR 11
10 39 M2 t(8:21) CR 8
11 88 M2 N No Cr 47
12 61 M2 N CR 2
13 66 M2 N CR 1
14 16 M4 N CR 1
15 69 M4 7q-,+8 CR 343
16 30 M4 t(6:11) CR 126
17 23 M4 t(16;16) CR 84
18 78 M4 N No Cr 45
19 4 M4 N CR 14
20 73 M4 N CR 18
21 32 M4 N CR 48
22 51 M5 +8 CR 85
23 49 M5 +8 CR 30
24 9 M5 t(10:11) CR 3
25 54 M5 7q- No Cr 11
26 63 M5 N No Cr 32
27 46 M5 N CR 44
Table 1: Patient characteristics 
A total of   27 samples of  patients with newly diagnosed AML were included in this study. Patients were 
selected to give a good representation through out the FAB classes. cytogenetics were determined for all 
samples, cytogenetic abnormalities are included if  observed.samples from AML-M3 patients are absent 
as we were unable to generate reliable results in the NOD/SCID using these samples.
Initial therapy response was defined as CR if  the patient achieved a complete remission, No Cr if  the 
patient failed to get in to remission or only achieved a partial remission.
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6.4. Results
Variability in the outgrowth of AML cells in the NOD/SCID mouse.
The NOD/SCID mouse model was used to investigate the in vivo leukemia-initiating 
capacity of  newly diagnosed AML.  Due to the large number of  cells needed for a re-
producible engraftment (3x107 cells/mouse) and the limited availability of  animals we 
were only able to analyze a limited number of  samples (n=27). Groups of  3 mice/
sample were injected with AML cells and analyzed at day 30 after transplantation. We 
were unable to analyze samples of  FAB class M3 as all samples of  this type injected 
into NOD/SCID resulted in death of  the mice within 24 hours after injection (with 
the highest mortality within 1 hour). This was most probably due to in vivo lysis of  the 
cells resulting in intravascular coagulation.
Patient details of  the analyzable samples are given in Table 1. Analysis of  the percent-
age of  engraftment shows a clear variability between the FAB classes (Fig. 1). The 
M0 and M1 samples gave rise to the highest median level of  chimerism whereas FAB 
M2 and M5 showed a low level of  engraftment. As indicated by the large interquar-
tile range there was an extreme variation within the M4 class. The median within this 
group was in the lower part of  this range as most samples only induced a relatively low 
engraftment. A closer study of  the clinical data indicated that the higher engraftment 
data in the FAB M4 class were by AML samples from patients that were likely to have 
had a previous history of  MDS. Because we could not exclude the possibility that such 
so-called “secondary AML” patient samples were also included in the other FAB class 
groups; we re-analyzed the other groups as well (Fig. 2). Indeed we found that in all 
cases the secondary AML samples induced a significantly higher level of  NOD/SCID 
engraftment as compared to primary AML samples.
When we excluded the secondary AML samples from our analyses, the highest level of  
engraftment was still observed in FAB class M0 and M1, however, statistical analysis 
showed only significant differences between classes M0 and M2, M4 or M5 (p=0.036, 
0.025 or 0.024, respectively). As we only had six secondary AML samples in our data 
set we were not able to analyze this the engraftment ability of  population on the ba-
sis of  FAB class.A median engraftment of  8.9% was observed after pooling all pri-
mary AML samples irrespectively of  FAB class (Fig. 3). In contrast, secondary AMLs 
showed a median engraftment of  73.3%, which was significantly different from that of  
primary AML samples (p=0.01). Based on this clearly different ability of  both popu-
lations to engraft in the NOD/SCID the primary and secondary AML groups were 
separately analyzed in this study.
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We also investigated whether the ability to engraft the NOD/SCID mouse could be 
correlated to the initial response of  the patient towards therapy (Fig.4). In the prima-
ry AML samples there was a clear, though not significant, enhanced engraftment in 
the population who failed to achieve a complete remission (CR). Within the second-
ary AML samples no difference could be observed in engraftment between patients 
who achieved a CR and those who failed. Due to the low number of  secondary AML 
samples in the group who failed to respond to therapy no significant differences be-
tween primary and secondary AML samples could be found. In the group of  patients 
who achieved a CR the differences between these subtypes of  AML were significant 
(p=0.049). Further subdivision of  the patients achieving a CR in patients who remain-
ed in CR, and patients who relapsed within 23 months (our median observation pe-
riod) no differences could be observed for both primary and secondary AML (data 
not shown). The observation that, at least for the primary leukemias, there was a rela-
tion between poor prognosis (i.e. therapy failure) and an increased ability to engraft 
the mice led us to investigate whether this observation could be related to other im-
portant clinical parameters associated with patient prognosis. Correlation analysis for 
the patient’s age and the ability to engraft NOD/SCID revealed no relationship (data 
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Figure 1: Distribution of the engraftment of AML in NOD/SCID mice over the FAB-
classes.
The horizontal black lines in these figures represent the median observed chimerism. Shaded bars rep-
resent the interquartile range, whilst the error bars indicate extreme cases. Outlayers are marked by an 
asterisk. Numbers below the x-axis depict the number of  cases within each group. 
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Figure 2: Distribution of the engraftment of AML in NOD/SCID over the FAB classes 
corrected for primary and secondary AML.
Light shaded bars represent primary AML whilst dark shaded bars represent secondary AML. The hori-
zontal blackline indicates median values, bars represent the interquartile range, whilst the error bars in-
dicate extreme cases. For furhter legends see figure 1
Figure 3: Differences in the overall level of chimerism between primary and second-
ary AML. 
The horizontal black lines in these figures represent the median observed chimerism. Shaded bars rep-
resent the interquartile range, whilst the error bars indicate extreme cases. For furhter legends see figure 
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not shown). Application of  cytogenetic risk stratification to the data indicated an in-
creasing ability for the primary AML samples to engraft with a decreasing prognosis 
for the patient (Fig. 5). Though this relation was shown not to be significant, the most 
extreme responses were clearly in the poor prognosis group. As most secondary AML 
samples fell within the intermediate risk stratum no objective comparisons could be 
made within the other strata. In the intermediate risk group we could again observe 
a much higher level of  engraftment for the secondary leukemias as compared to the 
primary leukemias (p=0.026).  
Because an increasing white blood cell count (WBC) at diagnosis is also associated with 
poor prognosis, we performed a correlation analysis for this parameter with regard to 
NOD/SCID repopulation ability.  Even without taking into account the presence of  
both primary and secondary AML this was shown to be a highly significant parameter 
(p=0.0001, data not shown). However, this correlation was only linked to the primary 
AML samples (p=0.0000 compared to p=0.4680 for secondary AML). As can be seen 
in Figure 6, low WBC levels correlate with a low level of  engraftment of  primary AML 
samples in NOD/SCID. The observation that some samples fell outside of  the 95% 
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Figure 4: Relation between the level of engraftment in NOD/SCID and the initial 
therapy response of the patient.
CR group: Patients who achieved a complete remission in response to initial treatment, No CR group: 
Patients who failed to respond to therapy or only achieved a partial remission.  Light Shaded bars, Pri-
mary AML, Dark shaded bars, Secondary AML. For furhter legends see figure 1
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Figure 5: Distribution of the engraftment of AML in NOD/SCID over the cytogenetic 
risk groups.
Patients were stratified into cytogenetic risk groups according to the criteria as described in the Materials 
and Methods section. Light shaded bars, primary AML. Dark shaded bars, secondary AML. For furhter 
legends see figure 1
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Figure 6: Correlation between the level of chimerism observed in the bone marrow 
of NOD/SCID infused with primary AML samples and the white blood cell count at 
diagnosis. 
Each data point represents a single patient sample. Drawn lines indicate the fitted linear regression line 
and the calculated 95% confidence limits. 
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confidence interval suggest however that WBC counts are not the sole factor govern-
ing the NOD/SCID repopulating ability of  primary AML.
Differences in surface marker expression after passage in the NOD/SCID 
mouse.
To investigate whether expression of  the surface markers CD34 and CD38 either be-
fore or after passage in NOD/SCID could be linked to the engraftment of  the mice, 
we performed a two-color flowcytometrical analysis. From the input phenotypes no 
correlations could be derived between the expression of  CD34 and/or CD38 with 
regard to NOD/SCID repopulating ability. After passage in NOD/SCID only the 
CD34-CD38+ phenotype in the primary AML samples showed a low though signifi-
cant negative correlation with NOD/SCID repopulation (Pearsons correlation: -.659, 
p= 0.014, data not shown).  Correlation analysis between the phenotype of  the sam-
ples before and after passage in NOD/SCID revealed no correlation (data not shown). 
As this suggested that for the majority of  samples the phenotype of  the leukemia cells 
differed before and after passage in NOD/SCID mice, 16 samples were subjected to 
a more detailed analysis using three-color flowcytometry for the expression of  CD33, 
CD34 and CD38 (Table 2). 
FAB
Class
patient
No
input
phenotype
% of  
total
phenotype after
passage in NOD/SCID
% of  
total
M0 1 CD33+CD34- CD38+ 86.2 CD33-CD34+ CD38- 65.9 *
2 N.D. CD33-CD34+ CD38- 98.8
3 mix 
CD33+CD34+ CD38+
CD33-CD34+ CD38+
33.5
47.4
mix
CD33+CD34-CD38+
CD33+CD34+CD38+
40.1
28.8
*
M1 4 CD33+CD34+CD38+ 76.5 CD33+CD34-CD38+ 75.3 *
5 CD33+CD34-CD38+ 97.1 CD33+CD34-CD38- 82.1 *
6 mix 
CD33+CD34+ CD38+
CD33+CD34- CD38+
29.3
49.9
mix
CD33+CD34+CD38+
CD33+CD34-CD38+
47.6
54.5
M2 7 CD33-CD34+CD38- 77.9 CD33+CD34-CD38+ 61.9 *
8
N.D.
mix
CD33+CD34-CD38-
CD33+CD34-CD38+
26.5
40.0
Table 2: Phenotype of the AML before and after passage in NOD/SCID mice.
To be continued on the next page
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9 mix
CD33+CD34-CD38+
CD33+CD34+CD38+
58.7
27.3
mix
CD33+CD34-CD38+
CD33-CD34+CD38-
49.4
34.9
*
10 CD33-CD34+ CD38+ 75.8 CD33+CD34-CD38+ 83.6
11 N.D. N.D.
12 N.D. N.D.
13 N.D. N.D.
M4 14 mix
CD33+CD34-CD38+
CD33+CD34+CD38+
43.0
35.7
CD33+CD34-CD38+ 99.6 *
15 CD33-CD34+ CD38- 89.3 CD33+CD34-CD38+ 92.7 *
16 N.D. N.D.
17 N.D. N.D.
18 mix
CD33+CD34-CD38+
CD33+CD34+CD38+
48.9
25.5
CD33+CD34-CD38+ 96.0 *
19 N.D. N.D.
20 N.D. N.D.
21 N.D. N.D.
M5 22 CD33+CD34-CD38+ 90.2 CD33+CD34-CD38+ 90.1
23 CD33+CD34-CD38+ 91.4 CD33+CD34-CD38+ 90.1
24 N.D. N.D.
25 mix
CD33-CD34+CD38+
CD33+CD34+CD38+
63.5
23.7
mix
CD33+CD34-CD38-
CD33+CD34-CD38+
54.1
27.9
*
26 N.D. N.D.
27 CD33+CD34-CD38+ 78.2 CD33+CD34-CD38+ 80.5
table 2 cont’d
A total of  27 samples of  patients with newly diagnosed AML were included in this study. Patients were 
selected to give a good representation through out the FAB classes. cytogenetics were determined for all 
samples, cytogenetic abnormalities are included if  observed.
samples from AML-M3 patients are absent as we were unable to generate reliable results in the NOD/
SCID using these samples.
Initial therapy response was defined as CR if  the patient achieved a complete remission, No Cr if  the 
patient failed to get in to remission or only achieved a partial remission.
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This analysis revealed that in 10 out of  16 samples the phenotype of  the major popu-
lations changed with in vivo passage in the mice. The most frequent changes observed 
were a loss of  CD34 expression accompanied by an increased expression of  CD33 
and CD38 (if  those markers were not already expressed in the input population). Only 
in the FAB M0 class we found changes in phenotype from CD33+CD34-CD38+ to 
CD33-CD34+CD38-.  
Primary AML Secondary AML
in vitro proliferation 
index
correlation with 
NOD/SCID
in vitro proliferation 
index
correlation  
NOD/SCID
Growth factors
added
median range
corr. 
coeff.
p-
value
median range
corr. 
coeff.
p-
value
No Growth factor 9 1-131 -0.147 0.549 21 8-80 0.486 0.329
G-CSF 26 -10-309 -0.235 0.332 49 8-173 0.377 0.461
GM-CSF 22 1-185 -0.031 0.901 65 8-469 0.086 0.872
Il-3 36 2-172 -0.147 0.549 140 22-599 -0.029 0.957
M-CSF 9 -11-57 -0.054 0.828 10 -6-137 0.886 0.019
SCF 13 -43-278 -0.375 0.114 68 23-126 0.800 0.104
Table 3:  The responses of primary and secondary AML to growth factor 
stimulation 
This table shows the median response and the range of  primary and secondary AML to growth factor 
stimulation in a short-term thymidine incorporation assay.  Is also shows the absence of  correlation 
between these assays and the in vivo NOD/SCID model.
Responses are given as stimulation indexes defined as the fold-increase in thymidine incorporation 
between the test sample and an irradiated control sample. All values obtained from cytokine stimula-
tions are corrected for the component caused by the autonomous proliferation, thus explaining nega-
tive values.
The extent of autonomous or cytokine-induced in vitro proliferation does 
not correlate with NOD/SCID repopulation.
There have been contrasting reports on the use of  exogenous growth factors such as 
PIXY to enhance the level of  engraftment in the AML-NOD/SCID model. To test if  
in vitro growth factor responsiveness or growth factor independence might be indica-
tive for NOD/SCID repopulating ability of  AML we studied the cytokine respon-
siveness using a tritiated thymidine assay (Table 3). All growth factor response data 
were corrected for the autonomous responses, i.e. the 3H-TdR uptake in the absence 
of  growth factors. Though large differences in response could be observed, especially 
with G-CSF and SCF, neither the growth factor-induced, nor the autonomous prolif-
eration, proved to be indicative for repopulation of  the NOD/SCID bone marrow. 
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The secondary AML samples generally had both a higher autonomous proliferation 
and a higher cytokine-induced proliferation. However, differences between primary 
and secondary AML were found to be not significant at a level of  P< 0.05 (data not 
shown). 
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Figure 7: Median frequencies of various leukemic-CAFC  weektypes.
20 primary and 6 secondary AML samples were plated in the L-CAFC assay, after which the frequency 
of  the cobblestone area forming cells was analysed on a weekly basis. Primary AML, dotted lines. Sec-
ondary AML, solid lines.
NOD/SCID repopulation does not link with a specific leukemic cobblestone 
area forming cell subset.
The finding that in vitro incubation of  AML with 5-FU depletes early weektype 
L-CAFC combined with the finding that these samples at least partially retain their 
NOD/SCID repopulating ability
5
 led us to investigate whether we could find a corre-
lation between the level of  engraftment and L-CAFC frequencies. As shown in Figure 
7, no significant differences were observed between the frequencies of  L-CAFC week 
1-2 in primary versus secondary AML. Frequencies of  L-CAFC week 4-6 in secondary 
AML were at the lower threshold of  detection, i.e. 1 per 106 cells and appeared to be 
reduced in comparison to the primary AML. 
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No correlations could be observed between the level of  engraftment and any of  the 
L-CAFC weektypes (Table 4), nor could we find a correlation between L-CAFC fre-
quencies and FAB type, cytogenetics or white blood cell counts in patients (data not 
shown).
L-CAFC 
weektype
1 2 3 4 5 6
Primary AML
N 20 20 17 14 12 5
Corr. coeff. -0.128 -0.024 -0.183 0.133 0.421 0.200
p-value 0.591 0.920 0.482 0.651 0.173 0.200
Secondary AML
N 6 5 5 3 3
Corr. coeff. 0.543 0.900 0.500 0.866 0.000
p-value 0.266 0.037 0.391 0.333 1.000
Table 4:  Correlation analysis between the different L-CAFC weektypes and 
the chimerism observed in the bone marrow of NOD/SCID mice
This table shows the correlation coefficients and the p-values for Spearmans rho-test when ana-
lyzing for a correlation between the L-CAFC frequencies for the given weektypes and the level of  
human chimerism in the bone marrow of  the NOD/SCID mice.
6.5. Discussion
The availability of  an in vivo assay for human AML progenitors responsible for the 
maintenance of  the malignant clone(s) is important both for our understanding of  the 
basic biology of  AML as well as for the development of  new therapeutic strategies.
Over the last few years, we and other groups have shown the ability of  AML cells to 
engraft in the NOD/SCID mice. However, one of  the basic shortcomings of  this 
model has been the low and unpredictable level of  engraftment in this assay. 
To our knowledge, this paper is the first to show that primary and secondary AML 
greatly differ in the ability to engraft the NOD/SCID mice. In addition, we show that 
at least in primary AML repopulating capacity was highly correlated to the patient’s 
white blood cell counts at diagnosis. Covariant analysis of  level of  the engraftment 
and FAB class with the patient’s WBC as a covariant could not fully explain our results 
thus suggesting there also is a FAB-specific factor involved in determining the level of  
engraftment. Similar covariant analysis, with WBC counts as a covariant, could how-
ever fully explain the observed correlation between the level of  engraftment and the 
cytogenetic risk groups, i.e. poor, intermediate or good prognosis cytogenetics. The 
above findings might also explain a similar correlation with cytogenetics observed 
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by Ailles at al.26 who did not distinguish between primary and secondary AML, nor 
looked at the relation with WBC. It might also explain why these authors observed dif-
ferent levels of  engraftment in the various FAB classes.
For the primary AML we were unable to find a correlation between the NOD/SCID 
repopulating ability and any of  the L-CAFC weektype frequencies. We could also not 
find a correlation between L-CAFC weektypes and any of  the CD34/CD38 subpopu-
lations, or between the CD34/CD38 subpopulations and repopulating ability. The lat-
ter two observations could be explained by assuming that both the SL-IC and L-CAFC 
only represent a minor subpopulation within any of  the phenotypes. The absence of  a 
correlation between NOD/SCID repopulating ability and any of  the L-CAFC week-
types could imply that the SL-IC is either a subpopulation contained in any of  the L-
CAFC weektypes, or is a cell more primitive than the L-CAFC week 6 and thus not de-
tectable in our assay. However, taken together our observations suggest that: A) there 
is a lack of  correlation between L-CAFC frequencies and engraftment in the mice 
and B) there is a high correlation between WBC counts and NOD/SCID repopula-
tion.  This strongly suggests that the level of  engraftment reached might rather reflect 
the proliferative capacity of  the AML cells than the number of  SL-IC infused. How-
ever, this proliferative capacity could not be correlated with either the autonomous or 
cytokine-induced proliferation in short-term thymidine incorporation studies. If  the 
proliferative capacity of  the samples is one of  the main variables determining the en-
graftment of  NOD/SCID mice this would also imply that assessing the number of  
SL-IC by limiting dilution in NOD/SCID can be biased by the proliferative ability of  
the sample under investigation. 
Though it has been observed that AML cells injected into NOD/SCID have a similar 
dissemination pattern as in patients16, we demonstrate here that in 10 of  the 16 inves-
tigated samples the phenotype of  the cells after passage in the mice differed markedly 
from the input phenotype. This phenotypic change of  the infused cells may have been 
due to the fact that a subclone with the phenotype observed after passage is responsi-
ble for outgrowth, or that the AML cells undergo a different differentiation pattern in 
mice than in patients. 
Whilst from our previous study27 it has become clear that the presence of  internal tan-
dem duplications in the Flt3 gene in AML favours the outgrowth of  these samples in 
the NOD/SCID model, the current study has been able to identify some additional 
important variables involved in determining the NOD/SCID repopulating ability of  
the Flt3 gene wildtype population. 
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Our present identification of  parameters that determine the outgrowth of  AML sam-
ples in NOD/SCID mice may contribute in selecting patient samples for therapy 
development in these immunodeficient mice.
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7.1. Do Flt3-mutations occur at the level of the leukemic stem cell?
Recently the concept of  leukemic stem cells1 has gained increasing support. If  the 
leukemia within a patient arises from such a malignant stem cell the treatment should 
ideally be directed against these stem cells. 
Most of  the studies carried out to reveal the biological characteristics of  Flt3/ITD 
AML have been performed using cell line models, such as 32D and BAF/3, which are 
no proper tools to resolve the question whether Flt3/ITDs occur at the level of  the 
leukemic stem cells or at a later stage. However, certain observations in patients allow 
us to address this question. The observation that in clinical AML, Flt3/ITDs often oc-
curs at a mutant to wildtype ratio less than one strongly suggests that the Flt3/ITDs 
are not present at the level of  the leukemic stem cell. This is further supported by the 
observations of  Kottaridis et al.2 who, using 44 paired samples of  patients at diagnosis 
and relapse, observed that 6 of  the 18 patients who presented with Flt3/ITD at di-
agnosis had completely lost the original mutation at relapse. One of  these patients at 
relapse was found to have a mutation that had been absent at diagnosis. Four patients 
who at diagnosis were Flt3/wt, had acquired an Flt3/ITD at relapse. A second group3, 
using another technique, studied 108 paired AML samples. In this study, 8 patients 
who were originally Flt3/wt had acquired an Flt3/ITD at relapse. Sixteen of  the pa-
tients showed an ITD at both diagnosis and relapse, 8 of  these patients had more then 
one Flt3/ITD. Yet, the observation of  an increased outgrowth of  Flt3/ITD AML in 
NOD/SCID mice (See chapter 2 and Lumkul et al.4) suggests that in a large part of  
the Flt3/ITD positive leukemias the mutation is present at the level of  the malignant 
stem cell. Nevertheless, it is not clear if  the observed outgrowth is solely dependent 
on the transplanted leukemic stem cells or that also other, more committed, cells are 
able to expand in this model. In chapter 4 of  this thesis we show that the Flt3-induced 
up-regulation of  CXCR-4 results in an increased SDF-1 induced chemotaxis, whilst it 
may possibly also contribute to cell survival by providing an anti-apoptotic signal. Both 
of  these mechanisms could explain the increased outgrowth of  Flt3/ITD AML in the 
NOD/SCID model. The occurrence of  an enhanced survival of  Flt3/ITD AML is 
further supported by the observations by Schnitgger5 and Kottaridis2 who observed 
that Flt3/ITD patients who relapsed, for the greater part showed an increased mutant 
to wildtype ratio at relapse.
However be these studies still can not definitively exclude that the poor prognosis of  
Flt3/ITD AML is an epiphenomenon, i.e. the observed poor prognosis is not due to 
the mutations themselves but by some other feature of  the leukemic stem cells. Such a 
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mechanism could for example be a genetic instability that induces a tendency to result 
in the mutation of  both Flt36 and other genes, which in turn are the true cause of  the 
poor prognosis.
7.2. Clinical implications of Flt3 mutations in AML
7.2.1. Incidence of Flt3/ITD 
To date over 20 studies, in total comprising over 5000 patients, have been published 
investigating the incidence and clinical implications of  Flt3/ITDs in  adult or pediat-
ric AML. As is evident from the data summarised in Table 1 many studies involved a 
limited number of  patients or only a subset of  AML, which may explain the variations 
in incidence rates. Even more important, many of  the studies represent retrospective 
studies using banked leukemia samples. Using banked samples one would expect to 
induce a bias for samples with high WBC counts or bone marrow cellularity. As most 
studies indicate Flt3/ITDs to be linked to high WBC counts, one expects the incidence 
rates as depicted in this table to be somewhat over estimated. Incidence rates in the 
studies can also be influenced by source material (peripheral blood, bone marrow or 
plasma DNA7) or the techniques used to amplify and detect the Flt3 mutations. Most 
of  the studies are based on PCR amplification of  genomic DNA or RNA followed 
by simple agarose gel electrophoresis, whilst others use a single strand conformation 
polymorphism analysis to detect mutations not detected in the standard gel electro-
phoresis. Yet, with regard to incidence of  Flt3/ITDs several features are evident from 
the studies depicted in this table. First, the incidence of  Flt3/ITDs is increased in pa-
tients with FAB-M3 / Acute promyelocytic leukemia (APL) and patients with socalled 
intermediate risk cytogenetics. On the other hand the incidence is decreased in patients 
with t(8;21) or inv(16), the so called core binding factor (CBF) leukemias.
In this context, Libura et al.6 recently reported that Flt3 abnormalities in CBF-leuke-
mias with AML-ETO or CBF-β-MYH11 were mainly restricted to cases with variant 
CBF-β-MYH11 fusion transcripts and/or atypical morphology. However, most of  the 
presented clinical studies do not allow for the analysis of  the prognostic impact of  
Flt3/ITDs in this specific subpopulation of  CBF leukemias. Second, the incidence of  
the mutations in juvenile AML is reduced when compared to adult AML. However, 4 
of  the 6 studies involving juvenile AML have reported Flt3/ITD mutations to increase 
with age8-11. This is in contrast to adult AML where only one study reported an increas-
ing incidence of  Flt3/ITD with age5. 
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Though Flt3 mutations are clearly more common in FAB-M3, they otherwise appear 
to be very evenly distributed over all other FAB classes. Nevertheless, some studies do 
report significant differences in the incidence within certain FAB classes5,8,12. Still, as 
these studies indicate different FAB classes to be involved they are most likely caused 
by biases in the sampled populations. 
Taken together, from the data in Table 1 the occurrence of  Flt3/ITDs can be esti-
mated to be around 20% in adult AML (30% for the intermediate risk population) and 
around 14% in childhood leukemia. 
7.2.2. The impact of Flt3/ITDs on patient prognosis 
Of  the 15 studies involving adult AML presented in table 1, two exclusively studied the 
impact of  Flt3/ITDs in APL and both studies observed no effects of  Flt3/ITDs on 
patient prognosis13,14. However, it should be noted that the numbers of  these APL se-
ries were relatively small and thus the statistical power of  these analyses is limited. Of  
the remaining 13 studies, 12 provided an analysis regarding the impact of  Flt3/ITDs 
on the overall survival. Seven of  these studies observed a reduced overall survival (OS) 
in Flt3/ITD AML in general, whilst three others only found a reduced OS in patients 
with either a hemizygous deletion of  the wildtype allele (Whitman et al.15) or patients 
with a high mutant/wildtype ratio (Thiede et al.12, Steudel et al.16). Kainz et al.17, who 
studied a population with a relatively high APL frequency observed no effect of  Flt3/
ITDs in the total study population. Yet, when only patients of  cytogenetic intermedi-
ate prognostic risk were analysed, Flt3/ITDs had a clearly negative impact on OS. The 
two remaining studies, which failed to detect any effect of  Flt3/ITDs on OS both in-
volved an intensified conditioning regimen5,18. It should however be noted that whilst 
the median follow-up in the study by Boissel et al. is unknown, the study by Schnittger 
et al. only had a median follow-up 11.1 month, which might have been too early for 
detecting differences in OS. 
The major factor attributing to the lower survival of  Flt3/ITD AML appears to be the 
increased relapse rates. Only in two studies involving adult AML, including our own, 
Flt3/ITD AML showed a reduction in the remission rate19,20. 
Even though the incidence in childhood AML seems to be reduced when compared to 
adult AML, also in this subtype of  AML Flt3/ITDs appear to have a negative impact 
on patient prognosis. Similar to Adult AML, juvenile AML with Flt3/ITDs showed a 
reduced overall survival and an increased relapse rate. 
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Yet, in contrast to adult AML, three of  the five evaluable studies showed a significant 
reduction of  the CR rate in juvenile AML. This might explain why the effect of  Flt3/
ITDs on the overall survival appears to be even more dramatic than that in adult AML. 
Of  the total of  695 patients involved in the seven pediatric AML studies, 85 were iden-
tified as having an Flt3/ITD. Of  these patients only 19 were reported to have survived. 
This results in an overall survival of  22% for Flt3/ITD patients compared to 58% for 
the Flt3-wildtype patients in these pediatric studies.
Except for our own study, only the study of  Stirewalt et al.21 specifically investigated 
the prognostic impact of  Flt3/ITDs in elderly AML. In contrast to our study, the latter 
study failed to detect an effect of  Flt3/ITDs in elderly patients. However, the median 
OS of  seven months in the older age population may obscure a possible negative im-
pact of  these mutations in elderly patients. 
The majority of  the studies presented indicate the presence Flt3/ITDs to be a sig-
nificant and independent predictor of  an unfavourable clinical response. Yet, as many 
studies have focussed on specific subgroups of  AML patients and the duration of  the 
follow-up is quite heterogeneous, it is difficult to directly compare the overall prog-
nostic impact. This comparison is even more troubled by the variable incidence of  
Flt3/ITDs in the different studies. Also, in the first series of  studies published patients 
were only divided in Flt3/ITD positive or negative cases. Within the Flt3/ITD posi-
tive cases, the ratio wildtype and mutant Flt3, or loss of  heterozygosity was not taken 
into account. 
7.2.3. Mutant to wildtype ratio and Flt3/ITD in relapsed AML
An increasing number of  studies give evidence that the relative expression of  the mu-
tant Flt3 allele vs. the wildtype allele is an important factor in Flt3/ITD AML.
In 8 patients in which the wildtype allele could not be detected, Whitman et al.15 ob-
served an increased peripheral WBC count and an even poorer prognosis than in pa-
tients in which the wildtype allele was detectable. An increased WBC-count and the 
suggestion of  a poorer prognosis was also observed in the studies by Kottaridis et 
al.20 and Thiede et al.12. Several mechanisms, such as loss of  heterozygosity15 and ho-
mologous recombinations12 have been reported to attribute to the allelic loss of  the 
wildtype allele. Thiede et al. also noted that patients with a mutant/wildtype ratio high-
er than the median (i.e. 0.78) had a poorer prognosis than patients with a lower mutant 
to wildtype ratio and similar observations have been reported in the pediatric AML 
study by Zwaan et al.8. Libura et al.6 observed in a real-time quantification of  Flt3 of  
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141 AML samples that Flt3/ITD AML could be divided into cases with a high expres-
sion, which essentially belonged to the monocytic lineage, and those with a relatively 
low expression, which predominantly demonstrated PML-RARα or DEK-CAN trans-
locations. Unfortunately this study contained no data about the clinical implications of  
these observations and neither did the authors investigate if  the transcript levels cor-
related with the mutant to wildtype ratio at the DNA level.
Several groups have investigated the Flt3/ITD status in paired diagnostic and relapse 
samples2,3,5,22. Even though in a small fraction of  patients the mutation is lost at relapse, 
these studies conclude that there is a tendency for an increased mutant to wildtype 
ratio at relapse. Also patients who at diagnosis were Flt3/ITD negative may acquire 
Flt3/ITDs at relapse in similar rates as observed in primary AML. Shih et al.3 report-
ed that all of  the 6 patients presenting with multiple mutations at diagnosis showed 
changes in mutation patterns at relapse, suggesting selection and outgrowth of  a mu-
tant clone or evolution of  a new clone harbouring these mutations. These findings 
suggest that Flt3/ITDs are not just the result of  genetic instability but a distinct entity, 
which may affect cell survival.
7.2.4. Flt3/TKD mutations
Except for the ITDs in the juxtamembrane domain also other mutations, mainly in-
volving the tyrosine kinase domain of  the Flt3 gene, have been reported. 
The observation by Glover et al.23 of  mutations in Asp802 in the activating loop of  
c-Fms and similar mutations in the activating loop of  c-kit24 led two independent 
groups to investigate mutations in Asp835 of  Flt325,26. Both groups reported the pres-
ence of  mutations in this codon in about 7% of  AML patients. Of  these single base 
mutations the replacement of  aspartic acid to valine is the most common, though oth-
er mutations in this codon involving the hydrophobic amino-acids tyrosine and alanine 
have been reported2,27. Recently also mutations in the neighbouring codon I836 have 
been reported28 and it has also been demonstrated that a 2-amino acid elongation be-
tween codons 840 and 841 (840GlySer) within the activating loop represents an other 
form of  activating mutation29.
Similar to Flt3/ITD mutations, the frequency of  these so-called Flt3/TKD mutations 
appear to be reduced in pediatric AML30. As the overall occurrence of  Flt3/TKDs 
is less frequent than that of  Flt3/ITDs, only a limited number of  studies (see, Table 
2) have investigated the clinical implications of  Flt3/TKD mutations. Whilst in most 
studies Flt3/TKDs express no effect on overall- and relapse free survival, Thiede et 
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al.12 observed a reduced overall survival in patients with Flt3/TKDs, but failed to find 
any effect on the relapse rates. Nevertheless, interpretation of  the results from this 
study is complicated by the fact that 22% of  the patients who presented with Flt3/
TKDs also had an Flt3/ITD. Only Moreno et al.27 observed both a reduced overall- 
and relapse free survival in Flt3/TKD AML. Yamamoto26 observed no significant ef-
fects on relapse free survival, but did point out that all Flt3/TKD AML patients who 
achieved a complete remission relapsed within 28 months. 
Study
Presence of
TKD mutation
Treatment
Overall
survival
Relapse
Rates
Thiede12
7.7%
(75/979)a
Conventional ↓ ↔
Sheikha69
7.5%
(6/80)
Conventional ↔ ↔
Liang30
3.3%
(3/91)b
Conventional ↔ ↔
Moreno27
9.6%
(16/166)
Conventional ↓ ↓
Frohling65
14.2%
(32/224)
Intensified ↔ ↔
Yamamoto26
7.0
(30/429)
Conventional ↔ ↔c
Table 2: Occurrence and prognostic impact of Flt3/TKDs in AML 
a 22% of  the TKD mutations also contained an ITD.   ↓= reduced
b only juvenile patients studied     ↔ = no effect
c all TKD mutant patients reaching CR relapsed within 28 months
7.3. Mode of action of Flt3/ITDs
From studies in the 32D and BA/F3 cell line models it has been suggested that both 
Flt3/ITD and Flt3/TKD mutations result in ligand-independent dimerisation and 
phosphorylation, leading to constitutive activation of  STAT5 and MAP-kinase31-33. 
This is supposed to result in the ligand-independent proliferation observed in these 
models. Yet, Fenski34 reported that in only one out of  four patients with Flt3/ITD 
AML the receptor was ligand-independently autophosphorylated. Likewise, in the 
same study where constitutive autophosphorylation in cell lines was demonstrated, 
Kiyoi et al.35 were unable to show ligand-independent phosphorylation of  Flt3 in pa-
tient samples. Whereas it appears that the presence of  Flt3/ITDs is associated with 
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STAT5 activation in primary AML cells36, the levels at which the phosphorylated 
STAT5 is expressed in these samples was shown not to be associated with the pres-
ence of  Flt3/ITDs37. Our observation (chapter 2 and 3) of  a reduced in vitro prolif-
eration of  primary AML samples is in contrast with the ligand-independent prolifera-
tion as observed in the Flt3/ITD-transduced 32D and BA/F3 cell line models. Similar 
observations of  a reduced in vitro proliferation of  Flt3/ITD positive primary AML 
samples have later been reported by Bruserud38. It therefore seems unlikely that the 
mutations in the Flt3-gene cause ligand-independent proliferation of  the AML cells in 
patients. Thus, ligand-independent proliferation in the BA/F3 and 32D models could 
be specifically restricted to these models rather than represent an intrinsic effect of  
the mutated receptor. Yet, it has also been shown that Flt3/ITD transfected 32D cells 
are blocked in the G-CSF induced differentiation pathway39,40. We have shown (chap-
ter 4 of  this thesis) that Flt3/ITD AML is characterized by an increased expression 
of  CXCR-4. Furthermore in the presence of  high SDF-1 levels CXCR-4 signalling in-
duced a partial block in the G-CSF induced myeloid differentiation. We also observed 
that Flt3 is able to up-regulate the expression of  CXCR-4, thus explaining the link be-
tween Flt3/ITDs, which represent an activated form of  the receptor, and an increased 
CXCR-4 expression. However, it is unlikely that in clinical AML Flt3/ITDs are the 
primary cause of  a differentiation block. If  Flt3/ITDs would induce a differentiation 
block one would expect all Flt3/ITDs to arise in primary AML, which is not the case. 
It is known that Flt3/wt AML at relapse acquire Flt/ITDs at a similar rate as observed 
in primary AML. Though rarely, also the opposite may be true: primary AML present-
ing with Flt3/ITDs can loose this mutation and at relapse present with wildtype Flt3. 
Kelly et al.41 observed that mice transplanted with Flt3/ITD transfected bone marrow 
cells developed a lethal myeloproliferative disease within 40-50 days following trans-
plantation. This strongly suggests Flt3/ITDs to provide proliferative or survival sig-
nals while exerting little effect on differentiation. Binding of  the ligand to the wildtype 
Flt3 has been shown to reduce apoptosis in primary AML cells by prevention of  the 
up-regulation of  Bax42. Likewise, Minami et al.43 have shown the existence of  differ-
ent anti-apoptotic pathways, involving the BCL-2 family member BCL-X
L
, in wildtype 
and mutant Flt3 in the murine myeloid cell line 32D. Whilst ligand-binding to Flt3/
wt-transfected cells reduced apoptosis by maintaining the phosphorylation of  BAD, 
it did not restore the down regulation of  BCL-X
L
. On the other hand, in Flt3/ITD-
transfected 32D cells both the phosphorylation of  BAD and the expression levels of  
BCL-X
L
 were maintained. Consequently, it could be that mutations in Flt3 promote 
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the survival of  AML cells by suppressing apoptosis. Yet, the authors of  the latter study 
were unable to explain the mechanisms involved and treatment with antisense BCL-X
L
 
was only partially able to reduce the anti-apoptotic effects of  the Flt3/ITD. 
In the same series of  experiments where we showed that SDF-1/CXCR-4 interactions 
could induce a block in the myeloid differentiation of  32D cells, we also showed that 
SDF-1/CXCR-4 interactions provide a strong anti-apoptotic signal in the 32D system. 
It could therefore well be that the up-regulated CXCR-4 expression provides an anti-
apoptotic signal which, following chemotherapy, would result in an increased survival 
of  Flt3/ITD AML when compared to Flt3/wt AML.
7.4. Flt3/ITDs as therapeutical targets in AML
Even though the mechanisms by which Flt3/ITDs have their impact on patient prog-
nosis are not clear, the prognostic significance of  these mutations adds to the creden-
tials of  Flt3 as potential therapeutical target in the treatment of  AML. The recent clini-
cal success of  the ABL-kinase inhibitor STI571 (imatinib mesylate, Gleevec, Glivec) 
in the treatment of  CML has boosted research into the use of  kinase inhibitors for 
other types of  hematological malignancies. These tyrosine kinase inhibitors (TKIs) en-
compass a variety of  chemical classes but all are heterocyclic compounds containing a 
structure which mimics the purine component of  ATP44,45. Despite the fact that all of  
these compounds are likely to fit the ATP binding pocket of  the receptor, some do so 
by a mechanism of  an induced fit whilst others, such as STI571, bind in a lock-and-key 
manner46,47. Therefore not all TKIs are able to inhibit all subclasses of  RTKs with the 
same efficiency. Even within the same RTK family, levels of  inhibition might very con-
siderably. As an example, STI571 very effectively inhibits BRC-ABL, wildtype-c-Kit, 
some forms of  mutated c-Kit and PDGFR, however, it is not very effective in inhibit-
ing the kinase activity of  wildtype-Flt3 or mutated Flt3 (IC
50
 > 3μg/ml). 
The first Flt3 inhibitors described were AG1295 and AG129648,49, which originally 
were characterised as inhibitors of  the PDGFR50. Both of  these compounds are in 
vitro cytotoxic to Flt3-dependent cell lines at an IC
50
 of  300nM. AG1295 has been 
shown to be selectively cytotoxic to primary AML blasts with Flt3/ITDs48. CEP-701 
and CEP-5214 are two other orally available biomolecules that have been shown to 
more selectively inhibit wildtype-Flt3 and mutant-Flt3 (IC
50
 CEP-701 2-3 nM for Flt3 
compared to > 500nM for c-Kit)40,51. CEP-701 has been shown to be cytotoxic to cells 
harbouring Flt3/ITDs both in vitro, using transfected cell line models, and in vivo, 
using a mouse model of  Flt3/ITD leukemia51. SU5416, SU5614 and SU11248 also 
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inhibit the Flt3/ITD induced phosphorylation both in cell line models and in vivo52-55, 
but unlike the CEP-compounds, these TKIs also show considerable activity against 
other RTKs like c-Kit and VEGF. CT53518 is a novel quinazoline compound that 
inhibits Flt3, PDGFRβ and c-kit56. GTP-14564, a compound with structural charac-
teristics of  the part of  staurosporine that inhibits protein kinase-C by competing for 
ATP, has in vitro been tested against a wide range of  kinases. It inhibits members of  the 
class III RTKs including Flt3, c-Kit, c-FMS and PDGFRβ. In in vitro cell based assays 
the compound was able to inhibit the Flt3/ITD-induced phosphorylation with a 30 
fold lower concentration as was needed for wildtype-Flt357. Finally, PKC412 is a ben-
zoylstaurosporine which originally was developed to inhibit VEGF but which is also 
active against Flt358. Several of  these compounds are currently in clinical trials (Table 
3). Three of  these, CEP-701, SU5416 and PKC412, have entered phase II studies of  
patients with relapsed or refractory AML harbouring Flt3-activating mutations59,60. 
While the preliminary results of  these trials give reason for some optimism, there 
are some important considerations to take into account. First, the cytotoxic activity 
against Flt3 of  most compounds has only been shown in vitro, only of  a minority of  
compounds in vivo data from animal models are available. In vitro toxicity cannot always 
directly be translated to in vivo toxicity due to for example bio-distribution, degrada-
tion and clearance of  the compounds. Also binding to specific proteins could alter 
bio-availability in vivo, as for example was observed for the binding of  STI-571 to Al-
pha1 acid glycoprotein61. Further, none of  the TKIs are truly specific for mutated-Flt3. 
Though this could be seen as an advantage as most AML blasts express Flt3, it may 
also be a reason for concern. As part of  the hematopoietic progenitors and the HSC 
also express Flt3 there is a possibility that such a compound could delay the recovery 
from therapy- or leukemia related cytopenias. Another theoretical problem would be 
if  the drug would result in the suppression of  both Flt3 and c-Kit, as this could result 
in an even greater depletion of  these cells. Another factor to take into account is the 
large variability in the expression levels of  the mutated Flt3. Most of  the in vitro and 
in vivo models used for screening the cytotoxicity of  the potential TKIs show high ex-
pression levels of  the aberrant gene product, therefore it could well be that in patients 
with AML showing a relatively low expression of  Flt3 mutations the drugs are less ef-
ficient in killing the aberrant cells. Furthermore, Flt3/ITD and Flt3/TKD mutations 
are distinctly different types of  mutations, which could respond differently to TKIs. 
As Flt3/TKDs concern mutations in the kinase domain it might therefore be expect-
ed that some of  these mutations would confer a relative resistance to TKIs. Recently, 
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Grundler et al.62 have indeed observed that sensitivity for three different TKIs varied 
between different types of  Flt3-mutations. In this study Flt3/ITD and Flt3-Ile836del 
expressing cells showed a dose-dependent apoptosis in response to AG1296, whilst 
this compound did not result in an increased apoptosis of  Flt3-Asp835Tyr and Flt3-
Ile836Met mutations at any of  the concentrations tested. PKC412 at concentrations 
between 25 and 100nM rapidly induced apoptosis in cells expressing the TKD mu-
tations, whilst Flt3/ITD mutants displayed far less apoptosis. The third TKI tested, 
SU5416 induced apoptosis most effectively in cells expressing the Flt3-Ile836del mu-
tation. From the above mentioned study it is clear that some compounds are very well 
able to inhibit Flt3/TKD mutations but are relatively ineffective in inhibiting Flt3/
ITD mutations and vice-versa. Therefore, each of  the Flt3-mutations should be tested 
for sensitivity to the different TKIs before patients could be treated with these com-
pounds as it would be inappropriate to treat AML patients with Flt3-mutations known 
to be resistant to a given inhibitor. It should also be noted that in rare cases patients 
present with both Flt3/ITD and Flt3/TKD mutations, which makes treatment with 
kinase inhibitors even more complicated. This indicates that all patients should have 
sequence analysis of  both the juxtamembrane and kinase domains to enable selection 
the most effective treatment strategy. 
Compound IC
50
Clinical stage
AG129548,49 300 nM --
AG129648,49 300 nM --
CEP-70140,51 3 nM Phase II
SU541652,53 100 nM Phase II
SU561455 10 nM Phase I
SU1124854 50-250 nM Phase I
GTP-1456457 1µM --
PKC41258,60 < 10 nM Phase II
D-6440670 3 µM --
D-6547570 1 µM --
CT-5351856 30-100 nM Phase I
Table 3: Flt3 inhibitors
IC
50
 refers to the drug concentration required to inhibit the Flt3-auto-
phosphorylation by 50% as determined in a variety of  different assays.
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Finally, perhaps the most important factor to take in to consideration is that Flt3-mu-
tations most probably are late-occurring events. Therefore it is not clear whether the 
mutations play a crucial in the survival of  the Flt3/ITD AML. If  this is not the case, 
treatment with a kinase inhibitor alone does not eradicate the leukemia.
7.5. Conclusion
With an occurrence of  around 28 percent in adult AML, Flt3-mutations are to date 
the most frequent genetic mutations observed in AML. Although the mechanism by 
which mutations in the Flt3-gene influence patient prognosis is unresolved, it is clear 
that AML with Flt3/ITDs represent a subset of  leukemia with a poor prognosis. An 
increasing number of  studies indicate that the relative expression of  the mutant gene 
compared to the wildtype gene is an important factor in Flt3/ITD AML. The main 
factor contributing to the reduced outcome of  patients with Flt3/ITD AML is the in-
creased relapse rate. Whereas the incidence of  these mutations is reduced in juvenile 
AML, Flt3/ITDs predict for an even poorer response to therapy. In contrast to adult 
AML, in juvenile AML the presence of  Flt3/ITDs results in both a reduction of  the 
CR rate as well as an increased relapse rate.
While the preliminary results of  clinical trials using tyrosine kinase inhibitors for the 
treatment of  Flt3 mutant AML may pave the way to new effective targeted therapies 
for chemotherapy resistant AML, one should also be aware of  the potential limitations 
and pitfalls of  the approach. For instance, it is conceivable that TKIs might inhibit 
normal hematopoietic stem- and progenitor cells which also express Flt3 and other 
RTKs and the different types of  mutations may correlate with the broad variability 
of  TKI sensitivity. This would suggest the importance of  sequence analysis of  both 
the JM domain and the kinase domain in patients in order to correlate the therapeutic 
effect with the type of  mutation. Yet, the development of  Flt3 inhibitors as mono-
therapy is an unlikely scenario, as mutation of  the Flt3 gene as a single abnormality is 
insufficient to cause leukemia. Since multiple mutations are likely to be present in Flt3 
mutant AML, one would predict that treatment regimens combining chemotherapy 
and TKIs will need to be developed.
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In the process of  hematopoietic development errors may occur, resulting in the aber-
rant activation of  (proto-)oncogenes and inactivation of  tumor-suppressor genes. This 
aberrant gene expression may finally result in leukemia, a neoplastic disorder in which 
immature hematopoietic cells accumulate in the BM where they fail to fully mature and 
dislocate the normal progenitor cells hence bringing the normal homeostatic processes 
out of  balance. 
The fms-like tyrosine kinase 3 (Flt3) is expressed on multipotential HSC and progeni-
tor cells, suggesting a critical role in stem cell development and differentiation. In 1996 
Nakao et al. were the first to report a novel mutation in the Flt3 gene in a small number 
of  AML patients. These mutations were shown to be internal tandem duplications, 
mainly involving a tyrosine rich stretch at the end of  exon 14 (formerly known as exon 
11), coding for the juxtamembrane domain of  the receptor. Since at that time little was 
known about the biological characteristics and clinical relevance of  Flt3/ITD this led 
us to further characterise these mutations, the main aim of  the experiments described 
in this thesis.
Our studies (chapter 3) indicate that with around 20-25 percent of  adult AML ex-
pressing Flt3/ITDs, these mutations represent the most frequent genetic alterations in 
AML. Clinically these mutations were significantly associated with a high probability 
of  recurrence of  leukemia and reduced survival.
In chapter 2 we investigated the effect of  Flt3/ITDs on the proliferative capacity of  
leukemic cells in long-term culture. Using stromal support to maintain long-term cell 
production, we were able to show that Flt3/ITD AML samples lacked an increased 
non-adherent cell production in response to cytokine addition as was observed for 
Flt3/wt AML. This aberrant behaviour was also observed in short-term cultures using 
single cytokine stimulation (chapter 3). Our observations of  a reduced in vitro prolif-
erative ability of  these primary AML cells are in contrast to the reported growth fac-
tor independent proliferation following introduction of  Flt3/ITDs in cell line models 
(32D and BA/F). The decreased proliferative capacity of  the Flt3/ITD samples was 
probably not due to a decreased AML progenitor frequency as in the L-CAFC assay 
both the frequencies and the size of  the cobblestone areas derived from Flt3/ITD or 
Flt3/WT were similar. Remarkably, we observed an increased ability of  FLT3/ITD 
AML to engraft in the immunodefiecient NOD/SCID mouse. We have shown (chap-
ter 6) that primary (or de novo) and secondary AML differ greatly in their ability to 
engraft in the NOD/SCID model. However, as both the Flt3/WT and Flt3/ITD 
population were mainly comprised of  patients with primary AML this could not ex-
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plain these differences. We also showed that within the primary AML population there 
is a strong correlation between the patients WBC counts and the repopulation in the 
NOD/SCID mice. Even though Flt3/ITD patients in general showed an increased 
WBC count when compared to Flt3/WT samples, this did not explain the mechanism 
behind the increased repopulation. Peled et al. (Science 1999;283:845-8.) have reported 
that engraftment and repopulation of  normal human hematopoietic stem cells in the 
NOD/SCID mouse is dependent on the expression of  CXCR-4 which is the receptor 
for SDF-1. Yet, in chapter 4 we could not find a correlation between the NOD/SCID 
repopulating ability and the migratory abilities in response to SDF-1 or the overall ex-
pression of  CXCR-4 in both Flt3/ITD and Flt3/wt AML. However, we did observe 
a strong correlation between the NOD/SCID repopulating ability and the percent-
age of  CD34+ cells expressing CXCR-4. When compared to Flt3/wt AML, Flt3/ITD 
AML was characterised by both an increased percentage of  cells expressing CXCR-4 
as well as an increased expression of  CXCR-4 per cell. This increased expression of  
CXCR-4 in Flt3/ITD AML, which represents AML with a constitutively activated 
form of  Flt3, could be explained by our observation that activation of  Flt3 by its lig-
and results in an up-regulation of  the CXCR-4 expression. The increased expression 
of  CXCR-4 resulted in an increased SDF-1 induced chemotaxis of  Flt3/ITD AML 
when compared to Flt3/wt AML, which might suggest that Flt3/ITDs also alter the 
in vivo migratory behaviour of  Flt3 mutant AML. In addition, the observation that 
blocking of  CXCR-4/SDF-1 interactions induced apoptosis in the 32D system sug-
gests that CXCR-4 also provides a strong anti-apoptotic signal. It could therefore also 
be that the Flt3 induced up-regulation of  the CXCR-4 expression provides an anti-ap-
optotic signal which following chemotherapy would result in an increased survival of  
Flt3/ITD AML. The testing of  this hypothesis would require clinical data regarding 
the biodistribution, survival and proliferation of  Flt3/ITD AML. 
Even though the mechanisms by which Flt3/ITDs have their impact on patient prog-
nosis are far from clear, the prognostic significance of  these mutations adds to the 
credentials of  Flt3-mutations as a potential therapeutical targets in the treatment of  
AML. Whilst the preliminary results of  clinical trials using tyrosine kinase inhibitors 
for the treatment of  Flt3-mutant AML give reason for some optimism some impor-
tant considerations have to be taken in to account. On the one hand these concern the 
effects of  these kinase inhibitors on normal hematopoietic stem- and progenitor cells 
which also express Flt3 and other receptor tyrosine kinases and, on the other hand 
these concern the relative resistance to some of  the kinase inhibitors due to the dif-
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ferent types of  mutations which can be present. The latter observation also indicates 
that all patients should have sequence analysis of  both the JM domain and the kinase 
domain to decide for the most effective treatment strategy. Yet, the use of  Flt3-inhibi-
tors as monotherapy is unlikely, as mutation of  only the Flt3-gene does not result in 
leukemia, multiple mutations must be present in Flt3-mutant AML. Therefore optimal 
treatment regimens combining chemotherapy and tyrosine kinase inhibitors will need 
to be established.
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In het proces van bloedcelvorming kunnen fouten ontstaan, die kunnen resulteren in 
een afwijkende activatie van (proto-) oncogenen en/of  inactivatie van tumorsuppres-
sorgenen. Deze afwijkende genexpressie kan uiteindelijk resulteren in leukemie, een 
neoplastische afwijking waarbij onrijpe bloedvormende cellen in het beenmerg accu-
muleren en de normale hemostatische processen uit balans brengen.
De “fms-like” tyrosinekinase 3 (Flt3) wordt tot expressie gebracht op multipotente 
HSC en voorlopercellen, wat een kritische rol in de stamcelontwikkeling en differen-
tiatie suggereert. In 1996 waren Nakao et al. de eersten die een nieuwe mutatie in het 
Flt3 gen bij een klein aantal AML patiënten rapporteerden. Bij deze mutaties bleek het 
te gaan om interne tandemduplicaties, welke voornamelijk aanwezig waren in een ty-
rosinerijk gebied aan het einde van exon 14 (voorheen bekend als exon 11) coderend 
voor het juxtamembraandomein van de receptor. Aangezien er destijds weinig bekend 
was over de biologische eigenschappen en klinische relevantie van deze mutaties heb-
ben wij deze verder gekarakteriseerd, hetgeen het voornaamste doel werd van de ex-
perimenten beschreven in dit proefschrift.
Onze studies (Hoofdstuk 3) geven aan dat Flt3/ITDs voorkomen bij 20-25 procent 
van de volwassen AML patiënten, wat betekent dat Flt3/ITDs tot op heden de meest 
voorkomende genetische mutatie bij deze vorm van AML is. Klinisch zijn deze muta-
ties significant geassocieerd met een verhoogde kans op het terugkeren van de leuke-
mie en een verlaging van de overlevingskansen. 
In hoofdstuk 2 hebben we gekeken naar de effecten van Flt3/ITDs op de prolifera-
tieve capaciteiten van leukemiecellen in lange-termijnkweken. Door gebruik te maken 
van stromale lagen om de lange-termijnkweken te ondersteunen, waren we instaat om 
aan te tonen dat Flt3/ITD AML, in tegenstelling tot Flt3/wt AML, geen toename in 
de proliferatievecapaciteiten vertoonde in respons op de toevoeging van cytokines. Dit 
afwijkende gedrag van Flt3/ITD AML werd ook gezien in respons op cytokine-addi-
tie in kortetermijnkweken (Hoofdstuk 3). Onze observatie van een gereduceerde in 
vitro proliferatie van deze primaire AML cellen staat in contrast met de gerapporteerde 
groeifactor onafhankelijke proliferatie ten gevolge van de introductie van Flt3/ITDs 
in cellijn modellen (32D en BA/F3). Deze afgenomen proliferatieve capaciteit van de 
Flt3/ITD monsters is waarschijnlijk niet veroorzaakt door een afname in de frequen-
tie van AML-voorlopercellen, daar in het L-CAFC assay zowel de frequentie als de 
afmetingen van de cobblestone-area’s gelijk waren voor zowel Flt3/ITD als Flt3/wt 
AML. Opmerkelijk was de observatie dat Flt3/ITD AML een verhoogde uitgroei in 
de immuundeficiënte  NOD/SCID-muizen te zien gaf. Wij hebben laten zien (Hoofd-
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stuk 6) dat primaire (of  de novo) en secundaire AML een groot verschil vertonen in 
hun vermogen om in deze muis uit te groeien. Omdat zowel de Flt3/wt-  als de Flt3/
ITD-populatie voornamelijk bestonden uit monsters van patiënten met een primaire 
AML kon deze observatie het verschil in uitgroei in NOD/SCID-muizen niet verk-
laren. Tevens hebben we aangetoond dat er binnen de primaire AML-populatie een 
sterke correlatie bestond tussen de witte bloedcelaantallen gemeten in de patiënten en 
het repopulerend vermogen in NOD/SCID muizen. Hoewel Flt3/ITD patiënten in 
het algemeen een verhoogd aantal witte bloedcellen hadden in vergelijking met Flt3/
wt patiënten, kon ook dit het verschil in uitgroei niet verklaren. Peled et al. (Science 
1999;283:845-8.) hebben laten zien dat het aanslaan en de uitgroei van een transplan-
taat van normale bloedcelvormende stamcellen in de NOD/SCID muis afhankelijk is 
van de expressie van CXCR-4, de receptor voor de chemokine SDF-1.  In hoofdstuk 4 
waren wij evenwel niet in staat om een correlatie aan te tonen tussen het NOD/SCID-
repopulerend vermogen en de migratie in respons op SDF-1 voor zowel Flt3/ITD als 
Flt3/wt AML. Echter, binnen het cluster van CD34+ cellen was er een duidelijke cor-
relatie tussen de expressie van CXCR-4 en de uitgroei in NOD/SCID. In vergelijking 
met Flt3/wt AML is Flt3/ITD AML gekarakteriseerd door zowel een verhoogd per-
centage cellen dat CXCR-4 tot expressie bracht als door een verhoogde CXCR-4 ex-
pressie per cel. Deze relatief  verhoogde expressie van CXCR-4 in Flt3/ITD AML, 
welk een subtype van AML met een constitutief  geactiveerde Flt3 vertegenwoordigd, 
zou verklaard kunnen worden door onze observatie dat activatie van  Flt3 door zijn 
ligand  resulteert in een verhoogde expressie van CXCR-4 op het celmembraan. In vitro 
resulteerde de verhoogde expressie van CXCR-4 in een toename van de SDF-1 geïn-
duceerde chemotaxis van Flt3/ITD AML in vergelijking met Flt3/wt AML, hetgeen 
suggereert dat Flt3/ITDs mogelijk ook in vivo, in de patiënt, de migratoire eigenschap-
pen veranderd. Voorts wijst de observatie dat blokkering van de CXCR-4/SDF-1 in-
teractie apoptose induceert in het 32D systeem er ook op dat activatie van CXCR-4 
resulteert in een sterk anti-apoptotisch signaal. Het zou daarom ook kunnen dat de 
Flt3-geïnduceerde verhoging van de CXCR-4 expressie leidt tot een anti-apoptotisch 
signaal wat uiteindelijk resulteert in een verhoogde overleving van Flt3/ITD AML na 
chemotherapie. Het testen van deze hypothese vereist echter klinische data met betrek-
king tot de biodistributie, overleving en proliferatie van Flt3/ITD AML. 
Hoewel het mechanisme waarmee Flt3/ITDs de prognose van patiënten beïnvloedt 
verre van duidelijk is, zijn Flt3-mutaties een potentieel aangrijpingspunt voor therapie. 
De voorlopige resultaten van klinische trials naar het gebruik van tyrosinekinaserem-
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mers geven enige reden tot optimisme, maar toch verdienen enige punten de aandacht. 
Enerzijds hebben deze betrekking op het mogelijke negatieve effecten van deze kinase-
remmers op de normale stamcellen, die eveneens Flt3 en andere receptor-tyrosine-
kinases tot expressie brengen en anderzijds op de mogelijke resistentie voor sommige 
kinaseremmers, veroorzaakt door de diversiteit van de mutaties die aanwezig kunnen 
zijn. Deze laatste observatie geeft aan dat het noodzakelijk zal zijn om een sequen-
tie-analyse, van zowel het juxtamembraandomein als het kinasedomein van de recep-
tor, uit te voeren bij alle patiënten  die in aanmerking komen voor behandeling met 
kinaseremmers. Dit om de meest effectieve behandelingsstrategie te bepalen. Daar de 
mutatie van enkel het  Flt3-gen niet resulteert in leukemie, en in Flt3/ITD AML dus 
additionele mutaties aanwezig moeten zijn, is het evenwel onwaarschijnlijk dat Flt3-
remmers als monotherapie gebruikt zullen worden. Het zal daarom dan ook noodza-
kelijk zijn om behandelingsstrategieën op te zetten waarin chemotherapie en kinase-
remmers worden gecombineerd. 
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List of abbreviations
AML  Acute Myeloid Leukemia
APC  Allophycocyanin
BSA  Bovine Serum Albumin
CAFC  Cobbelestone Area Forming Culture
CD  Cluster of  Differentiation
CFU-c  Colony Forming Unit-culture
CML  Chronic Myeloid Leukemia
CR  Complete Remission
CSF  Colony Stimulating Factor
EFS  Event Free Survival
EPO  Erythropoeitin
FAB  French-American-British
FCS  Fetal Calf  Serum
FITC  Fluorescein-Isothiocyanate
FL  Flt3-Ligand
Flt3  Fetal Liver Tyrosine Kinase 3
G-CSF Granulocyte-Colony Stimulating Factor
GM-CSF Granulocyte Macrophage-Colony Stimulating Factor
HSC  Hematopoietic Stem Cell
IL  Interleukin
IMDM Iscove’s Modified Dulbucco’s Medium
ITD  Internal Tandem Duplication
JM  Juxtamembrane
L-CAFC Leukemic-Cobbelestone Area Forming Culture
LFS  Leukemia Free Survival
M-CSF Macrophage-Colony Stimulating Factor
MDS  Myelodisplastic Syndrome
MEM  Minimal Essential Medium
NOD/SCID Non-Obese Diabetic/Severe Combined Immunodeficiency
OS  Overall Survival
PBS  Phosphate Buffered Saline
PE  R-Phycoerythrin
RFS  Relapse Free Survival
RTK  Receptor Tyrosine Kinase
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SCF  Stem Cell Factor
SDF  Stromal cell Derived Factor
STAT  Signal Transducer and Activator of  Transcription
TK  Tyrosine Kinase
TKD  Tyrosine Kinase Deletion
TKI  Tyrosine Kinase Inhibitor
TPO  Thrombopoietin
WBC  White Blood Cell
WT  Wildtype
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